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General introduction 
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H1-antihistamines are used for the treatment of allergies such as allergic rhinitis 
or hay fever. They down-regulate allergic inflammation peripherally by inhibiting 
the effects of histamine. Older generation antihistamines also act on the central 
nervous system (CNS), thereby reducing the wake-promoting effects of centrally 
acting histamine, and consequently causing sedation. In case of allergy treatment 
this sedation is considered an unwanted non-therapeutic effect. However, the 
same sedative action is widely used and wanted in the treatment of insomnia 
and anxiety 1, as both disorders are associated with excessive arousal 2-4, and 
this arousal is reduced by the sedative properties of antihistamines. Therefore, 
older generation antihistamines such as diphenhydramine and hydroxyzine are 
nowadays used as sleep aids and anxiety treatments 5, 6.
 Depending on their clinical use, the central effects of antihistamines are 
thus either unwanted and therefore should be prevented or may indeed have a 
therapeutic effect, one which should perhaps be enhanced. On the one hand, 
for the treatment of allergic rhinitis, the prevention of central antihistamine 
effects is of importance in order to diminish sedation as this can impair 
cognitive functions such as attention and car driving 7-11. This impairment in 
cognitive functions has far-reaching consequences, because up to 40% of the 
population worldwide suffer from allergic rhinitis 12, and the subsequent use 
of antihistamines is therefore substantial. On the other hand, in the treatment 
of insomnia and anxiety, the central effects of antihistamines are of interest 
and possible enhancement of those effects can be beneficial. For instance, 
enhancing the central action of H1-antihistamines and other agents with H1-
antihistaminergic properties can lead to possible lower doses of treatment, 
which in turn might reduce other side-effects. 
 In order to prevent or enhance central antihistaminergic actions it is important 
to understand their underlying mechanism, and over the years the improvement 
of H1-antihistamines has indeed been drastic because of a significant progress 
in understanding the role of histamine as a central neurotransmitter 13. 
Recent research indicates that several factors modulate the sedative effects of 
antihistamines such as individual differences in transport across the blood-brain 
barrier, genetic variation in drug metabolism, and circadian variation in central 
histaminergic activity. Gaining further knowledge about these mechanisms 
and their effects in humans may lead to an optimization of antihistaminergic 
treatments.
Histamine and antihistamines
Histamine is a chemical messenger synthesized from the amino acid histidine by 
L-histidine decarboxylase 14, 15. Histamine occurs in various systems such as the 
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gastrointestinal system and the immune system where it plays a role in allergy 
and inflammation. During inflammation, an allergic person comes into contact 
with an allergen, and the immune system causes IgE antibodies to be secreted 
which attach to the cell surface of mast cells. Mast cells are the predominant 
storage sites of histamine in the skin, the bronchial tree and the intestinal mucosa 
membrane. When IgE antibodies are attached to the mast cells, histamine is 
released and this release results in rhinitis (hay fever symptoms) and urticaria 
(skin rash) 14, 16.
 Histamine is also a “wake-promoting” neurotransmitter in the CNS, where 
it plays a role in the circadian sleep-wake cycle, in the regulation of vigilance, and 
in cognition 13, 15. Histamine is produced in neurons in the tuberomammillary 
nucleus (TMN) of the hypothalamus and projects widely throughout the brain, 
covering the major parts of the cerebrum, cerebellum, posterior pituitary and the 
spinal cord 17. Histaminergic neurons fire spontaneously with a variation of firing 
rate across the sleep-wake cycle. The firing of these neurons is highest during 
the waking state and less or absent during the sleep stages 18-20. 
 There are four histamine receptor subtypes classified: H1R-H4R. H1Rs 
mediate, amongst others, the afore-mentioned sleep-wake cycles and also play a 
role in vigilance and learning 15. The main function of the H2R is the mediation 
of gastric release. H3R mediates negative feedback on histamine synthesis 
and release as an autoreceptor, and plays a role in central and peripheral 
neurotransmission as it regulates levels of a variety of neurotransmitters as a 
heteroreceptor 21. Additionally, it is suggested that H3R might play a role in 
neurological disorders such as schizophrenia. The H4R is the latest identified 
member of the histamine receptors and occurs mainly in peripheral tissue 14. 
Recent preclinical research indicates that H4R may play a role in allergic asthma 
and rheumatoid arthritis 16. 
 Histamine receptors have a basal activity without ligand binding. This 
degree of receptor activity in the absence of histamine is called ‘constitutive 
activity’. The active and inactive states of the receptors exist in equilibrium. 
Histamine acts as an agonist with affinity for the active state and can therefore 
shift the equilibrium towards this state 15, 22.
 H1-antihistamines act as inverse agonists and bind to the inactive form of 
the H1R causing a shift in the equilibrium towards the inactive state. They down-
regulate inflammation and inhibit histamine release 15, 22. H1-antihistamines 
are generally divided into 1st and 2nd generation antihistamines. The older, 1st 
generation antihistamines are the more centrally active antihistamines and 
cause more sedation as compared with the 2nd generation antihistamines. Also 
other medications can affect H1Rs (such as antidepressants with affinity for the 
H1R) and can subsequently cause sedation. 
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Mechanisms of central action
In order to be centrally active, substances have to cross the blood-brain barrier 
(BBB). One important function of the BBB is to protect the CNS from the 
direct influences of potentially unsafe compounds circulating in the blood 23. 
The BBB is formed by endothelial cells that are characterized by tight junctions, 
forming an almost impermeable barrier to fluids 24. These tight junctions ensure 
that components that do not dissolve in fats (i.e. lipophobic substances) and 
that consist of large molecules can not automatically enter the BBB 25. This 
mechanism is believed to be involved in the (dis)ability of H1-antihistamines to 
enter the brain. However, this mechanism alone can not explain all variations 
in the amount of sedation caused by H1-antihistamines. More recent research 
indicates that other factors might play a role as well 19, 26-29. These factors 
include, amongst others, (i) the metabolism of H1-antihistamines; (ii) the ability 
of antihistamines to bind at the P-glycoprotein transporter; and (iii) time of drug 
administration relative to circadian fluctuation in brain histamine levels. 
Metabolism of H1-antihistamines
CYP2D6 is the major route of metabolism for, amongst others, antihistamines. 
The human population can be divided into either poor or extensive metabolizers 
of CYP2D6, indicating human variability in the kinetics of CYP2D6 substrates 
29-31. More precise, about 5-10% of the Caucasian populations in Europe are 
poor metabolizers of CYP2D6 substrates which can cause elevated substrate 
concentrations 30. This variability in metabolism might be a possible mechanism 
in variation in central antihistamine actions.
Binding at the P-glycoprotein transporter
As mentioned before, in order to be centrally active H1-antihistamines have to 
enter the BBB. Lipophilicity and consisting of smaller molecules enables certain 
antihistamines to cross the BBB through diffusion and to block H1Rs in the CNS 
9. However, P-glycoprotein is another mechanism at the BBB that is believed to 
play a role in central actions of antihistamines. P-glycoprotein is an active efflux 
transporter located, amongst others, in the endothelial cells of the BBB and is 
known to transport a range of different substrates out of the brain 27, 32, 33. Even 
though a substrate for P-glycoprotein can enter the brain through diffusion, 
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the penetration of brain tissue can be decreased by this efflux transport. This 
mechanism is thought to be a reason for the lack of highly sedative effects of 
non-sedative antihistamines.
Circadian fluctuations in brain histamine levels
Because histaminergic neurons in the tubero-mammillary nucleus (TMN) fire 
spontaneously 34, 35 with a variation of firing across the circadian rhythm 18-20, 36. 
This circadian variation in firing might be the third mechanism playing a role in 
central antihistamine actions. More precise, it can be expected that the sedative 
effects of a 1st generation antihistamine would be maximal in the evening when 
histamine levels are low and less in the morning when histamine levels are high, 
as a result of increased competition between histamine and the antihistamine in 
the CNS in the morning.
Aim of the dissertation
The aim of this dissertation is to improve our understanding of (neuro) 
pharmacological and pharmacokinetic mechanisms underlying central H1-
antihistamine effects in humans. These mechanisms are investigated in 4 
experimental studies. In the first study, driving performance after administration 
of a 1st and 2nd generation antihistamine was compared in order to reestablish 
and confirm the differential sedative profiles between 1st and 2nd generation 
antihistamines. Next, a study was conducted with similar methodology, but 
with an additional focus on the role of genetic variation in drug metabolism. 
Third, a study was conducted in order to elucidate the role of the P-glycoprotein 
transporter in the impairing effects of antihistamines, focusing on behavior 
as well as on brain activation as measured with fMRI. Lastly, sedative action 
of antihistamines was studied as a function of circadian fluctuations in brain 
histamine levels, focusing on behavior as well as on electro-cortical activity 
(event-related potentials).
Outline of the dissertation
In chapter 2 and chapter 3 the role of H1-antihistamines on actual driving 
performance is discussed in order to establish the pharmacodynamic effects of 
H1-antihistamines and hence to evaluate antihistaminergic effects on real life 
performance. More precisely, chapter 2 describes a study assessing the difference 
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between 1st and 2nd generation H1-antihistamines on driving performance in 
22 healthy volunteers. The effects of two doses of bilastine (20 an 40 mg) on 
actual driving after single and repeated administration were compared with 
placebo and the 1st generation H1-antihistamine hydroxyzine (50 mg). 
 In chapter 3, a study is presented in which the residual effects on driving 
performance were assessed in 32 healthy volunteers who received nocturnal 
doses of esmirtazapine (1.5 and 4.5 mg) during one week treatment. These 
effects were compared with placebo and the hypnotic zopiclone (7.5 mg). 
Additionally, CYP2D6 phenotyping was determined in order to distinguish poor 
metabolizers from extensive metabolizers of esmirtazapine. 
 Chapter 4 presents a study assessing the role of the P-glycoprotein 
transporter in central antihistamine effects. The effects of combining 2nd 
generation antihistamine cetirizine with verapamil, a P-gp blocker, in 13 
volunteers were investigated. Participants received cetirizine (15 mg), verapamil 
(120 mg), a combination of cetirizine + verapamil, and a placebo. Brain activity 
was assessed during an attention task in a 3-T magnetic resonance scanner.
 Chapter 5 and chapter 6 present studies investigating the role of time 
of administration on sedation caused by 1st generation H1-antihistamine 
hydroxyzine. Chapter 5 explores the effects of evening and morning doses of 
hydroxyzine (50 mg) on cognition in 18 healthy volunteers. Performance was 
assessed using attention and impulsivity tasks. 
 Chapter 6 evaluates to what extend event-related potentials are affected 
by time of administration of hydroxyzine (50 mg) in 18 healthy volunteers. The 
effects were measured after an evening dose and after a morning dose, and 
compared with placebo. 
 Finally, in chapter 7 the results from the previous chapters are summarized 
and discussed. Furthermore, clinical implications are discussed and suggestions 
for further research are proposed.
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Chapter 2
Abstract
Bilastine is a new 2nd generation H1-antihistamine. Although 
bilastine has been demonstrated to produce no or little performance 
impairment on laboratory tests, it cannot be excluded that it produces 
impairments in real life performance such as driving. This study 
aims to assess the effects of two doses of bilastine (20 and 40 mg) on 
actual driving after single and repeated administration. Hydroxyzine 
50 mg was included as an active control. Twenty-two participants 
(11 females and 11 males) were tested in a placebo-controlled, 
randomized, double blind, 4 way cross-over design. Participants were 
treated with once daily doses for 8 consecutive days. On day 1 and 8 
of each treatment period participants performed an actual highway 
driving test. The primary variable was the standard deviation of 
lateral position (SDLP), which is a measure of weaving. Results 
demonstrated that hydroxyzine significantly increased SDLP on days 
1 and 8 of treatment. Bilastine did not affect SDLP. It is concluded 
that hydroxyzine produces severe driving impairment after single 
doses and that this impairment only partly mitigates over time due 
to a lack of complete tolerance. Bilastine did not produce any driving 
impairment after single and repeated doses and can be safely used in 
traffic in doses up to 40 mg.
Introduction
Antihistamines are the most commonly used medications for the treatment of 
allergic rhinitis. H1-antihistamines can be divided into 1st and 2nd generation 
antihistamines. 1st generation antihistamines easily penetrate the blood brain 
barrier and block H1 receptors in the CNS, causing unwanted side effects 
such as sleepiness and sedation. 2nd generation antihistamines are less likely to 
penetrate the brain and produce no or only mild CNS side effects 1-5.  
 Bilastine is a new 2nd generation H1-antihistamine that has been developed 
for the treatment of allergic rhinoconjunctivitis and chronic urticaria. Bilastine 
has shown to be rapidly absorbed after oral administration, with a tmax of 1-1.5 hrs 
and a half-life of 10-12 hrs 6.  Bilastine is highly selective for the H1 receptor as 
demonstrated in in vivo and in vitro studies 7, 8. The latter showed that bilastine 
is equally potent as cetirizine, so being equally effective in treating allergic 
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rhinitis and chronic urticaria, and more potent than fexofenadine. Moreover, 
bilastine has been found to have a longer duration of action than fexofenadine 9. 
First in-man-studies suggest that bilastine 20 mg is safe and well-tolerated with 
a similar effectiveness as cetirizine and desloratadine, but with less potential 
to produce adverse events 6. The most commonly reported adverse events for 
bilastine were headache, somnolence and fatigue. Bilastine in doses up to 40 mg 
did not produce psychomotor impairment in healthy volunteers as compared to 
placebo. Impairments only started to emerge at bilastine doses of 80 mg 10.  
 Although bilastine produced no or little performance impairment in 
laboratory tests of cognitive and psychomotor function, it cannot be excluded 
that the drug produces performance impairments in real life performance such 
as driving. Previous studies have demonstrated that tests measuring actual 
driving performance are more sensitive to sedative properties of psychoactive 
drugs than standard laboratory tests of psychomotor skills 5, 11-13. Previous 
driving studies with antihistamines, for example, have demonstrated that even 
the so called ‘non-sedative’ antihistamines can produce impairment of driving 
performance at therapeutic doses and/or double doses. Most of these studies 
have employed a standardized driving test 14 that is conducted on a primary 
highway open to normal traffic, for quantifying antihistamine effects on driving 
5, 12, 13. The primary outcome measure of the standard driving tests is the standard 
deviation of lateral position (SDLP), a measure of weaving. The standard driving 
test has also been calibrated for a wide range of blood alcohol concentrations 
(BAC) in order to quantify drug effects on driving in BAC equivalents 15.   
 The present study was designed to assess the effects of two doses of bilastine 
(20 and 40 mg) on actual driving performance after single and repeated dosing, 
and to assess the safety and tolerability of bilastine 20 and 40 mg. Hydroxyzine 
50 mg, a 1st generation antihistamine, was also included as a control treatment 
to demonstrate the sensitivity of the driving measure to the sedative effects of 
antihistamines.
Methods 
Subjects
Eleven healthy male and 11 healthy female volunteers (age range 21 to 45 years; 
mean ± SD: 29.5 ± 1.8 years) were recruited through poster advertisement. 
Participants were screened by means of a medical questionnaire and a physical 
examination. The latter included a 12-lead electrocardiogram evaluation, blood 
chemistry and haematology, urinalysis, and drug and pregnancy screening. All 
participants possessed a valid driver’s license for more than 3 years and had 
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driving experience of at least 5000 km per year on average. Furthermore, 
participants had a body mass index of 19 to 30 kg/m², and expressed willingness 
to use a double barrier contraceptive method. 
 Volunteers with a history of medical or psychiatric illness, hypersensitivity 
to H1-antihistamines, and/or seasonal allergic rhinitis or urticaria treated by 
antihistamines were excluded from the study. Additional exclusion criteria were 
alcohol consumption of more than 21 units per week; caffeine consumption 
of more than 6 cups per day; regular drinking of grapefruit juice; treatment by 
atropine or atropine-like drugs; treatment by a drug depressant of the central 
nervous system, and regular use of sedatives. Females could not participate 
when pregnant or breast feeding. 
 The study was approved by the standing medical ethics committee of 
Maastricht University and was carried out in compliance with the current 
revision of the Declaration of Helsinki (Seoul modification, 2008), International 
Conference on Harmonization guideline for Good Clinical Practice. Participants 
gave their written informed consent prior to study participation. 
Design and treatments
The study was conducted according to a randomized, double blind, 4 way cross-
over design with a placebo control, a positive control (hydroxyzine 50 mg), and 
bilastine 20 mg and 40 mg. Participants were treated with once daily doses for 
8 consecutive days. Treatment periods were separated by a washout period of at 
least 7 days. All treatments were administered as identical encapsulated tablets 
to ensure blinding. 
 During day 1 and day 8, the trial medication was taken at the study site 
under supervision of a research associate at 12.00 hrs. During days 2 to 7, trial 
medication was taken during the evening at the participants’ home. Time of drug 
intake was recorded in a diary. As a general rule, trial medication was taken 1 
hour before, or 2 hours after dinner on days 2 to 7. 
Procedure
Participants received a training of the standardized driving tests prior to the 
first treatment period. At arrival on the study site, on day 1 and day 8 of each 
treatment period, drug screens and pregnancy tests were conducted. On day 1 
blood samples and urinalysis were taken prior to dosing. On day 8 blood samples, 
urinalysis and ECG measurements were taken after the highway driving test. 
On day 1 and day 8, approximately 1 hour after intake of the medication (tmax) 
participants commenced the standard highway driving test. A detailed overview 
of the scheduled assessments is given in Table 1. 
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Table 1	 Study	overview
Screening Treatment periods Washout Period 
Assessments Day 1 Day 2-7 Day 8 Day 9-15
Dosing¹ • • •
Medical	history •
Physical	
examination • • •
Pregnancy	test	
(women	only) • • •
Drug	screen • • •
ECG • •
Vital	signs • • •
Highway	driving	test Training • •
Blood	sampling	/	
urinalysis² • • •
concomitant	
medication Whenever	concomitant	medication	was	used
Adverse	events Whenever	a	(serious)	adverse	event	occurred	
¹	On	day	1	and	8	trial	medication	was	ingested	at	12.00	hrs.	On	day	2-7	trial	medication	was	ingested	
1	hour	prior	or	2	hours	after	dinner.	
²	On	day	1	blood	samples	and	urinalysis	were	taken	prior	to	dosing.	On	day	8	blood	samples	and	
urinalysis	were	taken	after	highway	driving	test.		
Driving performance test
The highway driving test was standardised in 1982 for drug screening purposes 
and has since been used for measuring drug effects on driving performance 
14, 16. In the highway driving test participants operate a specially instrumented 
automobile over a 100 km (62 miles) primary highway circuit 17. The participants’ 
task is to maintain a constant speed of 95 km/hour (59 miles/hour), and a steady 
lateral position between the delineated boundaries of the right (slower) traffic 
lane. A licensed driving instructor, who has access to dual controls so that he can 
intervene if necessary, accompanies the participant. A video camera at the back 
of the car records the lateral position of the automobile relative to the left lane-
line. This signal is digitised at 4 Hz and stored on an onboard computer disk-file 
for editing. The offline editing routine involves the removal of data segments 
that show signal loss, disturbance, turnarounds or passing manoeuvres. The 
remaining data is used to calculate the Standard Deviation of Lateral Position 
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(SDLP), Speed and Standard Deviation of Speed (SDSP). SDLP is the primary 
outcome variable. It is a measure of the road tracking error, which in practical 
terms is a composite index of allowed weaving, swerving and overcorrecting. 
Speed and SDSP are secondary control measures.
 The clinical relevance of a change in SDLP has been previously determined 
by establishing the dose-effect relationship between blood alcohol concentration 
(BAC) and the SDLP 15. The results indicated that with a BAC of 0.5 mg/ml 
there is an increase in SDLP of about 2.4 cm. Because a BAC of 0.5 mg/ml is 
associated with a significant higher risk for traffic accidents 18, a SDLP of  2.4 
cm is considered to represent a clinically relevant drug effect.
Subjective measurements
The Groningen Subjective Quality of Sleep Questionnaire 19 was filled out every 
morning in order to asses the participants’ sleep quality and sleep duration of the 
previous night. This questionnaire scores sleep complaints, ranging from 0 (good 
sleep) to 14 (bad sleep).
 Prior to the highway driving test participants were asked to rate their 
subjective feeling of sedation on a visual analogue scale ranging from 0 mm 
(no sedation) to 100 mm (very much sedation), and to rate their expected 
driving ability on a visual analogue scale ranging from 0 mm (no influence from 
the medication on driving ability) to 100 mm (very much influence from the 
medication on driving ability). Furthermore, particpants were asked to rate 
their subjective driving quality after completion of the test on visual analogue 
scales ranging from 0 mm (very good driving) to 100 mm (very bad driving). The 
driving instructor also rated the participants’ driving ability on 100 mm visual 
analogue scales ranging from 0 (very good driving) to 100 (very bad driving), 
and the amount of sedation on 100 mm visual analogue scales ranging from 0 
(no sedation) to 100 (complete sedation). On days 2 to 7 participants reported 
their drowsiness on a visual analogue scale 1 hour post dosing. Possible adverse 
events and concomitant medication were also reported.
Safety assessment 
Only standard biological tests were conducted at the screening visit and at test 
days as no particular risk has been described with bilastine 6, 10, 20. The biological 
tests included the analysis of haematology parameters, blood chemistry and 
urinalyses. Vital signs were measured at the screening visit and at test days. 
Furthermore, an ECG was carried out at the screening visit and at day 8 of each 
treatment period. 
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Statistics
A power calculation revealed that a sample of 20 participants is sufficient for 
providing a power of more than 90% for detecting a clinically relevant effect of 
2.4 cm critical mean difference between a drug and placebo in SDLP. 
 All driving and subjective parameters were analyzed using repeated 
measure Analysis of Variance (ANOVA) with Treatment (placebo, bilastine 20 
mg, bilastine 40 mg, and hydroxyzine 50 mg) and Time of treatment (day 1 
and day 8) as within subject factors, and Gender as a between subject factor. 
Analyses showing a significant main effect (p<0.05) of Treatment or Treatment 
x Time of treatment, were followed by separate drug-placebo contrasts on each 
separate treatment day. The Statistical Package for the Social Sciences (SPSS) 
version 15.0 was used for the achievement of all listings, tables and analyses. 
Results
A total of 22 participants entered the study. However, only 18 participants 
(9 male and 9 female) were included in the per protocol population, which is 
the sample of interest for the evaluation of efficacy. Two participants were not 
included because of protocol violations. In one case, the participant was tested 
positive on a urine drug test for THC. The other case was excluded because 
of participation in another clinical study in the previous three months. Two 
other participants were not included because of missing data. For the analysis of 
safety and adverse events, all 22 participants were included. Demographics are 
summarized in Table 2.
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Table 2	 Demographics	for	the	safety	population	and	the	per	protocol	population	
 
Safety population Protocol population
(N=22) (N=18)
Gender	(N	(%))
Female 11	(50) 9	(50)
Male 11	(50) 9	(50)
Race	(N	(%)) Caucasian 22	(100) 18	(100)
Age	(Years)
Mean	(SD) 29.9	(7.9) 29.5	(7.7)
Median 26.5 26.5
Min-Max 21	–	45 21	–	45
Height	(cm)
Mean	(SD) 175.8	(10.5) 175	(10.8)
Median 174.5 173
Min-Max 160	–	197 160	–	197
Weight	(kg)
Mean	(SD) 74.8 75.4	(11.7)
Median 72.5 72.5
Min-Max 57	–	105 57	–	105	
Body	Mass	Index	(kg/
m2)
Mean	(SD) 24.18	(2.4) 24.6	(2.3)
Median 23.9 24.8
Min-Max 20.2	–	28.1 20.2	–	27.1	
Note:	N	=	number	of	subjects;	SD	=	standard	deviation;	Min	=	minimum;	Max	=	maximum.
Driving performance 
A summary of descriptives and statistics on parameters from the highway driving 
test is presented in Table 3. There were no significant effects of Gender or 
Gender by Treatment on any of the driving measures. Consequently, the factor 
Gender was dropped from the model.
 The overall effects of Treatment (F3,15=12.65; p<0.001) and Treatment x 
Time of treatment (F3,15=3.64; p<0.05) on SDLP reached significance. Drug-
placebo contrasts revealed that SDLP was significantly increased after treatment 
with hydroxyzine 50 mg on day 1 (mean increase 4.76 cm; F1,17=41.82; p<0.001) 
as well as on day 8 (mean increase 2.24 cm; F1,17=14.30; p=0.001). Both bilastine 
20 mg and bilastine 40 mg did not increase SDLP relative to placebo on both 
test days. Furthermore, hydroxyzine – induced impairment was significantly 
higher on day 1 compared to day 8 (F1,17=8.2; p=0.011). Mean (+SE) SDLP in 
each condition and for both days is shown in Figure 1. 
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Figure 1 Mean	(+	SE)	SDLP	for	each	treatment	on	Day	1	and	Day	8.	Treatments	are	Placebo	(plac),	
Bilastine	20	mg	(bila	20),	bilastine	40	mg	(bila	40),	and	hydroxyzine	50	mg	(hydrox).	*	=	significant	
differences	from	placebo,	P	<	0.01.	**	=	significant	differences	from	placebo,	P	<	0.001.
 Mean speed was not significantly affected by Treatment, Time of treatment 
or Treatment x Time of treatment. However, a significant Treatment x Time of 
treatment interaction was found for SDSP (F3,15=4.32; p<0.05). Drug placebo 
contrasts revealed that the SDSP for bilastine 40 mg was significantly increased 
on day 1 (F1,17=5.25; p<0.05), but not on day 8 (F1,17=2.32; p=0.15). Similarly, 
drug placebo contrasts for hydroxyzine showed that the SDSP was significantly 
increased on day 1 (F1,17=5.87; p<0.05), but not on day 8 (F1,17=0.26; p=0.62). 
Mean (SE) scores on driving and subjective measures, and a summary of overall 
effects are presented in Table 3.
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Table 3	Mean	(SE)	scores	on	driving	and	subjective	measures	in	all	treatment	conditions	and	a	sum-
mary	of	overall	effects	of	Treatment,	Time	of	treatment	and	their	interaction.	Significant	drug-placebo	
contrast	are	indicated	by	*	(p<.05)	and	**	(p<.001).	Treatments	are	placebo	(Plac),	bilastine	20	mg	
(Bila	20),	bilastine	40	mg	(Bila	40),	and	hydroxyzine	50	mg	(Hydrox).
Driving	test Subjective	Driving	Quality
Seda-
tion
Driving	
Quality	
Rated	
by	
Instruc-
tor
Sedation	
Rated	
by	
Instruc-
tor
Sleep	
Quality
SDLP
Mean 
speed
SDSP
Pre-
test
Post-
test
Day 1
Plac 18.6	(0.7)
95.2	
(0.2)
1.7	
(0.1)
13.9	
(3.1)
25.1	
(4.3)
14.3	
(2.8)
29.6	
(2.0)
10.6	
(1.7)
0.6	
(1.2)
Bila	20 19.2	(0.9)
95.3	
(0.3)
1.7	
(0.2)
16.3	
(3.4)
28.2	
(3.6)
13.3	
(2.0)
31.8	
(3.0) 7.8	(1.7)
1.3	
(0.6)
Bila	40 18.8	(0.8)
95.3	
(0.3)
1.9	
(0.1)*
11.8	
(3.0)
25.4	
(2.7)
11.4	
(3.7)
36.6	
(3.7)*
10.7	
(3.3)
0.8	
(0.3)
Hydrox 23.1	(1.0)**
95.3	
(0.3)
1.9	
(0.1)*
14.3	
(3.1)
43.6	
(4.5)**
17.3	
(3.3)
41.4	
(3.8)**
25.4	
(4.4)*
1.6	
(0.7)
Day 8
Plac 18.9	(0.9)
95.6	
(0.3)
1.9	
(0.2)
12.7	
(3.5)
24.6	
(3.7)
12.2	
(3.6)
29.2	
(1.9)
10.0	
(1.8)
1.2	
(0.5)
Bila	20 19.3	(0.9)
95.4	
(0.3)
1.9	
(0.2)
16.1	
(3.3)
30.7	
(4.6)
18.2	
(3.9)
33.3	
(3.1)
12.6	
(4.3)
1.4	
(0.6)
Bila	40 19.4	(0.8)
95.7	
(0.2)
1.7	
(0.1)
12.8	
(3.3)
28.2	
(3.9)
14.6	
(3.7)
37.7	
(3.8)*
10.5	
(2.0)
0.8	
(0.3)
Hydrox 21.1	(1.0)*
95.4	
(0.3)
1.9	
(0.2)
26.5	
(5.1)
33.2	
(3.6)**
21.3	
(3.8)
39.6	
(4.0)**
18.6	
(3.5)*
0.7	
(0.3)
ANOVA Overall Treatment effects 
Treatment (Df = 3, 15)
F 12.7 1.2 0.4 2.6 5.3 2.0 20.8 4.5 0.6
p 0.00** NS NS NS 0.01** NS 0.00** 0.02** NS
Time of Treatment (Df = 1,17)
F 0.6 2.6 2.4 4.0 0.7 1.8 0.0 0.3 0.0
p NS NS NS NS NS NS NS NS NS
Treatment x Time of treatment (Df = 3,15)
F 3.6 0.5 4.3 2.6 0.9 2.1 0.08 1.3 1.2
p 0.04* NS 0.00** NS NS NS NS NS NS
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Subjective measurements 
No significant main effects of Treatment, Gender, or Time of treatment were 
found on the participants’ expected driving ability prior to driving. After completion 
of the driving test, subjective driving quality differed between treatments 
(F3,15=5.30; p<0.05). Drug-placebo contrasts indicated that participants rated 
their driving quality as significantly worse in the hydroxyzine 50 mg condition 
compared to placebo (F1,17=17.42; p<0.01). The driving quality rated by the 
instructor was also affected by Treatment (F1,17=10.94; p<0.01). The instructor 
rated driving performance during bilastine 40 mg and hydroxyzine 50 mg  as worse 
(F1,17=23.47; p<0.001) compared to placebo. The driving instructor rated the 
participants’ sedation as being worse in the hydroxyzine condition (F1,17=14.18; 
p<0.01) compared to the placebo condition. 
 Furthermore, no significant main effects were found for the amount 
of sedation subjectively scored by the participants on day 1 and 8. Also, no 
significant differences between conditions were detected for sleep quality prior 
to test days.  
Adverse events
No serious adverse events were recorded during the study, and safety laboratory 
data and vital signs showed no clinically relevant time- or dose- related changes. 
Treatment with bilastine (20 and 40 mg) and hydroxyzine 50 mg were generally 
safe and well tolerated. The most frequently reported in-treatment adverse events 
were headache and fatigue. Headache was mainly observed after treatment with 
bilastine 40 mg. Fatigue was mainly observed after treatment with hydroxyzine 
50 mg. A summary of adverse events reported during all treatments is given in 
Table 4. 
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Table 4 Summary	of	the	total	amount	of	adverse	events	after	placebo,	bilastine	20	mg,	bilastine	
40	mg,	and	hydroxyzine	as	indicated	by	the	participants.	
Placebo Bilastine 20 mg
Bilastine 40 
mg Hydroxyzine
(N=22) (N=22) (N=22) (N=22)
Adverse event n	(%) n	(%) n	(%) n	(%)
Headache 3	(13.6) 1	(4.6) 5	(22.7) 2	(9.1)
Dizziness 0	(0.0) 1	(4.6) 0	(0.0) 3	(13.6)
Drowsiness 0	(0.0) 0	(0.0) 1	(4.6) 2	(9.1)
Sleeplessness 0	(0.0) 0	(0.0) 0	(0.0) 1	(4.6)
Migraine 0	(0.0) 0	(0.0) 1	(4.6) 0	(0.0)
Fatigue 0	(0.0) 1	(4.6) 1	(4.6) 4	(18.2)
Fever 0	(0.0) 1	(4.6) 0	(0.0) 0	(0.0)
Dry	mouth 0	(0.0) 1	(4.6) 1	(4.6) 1	(4.6)
Abdominal	pain 1	(4.6) 0	(0.0) 1	(4.6) 1	(4.6)
Vomiting 1	(4.6) 0	(0.0) 0	(0.0) 0	(0.0)
Esophageal	
discomfort 1	(4.6) 0	(0.0) 0	(0.0) 0	(0.0)
Nausea 0	(0.0) 1	(4.6) 0	(0.0) 0	(0.0)
Diarrhea 1	(4.6) 0	(0.0) 0	(0.0) 0	(0.0)
Backache 0	(0.0) 1	(4.6) 1	(4.6) 1	(4.6)
Cold 2	(9.1) 1	(4.6) 1	(4.6) 1	(4.6)
Sinusitis	NOS 0	(0.0) 0	(0.0) 0	(0.0) 1	(4.6)
Nasal	itching 0	(0.0) 0	(0.0) 0	(0.0) 1	(4.6)
Dry	eyes 0	(0.0) 0	(0.0) 1	(4.6) 0	(0.0)
Rash 0	(0.0) 0	(0.0) 1	(4.6) 0	(0.0)
Discussion
This study has been conducted in order to assess the effects of two doses of 
bilastine (20 and 40 mg) and hydroxyzine 50 mg on actual driving performance. 
The results of this study demonstrate that bilastine 20 mg and 40 mg did not 
affect any of the driving parameters as compared to placebo, with the exception 
of bilastine 40 mg on day 1 on SDSP. Hydroxyzine 50 mg, on the other hand 
significantly impaired driving performance on both day 1 and day 8. Additionally, 
the results show that treatment with 20 and 40 mg of bilastine was generally 
safe and well tolerated. Headache and fatigue were the most frequently reported 
adverse events. 
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 Bilastine did not affect the primary driving measure (i.e. SDLP) during 
treatments with 20 and 40 mg. The only indication for a bilastine effect on 
driving came from an increase in SDSP on the first day of treatment with the 
40 mg dose. It indicates that the participants’ speed was more variable during 
that treatment. This variability however did not affect the participants’ ability to 
adhere to the instructed mean speed of 95 km/h during the driving test. Overall, 
mean speed was not affected by any treatment. The lack of bilastine effects on 
driving performance is in line with a previous report by Garcia-Gea et al. 10. They 
only observed objective psychomotor impairment after 80 mg of bilastine, but not 
after 20 and 40 mg of bilastine. Subjective reports of side effects also supported 
the findings in the standardized driving test. One participant complained of 
fatigue during bilastine 20 mg, whereas only 2 subjects reported drowsiness/
fatigue after bilastine 40 mg. Overall, these data indicate that bilastine in doses 
up to 40 mg can generally be qualified as a ‘non-sedative’ antihistamine that can 
be safely used in traffic. 
 Hydroxyzine 50 mg significantly increased SDLP after single and repeated 
administration. On day 1, hydroxyzine increased SDLP with 4.5 cm, relative to 
placebo. This change in SDLP is comparable to driving impairment observed 
after a BAC of 0.8 mg/ml in the same driving model 15. The magnitude of driving 
impairment decreased after repeated treatment with hydroxyzine. On day 8, 
SDLP was increased by 2.2 cm. This change is close to the BAC equivalent of 
0.5 mg/ml (i.e. 2.4 cm). These data thus strongly suggest that hydroxyzine 50 
mg produces severe driving impairment after single doses and mild to moderate 
driving impairment after repeated doses. 
 It is interesting to note that hydroxyzine is the first sedative antihistamine 
for which full tolerance to its impairing potential on driving performance could 
not be demonstrated. In general, it has been shown that the acute impairing 
effects of sedative antihistamines rapidly decrease over time and disappear 
within one week of treatment due to tolerance 13, 21-25. The reason for this lack 
of tolerance after sub-chronic treatment with hydroxyzine remains unclear, 
but may be related to its pharmacological profile and/or to dose. Besides 
antihistaminergic effects, hydroxyzine is also known for its anticholinergic 
effects in the CNS. Anticholinergic effects may include memory impairment, 
impaired concentration as well as drowsiness and fatigue 26, 27. Partial tolerance 
to the behavioral effects of anticholinergic drugs has been reported 28 which may 
explain why hydroxyzine’s detrimental effect on driving only partially subsided. 
 Dose may also contribute to the degree of tolerance after repeated 
hydroxyzine administration. Previous studies with lower doses of hydroxyzine (i.e. 
20 mg) demonstrated that initial sedative effects as measured with psychomotor 
tests and visual analogue scales after acute administration, disappeared after 
7 days of repeated administration when steady state concentration had been 
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achieved 29. Hydroxyzine has a long elimination half-life of 20 +/- 4.1 hrs 30 and 
usually reaches steady state concentrations within one week of dosing. However, 
it cannot be excluded that tolerance to the impairing effects of hydroxyzine 
builds up more slowly after administration of higher doses, which will lead to 
higher steady state concentrations. 
 Subjective measures furthermore indicated that before the driving test 
participants did not expect that their driving ability would be impaired by any 
of the treatments. Only after completion of the driving test did the participants 
acknowledge that their driving performance had been significantly impaired 
during treatment with hydroxyzine. This is an important finding as it indicates 
that in normal life, hydroxyzine users will be unaware of potential impairments 
when taking the decision to drive a car.  Similar findings with comparable sedative 
antihistamines have been reported before 13, 31. It underscores the notion that 
users of sedative antihistamines should receive explicit warnings about these 
drugs’ deleterious effects on driving.
 Although it is clear that the primary measure of the standard driving test 
reflects a realistic and fundamental aspect of driving, i.e. road tracking control, it 
should not be taken as a measure of overall driving performance. The latter also 
includes understanding of traffic, decision-making, risk assessment, responses to 
changes in traffic control devices, interaction with other road user and involves 
higher level driving skills demanding effortful processing and attention. Thus, 
a more complex driving test might provide a better prediction of overall driving 
performance as compared to the current standard driving test that measures 
highly automated performance at an operational level. 
 It is concluded that hydroxyzine produces severe driving impairment after 
single doses and that this impairment only partly mitigates over time due to a 
lack of complete tolerance. Bilastine on the other hand did not produce any 
driving impairment after single and repeated doses and can be safely used in 
traffic in doses up to 40 mg. 
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Abstract
Esmirtazapine at low doses is evaluated as a novel drug for the 
treatment of insomnia. The present study was designed to assess 
residual effects of single and repeated doses of esmirtazapine 1.5 mg 
and 4.5 mg on actual driving performance in 32 healthy volunteers 
in a double-blind, placebo-controlled study. Treatment with single 
doses of zopiclone 7.5 mg was included as an active control. Driving 
performance was assessed by means of a standardized on-the-road 
highway driving test.The primary study parameter was the standard 
deviation of lateral position (SDLP), a measure of “weaving” measured 
during the driving test. All subjects were subjected to CYP2D6 
phenotyping in order to distinguish poor metabolizers from extensive 
metabolizers of esmirtazapine. Overall, low doses of esmirtazapine 
(1.5 mg) did not produce any clinically relevant change in SDLP after 
single and repeated dosing compared to placebo. Driving impairment 
(i.e. a rise in SDLP) did occur after a single-dose administration of the 
higher esmirtazapine dose (4.5 mg), but was resolved after repeated 
doses. Acute driving impairment was more pronounced after both 
doses of esmirtazapine in a select group of poor metabolizers (N=7). 
A single dose of zopiclone 7.5 mg also increased SDLP as expected. It 
is concluded that a single dose and repeated administration of 1.5 mg 
esmirtazapine are generally not associated with residual impairment. 
Single-dose administration of 4.5 mg esmirtazapine was associated 
with residual impairment that generally resolved after repeated 
administration. An exploratory analysis in a small group of poor CYP 
2D6 metabolizers suggested that these subjects are more sensitive to 
the impairing effects of esmirtazapine on car driving. These results 
emphasize the need to take factors which cause inter-individual 
variability in either treatment response or drug metabolism into 
account when investigating drug effects on car driving.
Introduction
Esmirtazapine maleate (Org 50081) is the maleate salt of the S(+)-enantiomer 
of the racemic drug mirtazapine. Racemic mirtazapine is marketed for the 
treatment of major depressive disorder. Mirtazapine is a close analog of its 
predecessor mianserin that also has been marketed for major depressive 
disorder. Esmirtazapine and mirtazapine bind to presynaptic α2 receptors as well 
as to postsynaptic 5HT2 and H1 receptors where they act as antagonists of the 
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endogeneous ligands 1, 2.However, compared with mirtazapine and R-mirtazapine, 
esmirtazapine has higher affinity to 5-HT2 receptors and low affinity to the 
5-HT3 receptors and to the muscarinic receptors 3, 4. Esmirtazapine is under 
development for the treatment of primary insomnia and hot flushes. 
 Antidepressants such as mirtazapine and mianserin are well known for 
their sedative properties 2, 5. A range of studies have demonstrated that these 
drugs produce subjective fatigue and sleepiness and impair psychomotor 
function, cognition and actual driving performance after acute dosing and to a 
lesser degree also after repeated dosing 6-13. Several studies have demonstrated 
that mirtazapine increases sleep efficiency, total sleep time and slow wave sleep 
in patients with major depressive disorder and in healthy subjects 14-18. Most 
of mirtazapine’s abilities to produce daytime sedation come from H1 blockade 
which is known to reduce arousal in humans. Mirtazapine’s action at the 5-HT2A 
receptor may also contribute to its sedative effect, however, antagonism at the 
5-HT2A receptor is not thought to be responsible for the residual sedative effects 
seen following nighttime administration of mirtazapine. In clinical practice, 
antidepressant drugs with H1-antihistaminergic properties such as mirtazapine 
have been frequently used for the treatment of insomnia comorbid with various 
psychiatric disorders 19, 20. Likewise, H1-antihistamines are commonly sold over 
the counter as hypnotics drugs to treat insomnia because of their sleep inducing 
properties? 20.
 Mirtazapine and mianserin clearly have H1 inverse agonism as their 
most potent pharmacological property. Yet both drugs are dosed far above the 
minimum dose needed to obtain maximal binding to H1 receptors (i.e. 30 mg 
or more), in order to achieve sufficient serotonergic and noradrenergic action 
that is required for an antidepressant response. Mirtazapine has a > 100 fold 
higher potency for the H1 receptor than for the 5HT3 and α2 receptors, and a 
10 fold higher potency for 5HT2 1, 20. For esmirtazapine, it is postulated that 
the action on sleep is mediated via antagonism of both, the H1 and the 5-HT2A 
receptors.  The affinity of esmirtazapine to both receptors is high. Considering 
the action of these drugs on the H1 and 5HT2 receptor alone, sleep promoting 
doses of these drugs can be far lower than the regular doses prescribed to treat 
depression. Effective sleep promoting doses of esmirtazapine are expected to 
range between 1.5 and 4.5 mg. The possibility of developing esmirtazapine as a 
drug for treatment of insomnia however also raises the issue of residual daytime 
drowsiness and driving impairment since esmirtazapine elimination half life is 
long (i.e. >20 hrs). 
 The effects of H1 inverse agonism by mianserin and mirtazapine on 
actual driving performance has been assessed by means of a standardized road 
tracking task in previous studies 8, 12. Acute, daytime doses of mianserin 10 mg 
tid produced elevations in the standard deviation of lateral position (SDLP) 
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during on-the–road driving that were equivalent to the effects of a blood alcohol 
concentration (BAC) of more than 1.0 mg/mL in the same driving test. After 
sub-chronic dosing the impairing effects of mianserin reduced in magnitude 
but were still comparable to a BAC between 0.5- 0.8 mg/mL. The impairing 
effects of mianserin (30-60 mg) on daytime SDLP however where much less 
(i.e. comparable to a BAC <.05 mg/mL) when the drug was administered in 
the evening, even though blood mianserin concentrations during driving after 
nocturnal and daytime doses were comparable 9. Likewise, mirtazapine 15-30 mg 
also produced mild residual driving impairment when administered as nocturnal 
doses. Single doses of mirtazapine 15 and 30 mg produced elevations in SDLP 
that were comparable to BACs of 0.5 and 0.8 mg/mL. However, mirtazapine no 
longer produced any clinically relevant changes in driving performance after one 
or two weeks of repeated dosing.
 The effect of 5HT2A/2C antagonism on actual driving has been previously 
assessed in a study by Van Laar et al 21. That study demonstrated that single and 
repeated doses of ritanserin 5mg b.i.d. increased nocturnal slow wave sleep, but 
failed to affect driving performance and sleepiness during daytime. This finding 
supports the present notion that residual impairment from esmirtazapine, if any 
at all, is more likely to arise from H1 blockade than from 5HT2 blockade.
 The present study was designed to assess the effects of low, nocturnal doses 
of esmirtazapine on next-day actual driving performance of healthy volunteers as 
assessed in a standardized on–the-road driving test and in laboratory performance 
tasks. Esmirtazapine is metabolized through CYP2D6 and its clearance is twice 
as low in poor metabolizers as compared to extensive metabolizers 22. In the 
design phase it was decided to select a representative population for this study, 
without restrictions on CYP2D metabolizer status. This allowed for an additional 
‘post hoc’ explorative analysis on the effects of esmirtazapine on actual driving 
performance for poor and extensive metabolizers as determined by cytochrome 
P450 2D6 (CYP2D6) phenotyping. 
Methods 
Subjects
Thirty-two healthy subjects, 16 men and 16 women (mean ± SD age = 33 ± 9) 
were recruited by advertisement in local newspapers. Subjects were screened by 
a telephone interview and a health questionnaire, and all underwent a medical 
examination (including a standard 12-lead electrocardiogram, blood hematology 
and chemistry, urinalysis, and drug and pregnancy screening). Selection was 
based on the following inclusion criteria: possession of a valid driving license 
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for more than 3 years, driving experience of more than 5000 km per year on 
average, normal binocular visual acuity corrected or uncorrected, willingness to 
use double barrier method of birth control, a body mass index of 18 to 30 kg/m2 
and a written informed consent. 
 Subjects who met one or more of the following criteria were excluded 
from the study: history or present evidence of a serious illness such as renal, 
hepatic, cardiovascular, pulmonary, endocrine, neurologic or psychiatric, 
hematologic, or gastrointestinal diseases; insomnia or other sleep disorders; 
pregnancy (as determined at screening) or breastfeeding; known hypersensitivity 
to medicinal drugs; treatment with an investigational drug within 3 months prior 
to screening; use of medicines (except oral contraceptives and paracetamol); 
excessive smoking (more than 5 cigarettes a day); night work or rotation shift 
work, overconsumption of alcohol (more than 2 units per day) or caffeine (more 
than 5 cups of regular coffee a day); a positive result of urine drug screening at 
the screening visit for alcohol and/or drug of abuse.
 The study was approved by the standing medical ethics committee of 
Maastricht University and was carried out in compliance with the current revision 
of the Declaration of Helsinki, International Conference on Harmonization 
(ICH) guideline for Good Clinical Practice (GCP).
Design and treatments
The study was conducted according to a randomized, double-blind, placebo-
controlled, 4-way crossover design. Treatments were administered in separate 
7-day series, and treatment orders were balanced following a Williams design 
and assigned by a predetermined randomization schedule, stratified by gender. 
The following treatment conditions were defined:  nocturnal doses of 1.5 mg 
esmirtazapine on Day 1-7; nocturnal doses of 4.5 mg esmirtazapine on Day 1-7; 
nocturnal doses of placebo on Day 1-7; and nocturnal doses of placebo on Day 
1-6 and zopiclone 7.5 mg on Day 7. The zopiclone treatment was included to 
serve as an active control and to demonstrate (assay) sensitivity of the driving 
test to residual drug effects. Zopiclone 7.5 mg has repeatedly been shown to 
produce residual driving impairment the in standardized highway driving test 23. 
During Days 1-7 of all treatment periods, trial medication was taken by the 
subjects at their homes. Subjects recorded the time of administration in a diary. 
On Days 2-6, trial medication was taken in the evening, within 30 minutes 
before going to bed. On Day 1 and Day 7 trial medication was administered 
under supervision of a research associate at a fixed time of drug administration 
(i.e. 21:30 hrs). Subjects went to bed within 1 hr after drug intake. The washout 
period between treatments was at least 7 days.
 Driving tests and cognitive tests were conducted at Day 2 and Day 8 of 
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treatment, with the driving test starting on average 11 hrs after drug intake 
(range: between 10-11.5 hrs) and the cognitive and psychomotor tests starting 
approximately 13 hrs after drug intake. All subjects scored negative on drug 
and alcohol screens at all times, that were conducted on test days prior to 
performance testing. A blood sample was taken between the driving test and the 
cognitive psychomotor performance tests. Subjects were instructed to refrain 
from alcohol use 24 hrs prior to and throughout treatment periods. A summary 
of treatment and performance assessments on Day 2 and 8 is given in Figure 1. 
Figure 1 Summary	of	treatments	and	activities	on	Day	2	and	Day	8	 in	every	treatment	condition	
(ESM	=	esmirtazapine,	PLA=placebo,	ZOP	=	zopiclone	7.5	mg).
Performance tests
Driving and psychometric tests were trained during two separate training sessions 
prior to the first treatment condition in order to minimize learning effects.
Highway driving test
In the highway driving test 24, 25 the subjects operates a specially instrumented 
vehicle for about 1 hour over a 100 km primary highway circuit while maintaining 
a constant speed (95 km/h) and a steady lateral position between the delineated 
boundaries of the right (slower) traffic lane. An electro-optical device mounted 
at the rear back of the car continuously measures lateral distance separating the 
vehicle and the left lane-line. This signal is digitized at a rate of 4 Hz and stored 
on an onboard computer disk file for later editing analysis. The off line editing 
routine involves removal of all data segments that reveal signal loss, disturbance 
or occurrence of passing manoeuvers. The edited dataset is then used to 
calculate means and variances for lateral position. The standard deviation of 
lateral position (SDLP) is taken as the primary outcome variable. SDLP is a 
measure of road tracking error, which in practical terms is a composite index 
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of allowed weaving, swerving and overcorrecting. The highway driving test has 
been calibrated in a manner allowing expression of any sedative drug effect in 
terms of the BAC required to achieve the equivalent level of driving impairment 
26. The alcohol calibration curve demonstrates that drinkers’ mean SDLP rises 
exponentially with BAC. Results from the alcohol calibration study can be used 
for describing drugs’ effects on SDLP in terms of respective BAC equivalencies. 
The change in SDLP at a BAC of 0.5 mg/ml has been used as a criterion level 
to quantify drug effects. Any drug induced changes in SDLP that exceed this 
criterion value are defined as clinically relevant impairing drug effect in the 
present study. 
Cognitive and psychomotor tests
The word learning task is a verbal memory test for the assessment of immediate 
recall and delayed recall 27. Fifteen monosyllabic nouns sounded for 2 seconds. 
At the end of the sequence the subject is asked to recall as many words as 
possible (recall-order is unimportant). The number of correctly recalled words 
is scored as the first trial score. This procedure is repeated three times and the 
summed trial score is referred to as the Immediate Recall Score. After a delay of 
at least 20 minutes the subject is again asked to recall as many words as possible 
(without a new presentation of the nouns). This number of correctly recalled 
words is referred to as the Delayed Recall Score. The word learning task was 
conducted during the highway driving test.
 The stop signal task requires subjects to make quick key responses to 
visually presented go signals and to inhibit any response when a visual stop 
signal is suddenly presented. The current test is adapted from an earlier version 
of Fillmore et al. 28 and has been validated for showing stimulant and sedative 
drug effects 29, 30. The go signals were four 1.5 cm letters (i.e. A, B, C, and 
D) presented one at a time in the center of a computer screen. Subjects were 
required to respond to each letter as quickly as possible by pressing one of two 
response buttons. One button is pressed to indicate that “A” or “C” appeared and 
the other to indicate that “B” or “D” appeared. Letters were displayed for 500 
msec and the computer screen was blank for a 1.5 sec inter-stimulus interval 
before the next letter was displayed. This provides a period of 2 sec during which 
the subject can respond to a letter. A single test consists of 176 trials in which 
each of the 4 letter stimuli is presented equally often. A stop signal occurs in 48 
trials during a test. The stop signal consists of a visual cue (i.e. “*”), that appears 
in one of the four corners of the screen. Subjects are required to withhold any 
response when a stop-signal is presented. The task lasts about 10 minutes. The 
primary dependant variable is the reaction time in stop trials (msec). Secondary 
parameters are Response Time (msec) in go trials and number of errors in go and 
stop trials.
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 The critical tracking task measures the subject’s ability to control a displayed 
error signal in a first-order compensatory tracking task. The error is displayed as 
a horizontal deviation of a cursor from the midpoint on a horizontal linear scale. 
Compensatory joystick movements null the error by returning the cursor to the 
midpoint. The frequency at which the subject loses the control is the critical 
frequency or λc (rad/sec). The test includes five trials of which the lowest and 
the highest score are removed; the average of the remaining scores is taken as 
the final score.
 The divided attention task measures the subject’s ability to divide 
attention between two tasks performed simultaneously. The primary task 
consist of tracking task as described above but at a constant level of 
difficulty set at 50% of the subject’s maximum capacity. Tracking error is 
measured as the difference in mm between the position of the cursor and 
the midpoint of the scale. In the secondary task, the subject monitors 
a central display upon which single digits are presented at 1 second 
intervals. The occurrence of the digit “2” is a signal for the subject to 
remove the foot from a pedal as rapidly as possible. Inter stimulus interval 
varies between 1-2 sec. Mean Absolute Tracking Error (mm) and Average 
Reaction Time (msec) are the main performance measures. 
CYP2D6 phenotyping
CYP2D6 characterization was performed prior to the first intake of trial medication 
in period 1 of the 4-period cross-over sequences. Subjects received one tablet of 
dextromethorphan 30 mg together with 200 mL water before bedtime. Subjects 
had to empty their bladder pre-dose. Subsequently, subjects’ morning urine was 
collected in containers. The excretion ratio dextromethorphan/dextrorphan in 
urine determined the CYP2D6 metabolizer status of each subject. Subjects with 
an excretion ratio >= 0.3 were characterized as poor metabolizers, subject whose 
excretion ratio < 0.3 were characterized as extensive metabolizers. In total, 7 
(22%) subjects were classified as poor metabolizers (4 males and 3 females) and 
25 (78%) subjects (12 males and 13 females) as extensive metabolizers.
Pharmacokinetics
Blood samples (5 mL) for esmirtazapine determinations were collected at the 
time points indicated in Table 1 and processed to plasma. Plasma samples were 
stored and frozen at -20 °C and later analyzed by LC-MS-MS. The lower limit 
of quantification is 0.02 ng/mL.
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Statistics
Sample size was based on a power calculation for non-inferiority between 
esmirtazapine 4.5 mg and placebo after multiple dose administration with respect 
to actual driving performance as assessed by means of the SDLP. Given a mean 
population standard deviation of 4.0 cm, and a mean difference in SDLP of 0.5 
cm between multiple doses of esmirtazapine 4.5 mg and placebo, a test–retest 
>= 0.70 and a non-inferiority margin of 2.5 cm, a sample size of 26 subjects is 
sufficient to demonstrate non-inferiority with a power of at least 90% and a two-
sided α-level of 0.05. This sample size is also sufficiently large (i.e. power of at 
least 90%) for detecting a clinically relevant effect of 2.5 cm mean difference in 
SDLP between single dose zopiclone 7.5 mg and placebo to demonstrate assay-
sensitivity. Taking into account the possibility of drop-outs the total sample size 
was set at N=32 or 8 subjects per treatment cross-over sequence stratified by 
gender (i.e. 4 males and 4 females).
 Estimation of differences in SDLP between poor and extensive CYP2D6 
metabolizers was not pre-specified as an objective of this study, and hence, the 
study was not powered for these subgroup analyses. Therefore, the results of 
these subgroups have to be interpreted in the perspective of the explorative 
character of these analyses.
 Statistical analyses of the driving, cognition and psychomotor function 
parameters was done using a mixed model including fixed factors for treatment, 
period, treatment sequence, gender, day, and treatment by day interaction. 
Kenward-Roger approximation was used to estimate denominator degrees 
of freedom. Subject was included as a random factor and day as a repeated 
factor. No fixed structure was assumed for the repeated measures (co)variance. 
Least-squares estimates of contrasts to placebo and two-sided 95% confidence 
intervals (CI) were obtained from this model for single doses and multiple 
treatment doses separately. Efficacy analyses included all subjects randomly 
assigned to the treatment sequence, treated, for whom results from at least one 
driving test during treatment was available, and without any pre-defined protocol 
violations that might impact efficacy conclusions. Adverse events (AEs) were 
coded using the MedDRA dictionary. AEs occurring during the washout period 
were assigned to the treatment taken during the preceding treatment period. 
AEs that occurred before intake of zopiclone 7.5 mg in the placebo-zopiclone 
treatment period were assigned to placebo. AE tabulations included the number 
and percentage of subjects with at least one AE by MedDRA preferred term. 
Safety analyses included all subjects that were randomly assigned to treatment 
sequence and treated. For the efficacy evaluation, all complete and incomplete 
data were included in the statistical analyses (i.e. no imputation was performed 
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for missing data). Statistical analyses were performed using SAS® version 9.1.3.
The aim of the present study was to compare next-day driving performance, as 
expressed by the standard deviation of lateral position (SDLP), of esmirtazapine 
with placebo. The study was designed as a non-inferiority trial, with evaluation 
of SDLP effects in relation to a reference BAC concentration. For SDLP, non-
inferiority between treatments was concluded if the upper limit of the two-sided 
95% confidence interval (CI) of the mean difference in SDLP between drug and 
placebo below 2.5 cm. The upper limit of the non-inferiority margin is chosen 
such that it excludes with high certainty a drug effect > BAC 0.5 mg/ml, which 
is considered clinically relevant. 
Results
A total of 32 subjects entered the study. Twenty-nine subjects completed all 
four treatment periods whereas, 3 subjects prematurely discontinued. Two 
subjects dropped out during treatment with esmirtazapine 4.5 mg due to adverse 
events. In one case, the subject complained of asthenia, fatigue and muscular 
weakness starting 25 minutes after intake of the first dose and decided to stop 
study participation. This subject was a poor CYP2D6 metabolizer and the 
adverse events were considered related to study treatment. The other subject 
was discontinued after being diagnosed with breast cancer. In the judgment of 
the medical supervisor, this serious adverse event was not likely to be related to 
study treatments. Another subject dropped out between the 3rd and 4th treatment 
period because she could no longer adhere to study restrictions related to alcohol 
intake. Compliance to trial medication was 100% after single doses and multiple 
doses of all treatments. 
Highway driving, cognition and psychomotor function
Overall, mean (SD) SDLP after single doses of esmirtazapine 1.5 mg, 
esmirtazapine 4.5 mg, zopiclone 7.5 mg and placebo were 19.6 (3.6), 20.3 (3.4), 
20.6 (3.3) and 18.3 (2.9), respectively. Mean (SD) SDLP after repeated doses of 
esmirtazapine 1.5 mg, esmirtazapine 4.5 mg and placebo were 19.8 (3.6), 19.8 
(3.8) and 19.5 (3.3), respectively.
 Assay-sensitivity was clearly demonstrated as shown by the inferiority of 
zopiclone 7.5 mg to placebo: i.e. the lower limit of the 95% CI was above zero. 
Moreover, the estimated mean difference in SDLP between zopiclone and 
placebo was larger than the non-inferiority margin of 2.5 cm, with an upper 
limit of the 95% CI of 3.6 cm.
 The primary endpoint, mean difference in SDLP after multiple dose 
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treatment of esmirtazapine 4.5 mg with placebo, clearly showed non-inferiority, 
i.e. the upper limit of the 95% CI of the estimated mean difference in SDLP of 
multiple dose esmirtazapine 4.5 mg vs. placebo was lower than the non-inferiority 
margin of 2.5 cm. In agreement with this finding, the estimated mean difference 
in SDLP following single and multiple dose treatment of esmirtazapine 1.5 
mg as compared to placebo, also showed non-inferiority. However, following 
single doses of esmirtzapine 4.5 mg, non-inferiority to placebo could not be 
demonstrated;  the upper limit of the 95% CI of SDLP (3.2 cm) exceeded the 
non-inferiority margin of 2.5 cm. The mean (95% CI) differences from placebo 
in SDLP values for all treatment conditions are shown in Figure 2.
Figure 2	Mean	(95%	CI)	SDLP	difference	from	placebo	after	single	doses	of	esmirtazapine	(ESM)	and	
zopiclone	(ZOP),	and	after	multiple	doses	of	ESM.	*	=	non-inferiority	not	shown,	upper	bound	of	the	
95%	CI	is	above	the	non-inferiority	margin	of	2.5	cm.
 In total, 7 (22%) subjects were classified as poor metabolizers and 25 
(78%) subjects as extensive metabolizers. The explorative analysis on poor 
metabolizers (N=7) indicated inferiority compared to placebo following single 
dose administration of 1.5 and 4.5 mg esmirtazapine, as the upper limits of the 
95% CI of SDLP difference vs. placebo exceeded the non-inferiority margin 
and the lower limits were above zero. After multiple doses, non-inferiority was 
demonstrated for the lower dose of esmirtazapine, but not for the higher dose. 
 The analysis of the data subset from extensive metabolizers (N=25) yielded 
results similar to those obtained from the data of the entire study population. 
In extensive metabolizers, non-inferiority was shown for the mean difference vs. 
placebo in SDLP after a single dose of esmirtazapine 1.5 mg and after multiple 
doses of esmirtazapine 1.5 and 4.5mg. Non-inferiority vs. placebo was not shown 
for SDLP after a single dose of esmirtazapine 4.5 mg.  Mean (95% CI) SDLP in 
poor and extensive metabolizers is shown in Figure 3. 
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Figure 3 Mean	(95%	CI)	SDLP	difference	from	placebo	after	single	doses	of	esmirtazapine	(ESM)	
and	 zopiclone	 (ZOP)	 and	 after	multiple	 doses	 of	 ESM	 in	 poor	 (N=7)	 and	 extensive	metabolizers	
(N=25).	*	=	non-inferiority	not	shown,	upper	bound	of	the	95%	CI	is	above	the	non-inferiority	margin	
of	2.5cm.
 When comparing poor and extensive metabolizers, there were no statistically 
significant differences between the two metabolizer groups for any of the four 
treatment comparisons for interest (i.e. for the comparison of esmirtazapine 
single dose 1.5 mg to placebo (p=0.43), single dose 4.5 mg to placebo (p=0.09), 
multiple dose 1.5 mg to placebo (p=0.26), and multiple dose 4.5 mg to placebo 
(p=0.29)). It should be noted that the study was not powered to draw conclusions 
on non-inferiority within or between subgroups.
 Laboratory test demonstrated that the effects of zopiclone on cognition and 
psychomotor function were not shown to be statistically different from placebo. 
In general, the cognitive tests results for mirtazapine did not show a clear dose-
response relationship or major differences between the results following a single 
dose and multiple doses. Moreover, esmirtazapine did not show statistically 
differences from placebo for most laboratory measures, except for tracking error 
in the divided attention task. The performance on this task was statistically 
significantly worse than placebo after single and multiple doses of 1.5 mg and 
single doses of 4.5 mg esmirtazapine, but not after multiple dose of 4.5 mg 
esmirtazapine. Following esmirtazapine 1.5 mg single doses only, delayed recall 
in the word learning task and response time in the divided attention task also 
showed a statistically significant worsening compared with placebo. A summary 
of performance on cognitive and psychomotor measures is given in Table 1.
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Table 1	Mean	(SD)	difference	from	placebo	and	95%	confidence	interval	(CI)	for	cognitive	and	psy-
chomotor	measures	in	all	treatments.	*	=	significant	difference	at	5%	level;	a	=	least	square	mean	
differences	and	95%	CIs	obtained	from	mixed	model	analyses.
Parameter Drug/dose N Mean	(SD) Difference	a 95%	CI	a Significance	
Word Learning Task
Immediate
Recall	Score	
(#)
PLA	(s) 31 26.3	(4.8)
ESM	1.5	(s) 29 24.4	(5.3) -1.7 [-3.8,	0.4]
ESM	4.5	(s) 29 26.6	(5.8) 	0.4 [-1.2,	2.1]
ZOP	(s) 29 26.0	(5.1) -0.1 [-2.0,	1.8]
PLA	(m) 28 27.0	(5.7)
ESM	1.5	(m) 30 26.7	(6.5) 	0.2 [-2.3,	2.6]
ESM	4.5	(m) 30 26.8	(5.9) -0.2 [-2.7,	2.3]
Delayed
Recall	Score	
(#)
PLA	(s) 31 9.3	(2.9)
ESM	1.5	(s) 29 7.8	(3.3) -1.4 [-2.5,	-0.3] *
ESM	4.5	(s) 29 8.6	(3.6) -0.7 [-1.6,	0.2]
ZOP	(s) 28 8.7	(3.0) -0.6 [-1.5,	0.3]
PLA	(m) 28 8.9	(3.3)
ESM	1.5	(m) 30 9.4	(3.5) 	0.7 [-0.4,	1.8]
ESM	4.5	(m) 29 9.3	(3.1) 	0.6 [-0.4,	1.6]
Divided Attention Task
Tracking	
Error	(mm)
PLA	(s) 31 19.9	(3.8)
ESM	1.5	(s) 29 21.3	(4.2) 	1.4 [0.6,	2.3] *
ESM	4.5	(s) 31 21.8	(4.3) 	2.0 [0.9,	3.1] *
ZOP	(s) 29 20.1	(4.6) 	0.2 [-0.9,	1.3]
PLA	(m) 30 20.1	(4.5)
ESM	1.5	(m) 30 21.4	(4.1) 	1.2 [0.1,	2.2] *
ESM	4.5	(m) 30 21.1	(4.6) 	0.9 [-0.1,	2.0]
Respone	Time	
(msec)
PLA	(s) 31 1770	(246)
ESM	1.5	(s) 29 1899	(261) 139 [33,	246] *
ESM	4.5	(s) 31 1859	(247) 	95 [-3,	192]
ZOP	(s) 29 1833	(205) 	62 [-33,	157]
PLA	(m) 30 1783	(228)
ESM	1.5	(m) 30 1812	(202) 	27 [-50,	105]
ESM	4.5	(m) 30 1811	(211) 	30 [-49,	109]
Critical Tracking Task
Critical	Fre-
quency	(rad/
sec)
PLA	(s) 31 3.43	(0.62)
ESM	1.5	(s) 30 3.36	(0.61) -0.10 [-0.22,	0.02]
ESM	4.5	(s) 32 3.29	(0.68) -0.15 [-0.33,	0.03]
ZOP	(s) 30 3.38	(0.79) -0.05 [-0.22,	0.12]
PLA	(m) 30 3.41	(0.72)
ESM	1.5	(m) 30 3.44	(0.62) 	0.02 [-0.12,	0.16]
ESM	4.5	(m) 30 3.34	(0.70) -0.07 [-0.22,	0.08]
Stop Signal Task
Stop	Reaction	
Time	(msec)
PLA	(s) 31 288	(48)
ESM	1.5	(s) 30 292	(46) 	4 [-15,	23]
ESM	4.5	(s) 32 297	(51) 	8 [-13,	30]
ZOP	(s) 30 292	(49) 	4 [-15,	23]
PLA	(m) 30 285	(45)
ESM	1.5	(m) 30 297	(57) 	13 [-11,	36]
ESM	4.5	(m) 30 288	(49) 	3 [-18,	24]
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Pharmacokinetics
A summary of mean (SD) and median esmirtazapine concentrations is given 
in Table 2. In general, mean and median esmirtazapine concentrations in poor 
metabolizers were about twice as high as those of extensive metabolizers.
Table 2 Mean	(SD)	and	median	esmirtazapine	plasma	concentrations	(ng/mL)	in	poor	and	extensive	
metabolizers.
Extensive	metabolizers
(N=25)
Poor	Metabolizers
(N=7)
Overall
(N=32)
Esmirtazapine Day	2 Day	8 Day	2 Day	8 Day	2 Day	8
1.5	mg Mean	(SD)
0.53	
(1.02)
0.54	
(0.42)
0.67	
(0.27)
0.97	
(0.70)
0.56	
(0.91)
0.63	
(0.51)
Median 0.34 0.47 0.66 0.81 0.35 0.48
4.5	mg Mean	(SD)
1.05	
(0.44)
1.52	
(0.66)
2.07	
(0.84)
2.12	
(0.96)
1.28	
(0.70)
1.64	
(0.75)
Median 0.92 1.29 1.80 2.53 1.10 1.38
Adverse events
Treatment of esmirtazapine for 7 days was generally safe and well tolerated. 
Overall, somnolence and fatigue were the most frequently reported adverse events. 
Somnolence was mainly experienced by subjects treated with esmirtazapine 1.5 
or 4.5 mg.  A summary of adverse events reported with incidence of at least 
5% in any treatment during all treatments and during the first 24 hrs after first 
treatment dose is given in Table 3 and 4 respectively. 
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Table 3 Summary	of	adverse	events	with	an	incidence	of	at	least	5%	in	any	treatment	group.
Adverse events
Placebo Esmirtazapine1.5	mg
Esmirtazapine
4.5	mg
Zopiclone
7.5	mg
(N=31) (N=30) (N=32) (N=30)
n	(%) n	(%) n	(%) n	(%)
Fatigue 11	(35.5) 12	(40.0) 9	(28.1) 3	(10.0)
Somnolence 1	(3.2) 9	(30.0) 10	(31.3) 1	(3.3)
Headache 2	(6.5) 4	(13.3) 1	(3.1) 1	(3.3)
Poor	quality	sleep 6	(19.4) 3	(10.0) 1	(3.1) 1	(3.3)
Dysgeusia 4	(12.9) 2	(6.7) 1	(3.1) 1	(3.3)
Nasopharyngitis 1	(3.2) 2	(6.7) 1	(3.1) 0	(0.0)
Dizziness 1	(3.2) 2	(6.7) 2	(6.3) 1	(3.1)
Disturbance	in	attention 1	(3.2) 2	(6.7) 1	(3.1) 0	(0.0)
Oral	herpes 0	(0.0) 2	(6.7) 0	(0.0) 0	(0.0)
Oropharyngeal	pain 0	(0.0) 2	(6.7) 0	(0.0) 0	(0.0)
Dry	mouth 1	(3.2) 1	(3.3) 2	(6.3) 0	(0.0)
Vomiting 2	(6.5) 0	(0.0) 1	(3.1) 1	(3.3)
Irritability 2	(6.5) 0	(0.0) 0	(0.0) 0	(0.0)
Table 4	Summary	of	adverse	events	during	the	first	24	hr	after	first	drug	intake	only,	with	an	
incidence	of	at	least	5%	in	any	treatment	group.
Adverse events
Placebo Esmirtazapine1.5	mg
Esmirtazapine
4.5	mg
Zopiclone
7.5	mg
(N=31) (N=30) (N=32) (N=30)
n	(%) n	(%) n	(%) n	(%)
Fatigue 6	(19.4) 10	(33.3) 9	(28.1) 2	(6.7)
Somnolence 1	(3.2) 4	(13.3) 8	(25.0) 0	(0.0)
Dysgeusia 3	(9.7) 2	(6.7) 1	(3.1) 1	(3.3)
Disturbance	in	attention 0	(0.0) 2	(6.7) 1	(3.1) 0	(0.0)
Headache 1	(3.2) 2	(6.7) 0	(0.0) 1	(3.3)
Poor	quality	sleep 5	(16.1) 1	(3.3) 0	(0.0) 1	(3.3)
Irritability 2	(6.5) 0	(0.0) 0	(0.0) 0	(0.0)
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 After single dose administration, somnolence and fatigue were also the 
most frequently reported adverse events. Note that adverse events summarized 
under placebo were reported on two single dose days (i.e combining the 1st 
day of placebo in the zopiclone group and 1st day of placebo in the placebo 
group). Furthermore, while the single dose safety evaluation of placebo and 
esmirtazapine refer to the 1st day of treatment, the  single dose zopiclone results 
refer to the 7th day of treatment, where subjects are less likely to report AEs 
(including drug related AE) if these AE were already reported earlier during 
this treatment period while on placebo.  As can be seen in Table 4, the overall 
frequency of adverse events as well as the frequencies of reported somnolence 
and fatigue while on zopiclone is lower than that reported while on placebo.
Discussion
Overall, non-inferiority vs. placebo was demonstrated for multiple doses of 
1.5 mg and multiple doses of 4.5 mg esmirtazapine as compared to placebo. 
The results for these esmirtazapine doses indicated that the overall effects of 
esmirtazapine on car driving were mild and of no clinical relevance after one 
week of dosing. However, following a single dose of 4.5 mg esmirtazapine, non-
inferiority could not be demonstrated as compared to placebo. While the mean 
SDLP difference vs. placebo was somewhat lower than the effect observed with 
0.05 BAC, the upper limit of the 95% CI exceeded the non-inferiority margin. 
Thus, a single dose of 4.5 mg esmirtazapine produced a statistically and clinically 
significant driving impairment.  After repeated administration for one week, both 
doses of esmirtazapine did not produce any residual impairment as is evident by 
the finding that the 95% CI of mean difference in SDLP vs. placebo always 
contained zero and its upper limit was well below the non-inferiority margin. 
The finding of driving impairment after single dose of 4.5 mg but not after single 
doses of 1.5 mg esmirtazapine suggests that the acute effect of esmirtazapine on 
driving impairment is dose dependent. This effect rapidly resolves after repeated 
administration.  
 Previous studies 8, 31 on the effects of H1-antihistamines on actual driving 
performance have shown more pronounced effects on SDLP than those observed 
after esmirtazapine in the present study, however, the overall pattern was similar. 
Antidepressants with strong H1-antihistamine activity such as amitriptyline, 
imipramine and doxepin all produced significant driving impairment after single 
doses administered during the day. Difference in SDLP from placebo after 
single doses of these sedating antidepressants were comparable to those seen 
in drivers conducting the same test with a blood alcohol concentration (BAC) 
of 0.8 mg/mL or higher. The impairing effects of sedating antidepressants 
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such as mirtazapine on next-day driving performance however were markedly 
lower when given in the evening. The impairing effects of antidepressants on 
driving were mostly present after single doses but disappeared after one week 
of repeated dosing due to tolerance 8. Likewise, single doses of antihistamines 
have been demonstrated to significantly increase SDLP in a dose related 
manner 31. However, the impairing effects of antihistamines on actual driving 
also resolved after 4-7 days after repeated dosing.  In the present study, a single 
dose of esmirtazapine 4.5 mg also produced significant driving impairment, 
but the impairing effects rapidly resolved after one week of repeated dosing. 
The implications will be twofold. First, next day driving need not be a priori 
contraindicated for esmirtazapine 1.5 mg as overall it did not produce relevant 
driving impairment after single and repeated doses. Second, next day driving is 
not advised for patients taking a higher dose of esmirtazapine (i.e. 4.5 mg), but 
only during treatment initiation or initially after dose increase. 
 However, while the overall effect of esmirtazapine on driving performance 
is limited and transient, some subjects may be more susceptible to drug effects 
on driving impairment. In the case of esmirtazapine, which is a substrate for 
CYP2D6, patients who are poor metabolizers of CYP2D6 may experience 
greater impairment. In general CYP2D6 has high relevance in drug metabolism. 
CYP2D6 is involved in the metabolism of 20%–25% of clinically used 
drugs and exhibits a clinically relevant gene polymorphism that modifies the 
pharmacokinetics in patients that are either poor or extensive metabolizers 32, 
33. About 5-10% of the Caucasian populations are poor metabolizers of 
CYP2D6 substrates which may cause elevated substrate concentrations 
in blood of these individuals. In the present study, 7 subjects (22%) were 
phenotyped as poor metabolizers. Especially for 4.5 mg esmirtazapine, 
mean and median plasma concentrations of esmirtazapine were about twice as 
high as the levels observed in extensive metabolizers. Poor metabolizers also 
appeared to be more sensitive to the impairing potential of esmirtazapine. 
Increments in SDLP were more pronounced compared with placebo after single 
doses of esmirtazapine 1.5 and 4.5 mg in poor metabolizers. After a week of 
repeated dosing, the low dose of esmirtazapine no longer produced any relevant 
impairment in poor metabolizers. However, while the absolute effect on SDLP 
compared to placebo for poor metabolizers was still below the non-inferiority 
margin of 2.5 cm, the highest dose still produced an increment in SDLP after 
one week of dosing, which may indicate that tolerance to impairing effects 
of esmirtazapine may not have been complete after 7 days of dosing. These 
findings support the notion that dose effects of esmirtazapine on driving are 
closely related to the drug’s concentration in plasma.
 For the extensive metabolizers, the results were similar to those obtained in 
the main analysis. No relevant impairment was observed after single and multiple 
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doses of esmirtazapine 1.5 mg, whereas esmirtazapine 4.5 mg produced a small, 
but clinically relevant increase in SDLP only after the initial dose. 
 A limitation of this explorative analysis on poor metabolizers is (N=7) 
is that the present study was not powered to demonstrate non-inferiority 
of esmirtazapine to placebo in this small number of subjects (N=7). Small 
numbers of subjects lead to wider confidence intervals which increase the 
chance that upper limits of 95% confidence intervals exceed a pre-specified 
limit, hampering their interpretation. For example, CIs in poor metabolizers 
(N=7) are about twice as wide as those in extensive metabolizers (N=25). 
Consequently one must be cautious when comparing the upper CI limit of the 
mean difference in SDLP with placebo in poor metabolizers to a pre-established 
alcohol equivalent, as the CI may actually become less wide with increasing 
subject numbers. Nonetheless, the results of the current analysis indicated 
more pronounced driving impairment in poor metabolizers after treatment with 
esmirtazapine. Although the exact magnitude of this driving impairment should 
be determined in a larger subject sample when comparing to alcohol criterion 
levels, these results are in line with the observation that esmirtazapine has a 
dose dependent effect on driving performance, with impairment observed after 
a single dose of 4.5 mg or higher.  In subjects with higher exposure, such as 
CYP2D6 poor metabolizers, the effect on driving performance is therefore likely 
to be more pronounced and impairment may be experienced even with a lower 
dose. It should be noted that the CYP2D6 phenotype only accounts for some of 
the inter-individual variability observed in the driving performance.  While an 
effect on performance by gender and age, for example, was not observed, other 
factors may still exist that significantly influence the subject’s susceptibility to 
drug effect on car driving performance. Thus, the general implications of these 
findings with regards to clinical practice may result in a recommendation to start 
treatment with the lowest available dose until therapeutic effect and tolerability 
are evaluated. Esmirtazapine is being evaluated for the treatment of insomnia in 
the dose range of 1.5-4.5 mg. Given the acute effect of esmirtazapine at 4.5 mg 
on driving performance, a 1.5 mg/day starting dose of esmirtazapine treatment 
may be recommended until therapeutic effect and tolerance is evaluated and 
the need to increase the dose is confirmed.  
 It should be noted here that factors that influence variability in drug 
response in general, and specifically CYP2D6 phenotype, do not just pertain 
to esmirtazapine. For example, CYP2D6 is the major route of metabolism for 
many sedative CNS drugs such as antidepressants, antipsychotics, opioids and 
antihistamines 32. Previous studies on the effects of drugs on driving have never 
taken CYP2D6 genotype into account. These explorative results indicate that 
subjects with genetic CYP deviations (e.g. poor CYP2D6 metabolizers) may 
be at higher risk to be exposed to higher levels of drugs or metabolites which 
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have the potential to impair car driving. A distinction in poor and extensive 
metabolizers may be of particular importance when overall driving impairment 
levels in the general study population are mild. Based on such an overall finding, 
the conclusion would be that driving is not contraindicated for a particular 
substance. However, factors which influence exposure to these drugs need to be 
taken into account. Especially if there is a dose-response relationship between 
car driving performance and dose of the drug, then factors which increase 
exposure (e.g. gender, race, age or P450 polymorphism) are likely to display 
more pronounced car driving impairment, which may reach levels of clinical 
relevance. Consequently, it should be recommended to always take factors likely 
to affect drug exposure and response, such as cytochrome P450 polymorphism, 
into account when designing future studies on drug effects on driving.  
 In the present study, single doses of zopiclone 7.5 mg increased SDLP by 2.6 
cm over placebo. Mean difference in SDLP with placebo and its 95% CI upper 
limit exceeded the non-inferiority margin of 2.5 cm and the CI excluded zero. 
These data support findings from a number of previous studies that assessed 
the influence of zopiclone 7.5 mg on SDLP as measured in the standardized 
highway driving test 23, 34, 35. All of these studies demonstrated that evening doses 
of zopiclone produced residual driving impairment in the morning. In all studies, 
the impairing effects of zopiclone 7.5 mg where comparable to a BAC between 
0.5 and 0.8 mg/mL. In the present study, impairment after zopiclone confirmed 
the sensitivity of the highway driving test for sedative drug effects and confirmed 
previous warnings concerning driving 23, 34, 35.
 Overall, low doses of esmirtazapine (1.5 mg) did not produce any relevant 
driving impairment after single and repeated dosing. Driving impairment did 
occur after a higher single dose of emirtazapine (4.5 mg) but resolved after 
repeated doses. The explorative results on the subgroup of poor metabolizers 
(N=7) indicated more pronounced car driving impairment after both doses of 
esmirtazapine, but not on the subgroup of extensive metabolizers (N=25). In 
these individuals, impairment appeared to persist after 7 days after administration 
of the highest dose. 
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Abstract
P-glycoprotein (P-gp) is a drug efflux pump expressed, amongst others, 
on the luminal surface of the cerebral endothelial cells forming 
the blood-brain barrier. Studies in rodents have demonstrated that 
antihistamines that are substrates of the P-gp transporter display 
no or minor central nervous system (CNS) effects as compared to 
antihistamines that are not P-gp transporter substrates. The present 
study explored whether P-gp contributes in similar ways to the 
occurrence of sedative effects of antihistamines in humans.
 An fMRI study was conducted according to a double-blind, 
randomized, placebo-controlled, cross-over design in 13 healthy 
volunteers. Participants received cetirizine 15 mg (an antihistamine); 
verapamil 120 mg (a P-gp blocker); a combination of cetirizine 
+ verapamil; and a placebo. Brain activity was assessed while 
conducting the attention network task (ANT) in a 3T magnetic 
resonance scanner. The ANT measures three independent attention 
domains: i.e. alerting, orienting and executive attention. It was 
expected that the combined treatment of cetirizine with verapamil 
would prevent efflux of cetirizine from the CNS, thus increasing 
attentional impairment, as compared to cetirizine administered 
alone. 
 The present study provides evidence that the P-gp transporter is 
involved in central antihistamine effects in humans. Participants were 
less alert during the combined treatment of cetirizine and verapamil 
as indicated by longer reaction times and decreased BOLD response 
in the right superior temporal gyrus. It is concluded that the affinity 
for the P-gp transporter may contribute to the lower incidence of 
CNS side effects of certain antihistamines. 
Introduction
Sedation is a frequently occurring side effect of antihistamines (AHs) that can 
produce attentional impairments in day to day operations such as driving a car 
and working 1-8. The magnitude of sedation varies between individual AHs, but 
is more prominent in first generation AHs as compared to second generation 
AHs 5, 9-11. It is thought that the lipophilicity of first generation antihistamines 
enables them to cross the blood-brain barrier and bind to central histamine-1 
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receptors (H1Rs) whereby they reduce the wake-promoting effects of centrally 
acting histamine. Second generation antihistamines are less lipophilic and 
therefore produce less sedation 10.
 Besides lipophilicity, the presence and/or magnitude of sedation may 
also be determined by the P-glycoprotein (P-gp) transporter 12-16. P-gp 
is an efflux transporter that is expressed on the luminal surface of the 
cerebral endothelial cells forming the blood brain barrier. P-gp and other 
transporters actively pump substrates out of the brain, thereby limiting 
their effects in the central nervous system (CNS) 12, 13, 17-19.  
 Studies in experimental animal models have demonstrated that the 
P-gp transporter may reduce CNS effects of 2nd generation AHs. When 
comparing wild-type mice with P-gp knockout mice, the latter showed 
significantly higher brain distribution of non-sedative 2nd generation AHs 
such as cetirizine, loratadine, and desloratadine. On the other hand, brain 
penetration of sedative 1st generation AHs hydroxyzine, diphenhydramine, 
and triprolidine did not differ between wild-type and P-gp knockout mice 
13, 20. This apparent difference between 2nd and 1st generation AHs is in 
keeping with the knowledge that only the former are P-gp substrates 16.  
P-gp is also expressed in the small intestine, liver and kidney, and studies 
in humans have revealed that P-gp affects the pharmacokinetics of AHs. 
For example, P-gp inhibition has been shown to increase blood plasma 
concentrations of the second generation antihistamine fexofenadine 21-
23. However, to our knowledge, no human studies have been conducted 
to study the role of the P-gp transporter on pharmacodynamic effects 
caused by AHs, such as CNS sedation. Data from animal research may 
serve as a translational model for potential effects in humans, but these 
results need to be confirmed and validated in human subjects. 
 This project focused on the role of the P-gp transporter in the occurrence of 
CNS sedation after administration of cetirizine, a 2nd generation antihistamine, 
in healthy volunteers. Blocking the P-gp transporter was expected to increase 
the distribution of cetirizine and to produce more CNS sedation due to 
enhanced H1R binding in the brain. It was hypothesized that sedation after 
cetirizine would be apparent in combination with a P-gp blocker, but not when 
administered alone.
 Impairing effects of antihistamines have often been demonstrated in 
attention tasks 9, 24-26. In the present proposal we selected the Attention Network 
Test (ANT) to assess the sedative effects of cetirizine with and without P-gp 
blockade, in three independent attention domains: i.e. alerting, orienting and 
executive attention. The ANT task was conducted during functional MRI in order 
to assess drug induced changes in the neural networks underlying performance 
in the three attention domains. Previous research has shown that fMRI can be 
effectively used to examine drug induced changes in CNS functions 27, 28. 
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Methods
Subjects
Eight healthy male and eight healthy female volunteers were recruited through 
poster advertisement. However, four participants could not complete all 
sessions. Hence, data will be reported on 13 participants for the behavioural 
data (7 male and 6 female; age range 19 to 33 years; mean ± SD: 22.31 ± 3.6 
years), and 12 participants for the imaging data (7 male, 5 female; age range 
19 to 33 years; mean ± SD: 22.42 ± 3.8 years). The 13 participants had a body 
mass index between 19.3 and 24.3 kg/m² (mean ± SD: 21.25 ± 1.5). Participants 
were screened using a medical questionnaire and a physical examination. The 
latter included a 12-lead electrocardiogram evaluation, blood chemistry and 
haematology, urinalysis, and drug and pregnancy screening. 
 Volunteers with a history of medical or psychiatric illness, any major 
medical, endocrine and/or neurological condition, hypertension (diastolic>100; 
systolic>170); hypersensitivity to H1-antihistamines and/or seasonal allergic 
rhinitis or urticaria treated by antihistamines were excluded from the study. 
Additional exclusion criteria were alcohol consumption of more than 21 units 
per week; smoking; caffeine consumption of more than 6 cups per day; history 
of drug abuse or addiction; treatment with atropine or atropine-like drugs; and 
treatment with CNS depressants. Female volunteers could not participate when 
pregnant or breast feeding, and were allowed to use oral contraceptives. 
 The study was approved by the standing medical ethics committee of 
Maastricht University/University Hospital Maastricht and was carried out in 
compliance with the code of ethics on human experimentation established by 
the Declaration of Helsinki (1964), amended in Seoul (2008), and the principles 
of the International Conference on Harmonization guideline for Good Clinical 
Practice. Participants gave their written informed consent prior to study 
participation. 
Design and treatments
The study was conducted according to a randomized, double blind, 4-way cross-
over design with treatments consisting of cetirizine 15 mg, verapamil 120 mg, 
cetirizine 15 mg and verapamil 120 mg, and placebo. Cetirizine is a widely used 
H1-antihistamine for the treatment of seasonal and perennial allergic rhinitis, 
urticaria and pruritis 5, 20. It is a mildly-sedative H1-antihistamine, causing slight 
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sedation at low doses 29. Peak plasma concentrations are reached between 1 and 
1.5 hours after oral ingestion. Its half-life varies on average between 7 and 11 
hours 30.
 Verapamil is a calcium ion influx inhibitor and used in order to treat 
tachycardia, arterial fibrillation, and hypertensions. It is also known as a P-gp 
inhibitor 31-33. Peak plasma concentrations are reached between 0.5 and 1.5 
hours after oral ingestion. Its half-life varies from 7 and 15 hours 31, 34. 
 Participants visited the facility on two separate test days incorporating the 
four treatment conditions. More precisely, on each test day participants received 
two treatments and were scanned twice. The participants received either (i) 
placebo before the first scan session and verapamil 120 mg before the second 
scan session; or (ii) cetirizine 15 mg before the first scan session and verapamil 
120 mg before the second scan session. Because of the relative long half-life 
of cetirizine (7 – 11 hours), during the second scan session on day (ii) the 
combination of cetirizine with verapamil 120 mg was measured instead of only 
verapamil 120 mg. Test days were separated by a washout period of at least 
7 days. All treatments were administered as identical encapsulated tablets to 
ensure blinding, and test day order was randomized and counterbalanced across 
participants.
Procedure
Participants received a training of the tests and a habituation session before the 
first test day. Drug screens and pregnancy tests were conducted upon arrival on 
the study site. Participants had a light breakfast two hours prior to medication 
intake. Approximately one and a half hour after medication intake, blood samples 
were taken and questionnaires were filled out after which participants performed 
the Attention Network Tes (ANT) while being scanned in an event-related fMRI 
experiment.  The second medication intake was at the end of the first scan 
session, after filling out another questionnaire. Approximately one and a half 
hours after the second treatment blood samples were taken, questionnaires were 
filled out and the second scan session, which was identical to the first scan 
session, started.  A detailed flowchart of the test days is given in Figure 1.
Figure 1 Flowchart	of	the	test	days.		Pla	=	placebo;	Cet	=	cetirizine;	Ver	=	verapamil.	*	=	Because	of	
the	relative	long	half-life	(7	–	11	hours)	of	cetirizine,	during	the	second	scan	session	the	combination	
of	cetirizine	15	mg	with	verapamil	120	mg	was	measured	on	the	day	that	cetirizine	was	administered	
before	test	session	1.	
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Assessments
Pharmacokinetic assessment 
Blood samples (10 ml) for drug monitoring were collected before each scan 
session, i.e. 65 minutes post drug. The blood samples were centrifuged to 
separate plasma and frozen at −20°C. Plasma samples were analyzed after liquid-
liquid extraction using a triple quadrupole LC/MS system in MRM mode. The 
lower limits of quantification were 0.002 mg/l for verapamil and 0.003 mg/l for 
cetirizine.
Subjective evaluations
The Groningen Subjective Quality of Sleep Questionnaire (GSQS) was filled 
out at the beginning of a test day in order to assess the participants’ sleep 
quality and sleep duration of the previous night (Mulder-Hajonides, 1981). This 
questionnaire scores sleep complaints, ranging from 0 (good sleep) to 14 (bad 
sleep). 
 Before the scan sessions, subjective evaluations of alertness, contentedness 
and calmness were rated with the Bond and Lader questionnaire using visual 
analogue scales (Bond & Lader, 1974). Subjective feelings of daytime sleepiness 
were rated with the Karolinska Sleepiness Scale (KSS) which provides scores 
ranging from 1 (‘extremely alert’) to 9 (‘very sleepy’, ‘fighting sleep’) (Akerstedt 
and Gillberg, 1990).
 The Rating Scale Mental Effort (Zijlstra, 1993) was used in order to rate 
the degree of effort it took the participants to perform the scan session. The 
scale is a visual analogue scale (150 mm) with labels ranging from ‘extremely 
demanding’ to ‘not demanding at all’.
Attention Network Test (ANT)
The Attention Network Task measures three independent attention networks: 
i.e. the alerting network, the orienting network and the executive control network 
35, 36. Alerting is defined as response readiness to a warning cue (phasic alertness) 
as well as cognitive control of wakefulness and arousal (tonic alertness). 
Orienting is the allocation of attentional focus to a potentially relevant area, 
and executive control is the more complex mental operation of resolving conflict 
amongst responses 37, 38.
 During the ANT, participants are asked to determine whether a central 
arrow (the target display) points to the left or to the right. The arrow appears 
above or below a fixation point and is accompanied by four arrows that either 
point in the same direction (congruent flankers) or in the opposite direction 
(incongruent flankers). Each trial begins with the presentation of a fixation cross 
and before the display of the arrows, a warning cue may appear in the center 
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(center cue condition), above or below the fixation cross (spatial cue condition), 
or not at all (no cue condition) for 200 ms. After a variable duration (300 – 
11800 ms) the arrows appear and remain visible on the screen until a response 
is made (pressing a key indicating the direction of the target arrow) 39. The time 
between the onset of the target and the start of the next trial varies between 
3000 – 15000 ms. There are 6 runs with 38 trials (216 trials in total) in which 
combinations of the flankers and cues are randomly presented. Each run lasted 
approximately 6 minutes. Participants performed 3 runs consecutively after 
which they had a break for approximately 9 minutes. After the break, the second 
half (i.e. 3 runs) of the test was conducted. 
 Previous research conducted b Fan et al. (2005) has demonstrated strong 
modulations of the BOLD signal associated with the ANT contrasts for alerting, 
orienting and executive network in the thalamus, the parietal cortex, and the 
anterior cingulate cortex, respectively 35. In the present study, we used the same 
event-related design and the same timing parameters to study the change in 
activations of the attention networks after medication intake. In order to separate 
brain activity to the cues and targets, time intervals between cue and target and 
between target and the next trial were jittered, similarly to the Fan et al. (2005) 
study.
 Also in line with the study conducted by Fan et al. (2005), efficiency of the 
alerting network was defined as the difference in brain activity and reaction time 
(RT) between center-cue (the warning cue) and no-cue conditions;.efficiency 
of the orienting network was defined as the difference in brain activity and RT 
between center- and spatial-cue conditions; and efficiency of the executive 
network was defined as the difference in brain activity and RT between 
incongruent and congruent flankers 39.
Image acquisition
MRI data were acquired using a Siemens MAGNETOM Allegra 3T head 
Scanner with a single channel quadrature transceiver head coil. All participants 
completed 4 experimental runs. A total of 32 axial slices covering the whole 
brain were obtained using a T2*-weighted gradient echo planner pulse sequence 
(TR = 2000 ms, TE = 30 ms, FoV = 224, slice thickness = 3.5 mm, matrix 
size = 64 x 64, flip angle = 90º). Voxel size was 3.5 mm³. Slice scanning order 
was interleaved. A high-resolution T1-weighted sequence was used to collect 
structural scans (TR = 2250 ms, TE = 2.6 ms, FoV = 256, slice thickness = 1 
mm, matrix size = 256 x 256, flip angle = 90º, number of slices = 192). 
Image pre-processing
Image preprocessing was conducted using SPM8 (Statistical Parametric Mapping, 
Wellcome Department of Imaging Neuroscience, Institute of Neurology, 
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London, UK) running in Matlab R2010a (MathWorks, Natick, Massachusetts). 
The first two volumes were discarded because of the T1 saturation effect and 
images were corrected for slice scan time differences. The functional data from 
all treatment sessions were aligned to the anatomical data from the first session, 
using unwrapped fieldmaps. When translational movement of more than 3.5 mm 
from the first volume and/or rotational movement of more than 2.3 degrees were 
apparent in more than three runs, those runs were removed from the dataset 
together with all other data from that participant. When movement of more than 
3.5 mm from the first volume was apparent in fewer than three runs, movement 
parameters across treatment conditions were compared in order to evaluate 
whether there were significant differences in movement between treatment 
conditions. In case of significant differences, the data from that participant was 
also removed. Each participant’s anatomical image was linearly co-registered 
to a standard template from the Montreal Neurological Institute (MNI), and 
its functional data was co-registered with this (co-registered) anatomical data. 
Next, the anatomical data was segmented into CSF, white matter and grey 
matter, and in the same procedure the non-linear normalization parameters were 
estimated. These parameters were used to non-linearly normalize the anatomical 
and functional data to the MNI template. Finally, functional data were spatially 
smoothed using a Gaussian filter (8 mm FWHM). 
Statistical Analyses 
All subjective parameters and behavioral data were analyzed in two steps. First, 
it was determined whether performance in both 1st scan sessions and in both 2nd 
scan sessions separately differed significantly, using paired samples t-tests. More 
precisely, comparison between the 1st scan sessions were conducted to reveal 
differences between placebo and cetirizine 15 mg. Comparison between the 2nd 
scan sessions were conducted to reveal differences between verapamil 120 mg 
and verapamil + cetirizine. 
 Secondly, to determine whether verapamil modulates cetirizine effects, 
change scores were calculated for the first scan sessions (cetirizine 15 mg 
minus placebo), and the second scan sessions (verapamil 120 mg and cetirizine 
combined minus verapamil 120 mg) separately, and than compared by testing for 
significance using paired samples t-tests. 
Imaging analysis
Statistical analysis using general linear modeling (GLM) was conducted in 
order to analyze the imaging data. At the first level data in the four treatment 
conditions were analyzed separately. For each participant and treatment 
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conditions regressors were created that represented the separate trial events, 
i.e.: fixation with no cue, central cue, spatial cue (the appearance of the fixation 
slide indicated the onset of these trials), and targets with congruent flankers, 
targets with incongruent flankers (the appearance of the targets was used as 
onset time). Six realignment parameters were used as covariates. Contrast images 
consisting of t-maps (center cue minus no cue for alerting, spatial cue minus 
center cue for orienting, and incongruent minus congruent for conflict) from 
each subject were calculated. In short, GLM with (i) alerting, orienting, and 
conflict attention, (ii) the six movement parameters as independent variables, 
and (iii) the BOLD response as dependent variable was calculated. 
 At a second level of analysis, the contrast images were used in order to 
analyze the effects of treatment (cetirizine vs. placebo and verapamil vs. cetirizine 
+ verapamil) on alerting, orienting and conflict with voxel-wise paired samples 
t-tests. The regions activated for alerting, orienting, and executive attention that 
were observed by Fan et al. (2005) were used as anatomical regions of interest 
(ROI) and defined a priori in the WFU Pickatlas (Wake Forest University, 
Winston-Salem, North Carolina). For the alerting network these regions were: 
the superior temporal gyrus; superior colliculus; thalamus, inferior parietal 
lobe; fusiform gyrus; inferior frontal gyrus, and the superior parietal lobe. For 
the orienting network: the fusiform gyrus; precentral gyrus; superior parietal 
lobe; superior frontal gyrus; postcentral en precentral gyrus. For the executive 
attention network the regions included: the thalamus; superior frontal gyrus; 
inferior frontal gyrus; fusiform gyrus; middle frontal gyrus; and the anterior 
cingulated gyrus. Comparisons were thresholded at p < .05, and familywise error 
(FWE) rate was corrected with a minimum cluster of 30 voxels. If no signiﬁcant 
results were found, a less conservative threshold of false discovery rate (FDR), p 
< .05 was applied.
Results
A total of 16 right-handed participants entered the study. However, only 13 
participants (7 male and 6 female) were included in the analyses of the behavioral 
data, because 2 participants experienced the scanning session as uncomfortable 
resulting in an early termination of the session, and one subject missed the 
sessions due to personal matters. 
Pharmacokinetic assessment 
Mean (± SE) cetirizine and verapamil concentrations in the 4 treatment conditions 
are presented in Table 1. T-tests revealed that mean cetirizine concentrations, 
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when given alone, did not significantly differ from concentrations when given 
in combination with verapamil. Likewise, verapamil concentrations did not 
significantly differ when given alone as compared to when given in combination 
with cetirizine.
Table 1	Mean	±	SE	plasma	concentrations	(mg/l)	of	cetirizine	(CET)	and	verapamil	(VER)	in	every	
treatment	condition.
No P-gp blockade
(without	verapamil)
P-gp blockade
(with	verapamil)
Treatment CET	(mg/l) VER	(mg/l) CET	(mg/l) VER	(mg/l)
CET 0.15	±	0.03 N/A 0.21	±	0.01 0.08	±	0.02
PLA N/A N/A N/A 0.06	±	0.02
Subjective measurements
Sleep quality and sleep duration as assessed with the GSQS did not differ 
between nights preceding both test days. Treatments did not affect subjective 
mood, calmness, and/or contentedness as measured with the visual analogue 
scales, KSS and mental effort ratings (see Table 2).
Attention Network Test (ANT)
The combination of cetirizine and verapamil increased the difference in RT 
between center-cue and no-cue (alerting) as compared to verapamil alone (see 
Figure 2a) (t12=3.11, p=0.009). Alerting, orienting and executive attention was 
not affected by cetirizine alone as compared to placebo. Comparison of change 
scores from scan session 1 (cetirizine 15 mg minus placebo) and scan session 
2 (verapamil 120 mg + cetirizine minus verapamil 120 mg) further confirmed a 
significant difference in the effect of cetirizine on alerting with and without P-gp 
blockade (t12=-2.88, p=0.014).
 Additional analyses were conducted to identify the effect of cetirizine in two 
separate cue conditions that contribute to the alerting effect (i.e. center-cue and 
no-cue). This analysis revealed that the significant difference between placebo 
and cetirizine after P-gp blockade was caused by an increased reaction time in 
the no-cue condition (t12=3.54, p=0.004), and not in the (alerting) center-cue 
condition (t12=0.87, p=0.466) (Figure 2b). Mean (± SE) RT during the alerting, 
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orienting, and executive trials are shown in Table 2.
 Taken together, the combination of verapamil and cetirizine increased the 
difference in RT between center-cue and no-cue. Further analyses revealed 
that blocking P-gp affected responsiveness (i.e. increased RT) when no warning 
cue was apparent, whereas it did not affect responsiveness when a prior cue 
indicated that a target would appear.
Table 2 Summary	of	the	results	from	the	Attention	Network	Test	and	the	Subjective	measurements,	
divided	into	placebo	(PLA)	and	cetirizine	(CET)	with	and	without	P-gp	blockade.	Results	indicate	that	
alerting	(reaction	times	no-cue	minus	reaction	times	center-cue)	between	placebo	and	cetirizine	after	
P-gp	blockade	differed	significantly	from	each	other.	df	=	degrees	of	freedom,	VAS	=	Visual	Analogue	
Scales	(Bond	&	Lader),	KSS	=	Karolinska	Sleepiness	Scale,	SME	=	rating	Scale	of	Mental	Effort,	msec	
=	milliseconds,	mm	=	millimeter.
No P-gp blockade (without verapamil)
Attention Network Test 
(Change	in	Reaction	Times,	msec)	
Mean	change	±	SE	per	treatment Paired	samples	t-test
PLA CET t df p
	Alerting 50.17	±	12.95 38.02	±	7.73 -0.89 12 0.39
	Orienting 49.54	±	9.11 53.67	±	7.60 	0.35 12 0.73
	Executive	control 82.08	±	13.83 79.38	±	9.05 -0.17 12 0.87
Subjective measurements
Mean	change	±	SE	per	treatment Paired	samples	t-test
PLA CET t df p
	VAS	Alertness	(mm) 68.27	±	5.00 69.13	±	3.73 -2.90 12 0.78
	VAS	Contentedness	(mm) 82.23	±	4.09 81.12	±	3.60 	0.41 12 0.69
	VAS	Calmness	(mm) 79.95	±	3.61 80.95	±	2.87 -0.61 12 0.55
	KSS	(range	1	–	9) 4.15	±	0.48 4.31	±	0.47 	0.31 12 0.92
	SME	(mm) 55.77	±	8.08 62.69	±	7.39 	0.97 12 0.35
P-gp blockade (with verapamil)
Attention Network Test	
(Change	in	Reaction	Times,	msec)	
Mean	change	±	SE	per	treatment Paired	samples	t-test
PLA CET t df p
	Alerting 28.55	±	9.50 66.55	±	10.07 	3.71 12 0.009*
	Orienting 52.63	±	12.23 33.85	±	11.67 -1.13 12 0.28
	Conflict 89.14	±	11.16 95.09	±	11.69 	0.68 12 0.51
Subjective measurements
Mean	change	±	SE	per	treatment Paired	samples	t-test
PLA CET t df p
	VAS	Alertness	(mm) 70.02	±	4.66 67.81	±	3.55 	0.67 12 0.52
	VAS	Contentedness	(mm) 78.69	±	5.28 76.65	±	4.91 	0.62 12 0.55
	VAS	Calmness	(mm) 80.65	±	3.60 80.77	±	2.89 -0.11 12 0.91
	KSS	(range	1	–	9) 4.38	±	0.45 4.92	±	0.49 	1.10 12 0.29
	SME	(mm) 57.54	±	7.52 56.39	±	6.0 -0.26 12 0.35
71
Chapter 4
Figure 2a	Mean	(+	SE)	changes	in	reaction	time	(RT)	in	the	Attention	Network	Test,	divided	into	
placebo	and	cetirizine	with	and	without	P-gp	blockade.	*	=	significant	difference	from	placebo,	indi-
cating	an	increased	difference	in	RT	between	no-cue	and	center-cue	conditions	(i.e.	alerting),	p<0.05.
Figure 2b	Mean	(+	SE)	RT	between	no-cue	and	center-cue	conditions	(i.e.	alerting)	of	the	Attention	
Network	Test.		*	=	significant	differences	between	no-cue	and	center-cue	conditions,	indicating	that	
in	all	conditions	the	task	manipulation	was	as	expected,	p<0.01.	**	=	significant	difference	between	
placebo	and	cetirizine	after	P-gp	blockade	in	the	no-cue	condition,	indicating	that	the	significant	re-
sult	in	Figure	2a	is	mostly	caused	by	the	no-cue	and	not	the	center-cue	(i.e.	warning	cue)	condition,	
p<0.005.
Figure	2a
Figure	2b
Alerting Orienting Conflict
Placebo Ceterizine
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Imaging data
Data from one participant was removed from the dataset due to excessive head 
movement. Therefore 12 participants (7 male and 5 female) were included in 
the analyses of the imaging data.
Task activation
The afore-mentioned regions associated with the alerting network (center-cue 
minus no-cue), the orienting network (spatial-cue minus center-cue), and the 
executive attention network (incongruent minus congruent) were used as regions 
of interest (ROI) 35. Within these areas, we detected significant task activation 
of the alerting network in the left inferior parietal lobe (t47=4.97, p=0.009, FWE 
corrected), left inferior frontal gyrus (t47=6.35, p=0.002, FWE corrected), and 
right superior temporal gyrus (t47=6.35, p=0.002, uncorrected). See table 3 for 
details. No significant task activation was detected for orienting and executive 
attention; therefore effects of treatments on orienting and executive attention 
were not further analyzed. 
Treatment effects 
The combination of cetirizine and verapamil increased the difference in 
BOLD activation associated with alerting in the right superior temporal 
gyrus as compared to verapamil alone. More precise, the difference in brain 
activity between center-cue and no-cue (i.e. the alerting effect) was larger in 
the cetirizine/P-gp blockade combination as compared with the placebo/P-
gp blockade combination (t11=8.39, p=0.05, FWE corrected). No significant 
differences between cetirizine alone and placebo were detected.
Treatment effects in center-cue and no-cue conditions
As the behavioral data revealed that the difference between placebo and 
cetirizine after P-gp blockade was primarily located in the no-cue condition, 
BOLD effects in center-cue and no-cue conditions were analyzed separately 
to determine if a similar pattern occurs at the neural level. These analyses also 
revealed that the effect of cetirizine was prominent in the no-cue condition, but 
not in de center-cue condition. Cetirizine + verapamil decreased the BOLD 
response relative to verapamil only in the no-cue condition, which approached 
significance in the right superior temporal gyrus (t11=7.68, p=0.06, FWE 
corrected). The comparison between verapamil and cetirizine + verapamil is 
depicted in Fig 3b and shows a positive difference of verapamil over cetirizine 
+ verapamil.
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Table 3 Regions	activated	during	the	attention	network	test,	divided	into	task	activation,	treatment	
effects,	and	treatment	effects	in	the	no	cue	condition.	Results	indicate	that	3	regions	are	activated	
during	alerting,	and	that	the	right	superior	temporal	gyrus	is	affected	by	cetirizine	after	P-gp	blockade	
as	compared	to	P-gp	blockade	alone.	BA	=	Brodmann	area,	Voxel	size	=	2	x	2	x	2	mm.	*	=	p-value	
peak	voxel	uncorrected.
Task activation
Brain	area BA x y z t p Voxel
Alerting 
R	superior	temporal	gyrus	 42 	52 -38 14 4.55 0.074 		75
L	inferior	parietal	lobe 		7 -28 -52 46 4.97 0.009 163
L	inferior	frontal	gyrus 44 -46 			4 32 6.35 0.002* 231
Orienting	
-	 - - - - - - -
Executive attention 
-	 - - - - - - -
Treatment effects Alerting
Brain	area BA x y z t p Voxel
Alerting
Cetirizine vs placebo after P-gp blockade
R	superior	temporal	gyrus 48 48 -8 -2 8.39 0.050 60
Treatment effects No cue condition
Brain	area BA x y z t p Voxel
Placebo vs cetirizine after P-gp blockade
R	superior	temporal	gyrus 39 46 -62 26 7.68 0.060 33
Treatment effects Center cue condition
- - - - - - - -
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Figure 3a fMRI	results	for	the	alerting	network	of	the	Attention	Network	Test,	showing	significant	
activation	in	the	left	inferior	parietal	lobe,	left	inferior	frontal	gyrus	and	right	superior	temporal	gyrus.
Figure 3b Significant	treatment	effects	in	the	alerting	network,	showing	activation	in	the	right	su-
perior	temporal	gyrus	when	comparing	cetirizine	after	P-gp	blockade	as	compared	to	P-gp	blockade	
alone.
Figure 3c	Treatment	effect	in	the	no-cue	condition,	showing	activation	in	the	right	superior	temporal	
gyrus	when	comparing	cetirizine	after	P-gp	blockade	as	compared	to	P-gp	blockade	alone.
Discussion
The present study was conducted in order to investigate the effect of the P-gp 
transporter on the central effects of AHs in healthy volunteers. It was expected 
that blocking P-gp with verapamil would increase the distribution of the second 
generation AH cetirizine in the CNS, which would result in increased H1R 
binding, and consequently would promote CNS sedation. The present study 
supports this hypothesis both at the behavioral and the neural level.
 At the behavioral level, cetirizine combined with verapamil reduced alertness 
in the ANT task, when compared to verapamil alone and when compared to 
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cetirizine alone. This impairing effect of cetirizine was apparent in the alerting 
network, but not in the orienting and executive attention network. Moreover, 
the influence of cetirizine was most apparent in the no-cue condition, rather 
than in the central-cue condition. This implies that participants were still able 
to profit from the alerting cue in the central-cue condition in every treatment, 
but were slow in their response during cetirizine in the absence of an alerting 
cue, indicating reduced sustained attention / top-down control 40. The locus of 
the cetirizine effect contrasts with previous work showing that drug or sleep 
induced changes in alertness are mostly reflected in the center-cue condition. 
For example, caffeine decreased RT in the center-cue condition while leaving 
RT in the no-cue condition unaffected 41. Likewise, sleep deprivation increased 
RT in the center-cue conditions, but not in the no-cue condition 38. The present 
data seem to indicate that central cetirizine affected intrinsic alertness (i.e. 
vigilance) more than readiness to a target / bottom-up activation of alertness 42.
Neural effects of cetirizine on alerting were apparent in the right superior temporal 
gyrus. Bold activations in this area were more pronounced after cetirizine and 
verapamil combined in comparison to verapamil alone. Further analyses of 
treatment effects in the center-cue and no-cue condition separately revealed 
that brain activations were less in the no-cue condition after the combination 
of cetirizine and verapamil. This decrement in brain activation coincides with 
the increment in RT that was measured at the behavioral level during combined 
treatment in the no-cue condition. The neural data in the present study support 
the conclusion from behavioral data showing that cetirizine decreases alertness 
when given in combination with verapamil. 
 Both behavioral and neural data support the hypothesis that P-gp affinity 
plays an important role in the occurrence of CNS sedation associated with 
antihistamines. Cetirizine is a 2nd generation antihistamine that is known to 
produce no or only mild sedation and has often been portrayed as a ‘non-sedating’ 
antihistamine 10. In the present study, cetirizine did not affect performance or 
brain activation in the ANT task when given alone. However, when given in 
combination with a P-gp blocker, CNS sedation became apparent. This finding 
demonstrates that CNS effects of antihistamines depend on the affinity of these 
drugs for the P-gp transporter. In case of high affinities, as in 2nd generation 
antihistamines, CNS side effects can be low. In case of no affinity, as in 1st 
generation antihistamines, CNS side effects can be high.
 The current finding may also have implications for other CNS drugs that 
have affinity for the P-gp transporter. P-gp plays a role in the distribution of 
many drugs besides antihistamines, such as antipsychotics, antidepressants 
and anti-cancer treatments 12, 43-45. Concerning those treatments, P-glycoprotein 
may play a role in treatment resistance. Research has shown that, for instance, 
antipsychotics appear to be P-gp substrates, which makes them less effective in 
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the treatment of schizophrenia as P-gp reduces their distribution in the CNS 
and consequently their effectiveness 46, 47. In that case the combined use of a 
P-gp blocker with an antipsychotic may promote or prolong therapeutic efficacy 
of certain medicinal drugs. Also, it has been shown that genetic variations in 
P-gp activity can change responsiveness to antipsychotic treatment 48. More 
knowledge about these genetic variations in P-gp activity might be of importance, 
as these can explain inter-individual variations in treatment response and may 
support the development and improvement of tailor-made treatment procedures.
Task activations in the present study partly confirmed previous definitions of 
brain networks involved in ANT performance 35. Alerting effects were prominent 
in a number of predefined ROIs such as the left inferior parietal lobe, the left 
inferior frontal gyrus, and the right superior temporal gyrus, but not in the other 
predefined ROIs that have also been associated with the alerting network. Cue 
and target conditions priming the orienting and the executive attention network 
respectively, did not produce any significant fMRI task activation. The lack of 
task activation during orienting and executive attention may have been caused 
by the lower number of volunteers in the present study, relative to the study by 
Fan et al. (2005).
 Several other studies confirm the involvement of parietal and frontal 
sites in alerting 49, 50. In addition, research has shown that activation of the 
left hemisphere can be associated with phasic alertness, and right hemisphere 
activation with intrinsic (or tonic) alertness 49, 51, 52. As the no-cue condition is 
associated with intrinsic alertness, the finding of no-cue related activation in the 
superior temporal gyrus in the right hemisphere is therefore in line with these 
findings.
 In general, the finding that decrements in alertness occur after central 
actions of an antihistamine is in line with previous work demonstrating that 
blockade of H1R decreases wakefulness 10, 53-55. However, the impact of sedative 
actions on attention networks may actually differ between antihistamines. Our 
group demonstrated in a previous study that the sedative actions of hydroxyzine 
as measured with the ANT caused impairment in the executive network, but not 
in the alerting and orienting network 24. Differential effects of antihistamines 
on attention networks may be caused by differences in binding affinities for 
H1R or may be due to differences in drug pharmacology. Cetirizine is the major 
metabolite of hydroxyzine, and displays selective binding affinity for H1Rs. 
Hydroxyzine in addition also binds to cholinergic and dopaminergic receptors 
that are known to produce sedation when blocked 56. Dopamine plays an 
important modulating role in the control of executive attention 35, 37, 57 which may 
explain why antihistamines with dopaminergic action affect executive attention.
Cetirizine blood plasma concentrations with and without verapamil did not 
significantly differ from each other. Yet, mean cetirizine levels still increased by 
77
Chapter 4
40% after P-gp inhibition. As P-gp is also expressed in the small intestine, liver 
and kidney 58, this may cause P-gp inhibition to alter plasma concentrations 
of P-gp substrates. Blood samples were taken at Tmax (i.e. 1 hr after drug 
administration) after cetirizine administration and also 4 hrs after cetirizine 
administration, at the Tmax of verapamil. Cetirizine has a relatively long half-
life of 7-11 hours, but nonetheless a decline in cetirizine plasma levels would be 
expected at 4 hours after administration. That this decline was not present can 
be interpreted as indicative of P-gp inhibition by verapamil. Indeed, increments 
in drug plasma concentration have previously been reported after combined 
administration of fexofenadine, a 2nd generation antihistamine, and a P-gp 
inhibitor 21-23.
 Cetirizine did not affect subjective rating of alertness, sleepiness or mental 
effort, before or after P-gp blockade. This suggests that participants did not 
subjectively experience the sedative effect of combined cetirizine and verapamil 
use that was apparent in objective measures of CNS sedation. Such discrepancy 
between subjective and objective measures of CNS effects of antihistamines 
has been reported before in studies assessing antihistamine effects on cognition 
and driving 59, 60. It underscores the notion that users of sedating antihistamines 
should receive explicit warnings that these drugs may cause deleterious effects 
on cognition that may go unnoticed.
 In conclusion, alertness was sensitive to the combined treatment of cetirizine 
with a P-gp blocker, and both plasma levels and brain activation underpinned 
this finding. These results suggest that P-gp blockade may exacerbate the 
effects of 2nd generation antihistamines. The affinity for the P-gp transporter 
may therefore contribute to the lower incidence of CNS side effects of certain 
antihistamines. 
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Abstract
It is well known that sedative properties of antihistamines can differ 
considerably between individual drugs. Several factors have been 
suggested to determine the presence, absence and/or magnitude 
of sedation by antihistamines. Research has suggested that the 
sedative effects caused by central H1 blockade partly depend on 
the availability of histamine competing for the same receptor, and 
that this competition is affected by a mechanism related to sleep. 
Consequently, the present study was designed to compare the effects 
of evening and morning doses of the 1st generation antihistamine 
hydroxyzine on cognition. It was expected that the sedative effect 
of hydroxyzine would be apparent in the evening after an evening 
dose, but would be smaller in the morning after a morning dose 
due to the greater release of histamine shortly after awakening. 
Eighteen participants (9 femalesand 9 males) participated in a 
placebo-controlled, randomized, double-blind, 3-way cross-over 
design. Performance was assessed using several psychomotor 
tests: i.e. the divided attention task, the critical tracking task, the 
stop signal task, the attention network test and the experimental 
attention switch task. Results demonstrated that evening doses of 
hydroxyzine impaired performance on the divided attention task 
and the attention network test. Impairment after morning doses was 
generally larger in magnitude and affected performance measures 
in all tasks. It is concluded that hydroxyzine induced impairment at 
tmax is more prominent after morning doses as compared to evening 
doses and that the present study could not present direct evidence 
to substantiate the hypothesis that histamine availability inversely 
affects the magnitude of antihistamine impairment. 
Introduction 
It is well known that antihistamines produce sedation and that the magnitude of 
sedation varies between individual drugs 1-4. First generation antihistamines, such 
as hydroxyzine, induce sedation by blocking the histamine 1 receptor (H1R) in 
the central nervous system. This sedation can impair cognitive functions such as 
psychomotor speed and attention 5-7. Also, this sedation can cause impairments 
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in real life performance such as driving 1, 8-11. Understanding the mechanism of 
sedation caused by antihistamines is therefore of importance. 
 It was long assumed that the difference in sedation between antihistamines 
could be explained by their capacity to enter the brain, and their selectivity 
for the H1R 12. First generation antihistamines are lipophilic. Therefore, they 
can easily cross the blood-brain barrier and block H1Rs in the central nervous 
system 5, which causes the sedation. Because 2nd generation antihistamines are 
more lipophobic, they cause less sedation 3. However, other factors may also 
determine the presence, absence and/or magnitude of sedation. 
 In 1993, Rhoers, Clairborue, Knox, and Roth 13 demonstrated that a 
60-minutes nap selectively neutralized the sedative effects of an H1-antihistamine 
but not the sedative effects of a benzodiazepine. Other studies have also 
suggested that sleep may affect the magnitude of impairment caused by H1-
antihistamines. It was demonstrated that performance impairments produced 
by mianserin (an antidepressant with strong H1 binding potential) were much 
larger after daytime doses as compared to doses given the night before, even 
though blood concentrations of mianserin were comparable at time of testing 14, 
15. Likewise, it has been shown that residual impairments after evening doses of 
sedative H1-antihistamine with long elimination half lives, such as mirtazapine 
and dexchlorpheniramine, are mild or negligible when tested in the morning 14, 
16, 17. Together, these results suggest that the sedative effects caused by central 
H1 blockade may be reduced by a mechanism related to sleep.  
 The histaminergic neurons in the tubero-mammillary nucleus (TMN) fire 
spontaneously 18, 19 with a variation of firing across the sleep-wake cycle 20, 21. The 
firing of these neurons is highest during the waking state 22, 23, slowing during 
light slow-wave sleep, and stops during deep slow wave sleep and REM sleep 
22, 24. A study conducted in freely moving cats demonstrated that the waking 
selective histaminergic neurons resumed their activity on, or a few seconds 
before, awakening 24. Furthermore, data suggest that H1Rs are involved in the 
transition from non-rapid eye movement sleep to wakefulness 25, and that the 
histaminergic TMN neurons play an important role in initiating wakefulness 26. 
Variations in histamine release throughout the sleep wake cycle may also explain 
some of the variations in performance impairments observed after nocturnal 
and daytime doses of H1-antihistamines. It has been hypothesized that the 
mechanism responsible for the reversal of sedative effects might be mediated by 
restoring the balance between histamine release and synthesis 14, 16. If histamine 
is released during waking state and histamine synthesis continues during sleep, 
then histamine availability will be largest shortly after awakening. Consequently, 
it could be expected that H1-antihistamines are less likely to bind to H1Rs 
in times when histamine availability is highest, due to extensive competition 
between histamine and antihistamine for binding at the H1R. In the present 
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study, it was hypothesized that the behavioral effect of a sedative antihistamine 
(in this case hydroxyzine) would be apparent in the evening after an evening 
dose, but would be smaller in the morning after a morning dose due to the 
greater release of histamine shortly after awakening. 
 The impairing effects of antihistamines are often demonstrated by 
perceptual motor tasks (e.g. critical tracking) and attention tasks (e.g. divided 
attention) 2, 27-29. The present study therefore used a critical tracking task and 
two attention tasks in order to assess the impairing effects of antihistamines 
in the evening versus morning. Also, this study was used to assess whether 
antihistamines would affect impulse control. Therefore, a stop signal test and an 
attention switch test were conducted as well. Consequently, the present study 
was designed to compare the time of dosing (morning versus evening) dependent 
effects of the 1st generation antihistamine hydroxyzine on a perceptual motor 
task, two attention tasks and two impulsivity tasks in healthy volunteers.  
Methods 
Subjects
Nine healthy male and 9 healthy female volunteers (age range 21 to 28 years; 
mean ± SD: 23.4 ± 2.0 years) were recruited through poster advertisement. 
Participants were screened by means of a medical questionnaire and a physical 
examination. The latter included a 12-lead electrocardiogram evaluation, blood 
chemistry and haematology, urinalysis, and drug and pregnancy screening. 
Participants had a body mass index of 19 to 30 kg/m². Furthermore, the 
volunteers were selected for being neither extreme morning types nor extreme 
evening types, by using a Dutch questionnaire for the selection of morning and 
evening type individuals 30.
 Volunteers with a history of medical or psychiatric illness, hypersensitivity 
to H1-antihistamines, and/or seasonal allergic rhinitis or urticaria treated by 
antihistamines were excluded from the study. Additional exclusion criteria 
were alcohol consumption of more than 21 units per week; smoking; caffeine 
consumption of more than 6 cups per day; treatment by atropine or atropine 
like drugs; treatment by a drug depressant of the central nervous system, and 
regular use of sedatives. Female volunteers could not participate when pregnant 
or breast feeding, and were allowed to use oral contraceptives. The menstrual 
cycle was not taken into account during the treatment periods. 
 The study was approved by the standing medical ethics committee of 
Maastricht University and was carried out in compliance with the code of ethics 
on human experimentation established by the Declaration of Helsinki (1964) and 
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amended in Seoul (2008), and the principles of the International Conference 
on Harmonization guideline for Good Clinical Practice. Participants gave their 
written informed consent prior to study participation. 
Design and treatments
The study was conducted according to a randomized, double-blind, 3 period 
cross-over design with hydroxyzine 50 mg, and a placebo control. Hydroxyzine 
is a 1st generation antihistamine, with plasma peak concentrations reached 
between 1.7 and 2.5 hours after oral ingestion. Its half-life varies on average 
between 15.9 and 24.1 hours 31, 32. Treatment conditions were hydroxyzine 50 
mg in the evening and placebo in the morning (HYE), placebo in the evening 
and hydroxyzine 50 mg in the morning (HYM), and placebo in the evening 
and placebo in the morning conditions (PBO). As earlier studies show strong 
significant performance impairments within 1 – 2 hours after hydroxyzine intake 
33, 34, tests were performed one hour following drug or placebo intake in the 
evening, and 1 hour following drug or placebo intake in the morning (labelled 
hereafter as HYEPM, HYEAM, HYMpM, HYMAM, PBOpM and PBOAM, respectively). 
Treatment periods were separated by a washout period of at least 7 days. All 
treatments were administered as identical encapsulated tablets to ensure 
blinding.
Procedure
Participants received a training of the tests and a sleep habituation session before 
the first treatment period. Each test session consisted of an evening, night and 
morning. In test sessions, drug screens and pregnancy tests were conducted 
upon arrival on the study site. In the evening of the test session, approximately 
one hour after intake of the medication, at 8.30 pm., participants conducted 
the laboratory tests until 10.00 pm. Participants were instructed to go to bed at 
11.00 pm. They were woken up at 07.00 am, after which the medication was 
administered. One hour later the laboratory tests were conducted for the second 
time. 
Assessments
Critical Tracking Task
The critical tracking task measures the subject’s ability to control a moving 
signal on a computer screen using a joystick. The signal deviates horizontally 
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from a midpoint and the subject has to compensate for this deviation by moving 
a joystick in the opposite direction. Over time, the signal deviations increase, 
causing the subject to compensate more frequently. The frequency at which 
the subject loses control is the critical frequency (λc). The test includes five 
trials of which the lowest and the highest score are removed; the average of the 
remaining scores is taken as the final score 35.
Divided Attention Task 
The divided attention task 36 measures the ability to divide attention between 
two tasks performed simultaneously. In one, the subject performs the above 
described critical tracking task at a constant level of difficulty, set at 50% of the 
subject’s maximum capacity. In the other task, the subject monitors a central 
display upon which single digits are presented for 17 milliseconds with a variable 
inter stimulus interval between 1.03 and 1.23 seconds 37. The occurrence of the 
digit “2” is a signal for the subject to remove the foot from a pedal as rapidly as 
possible. Mean Absolute Tracking Error (mm), Average Reaction Time (ms), and 
the amount of control losses and hits are the respective performance measures 
36.
Attention Network Test 
The attention network test combines warning cues and flanker displays in order 
to study the alerting network, the orienting network and the executive control 
network 38, 39. The subject is asked to determine whether a central arrow points 
to the left or to the right. The arrow appears above or below a fixation point and 
is accompanied by four arrows that either point in the same direction (congruent 
flankers) or in the opposite direction (incongruent flankers). Before the display 
of the arrows, a cue may appear in the center (center cue condition), above or 
below a fixation cross (spatial cue condition), or not at all (no cue condition). 
Each trial begins with the presentation of a fixation cross and at some variable 
interval a cue is presented for 200 ms. Four hundred ms after the offset of the 
cue, a target display appears and remains visible on the screen until a response is 
made (pressing a key indicating the direction of the target arrow) 40. A shortened 
version of the attention network test was used in which 114 trials, consisting of 
combinations of the flankers and cues, were randomly presented. Efficiency of 
the alerting network is examined by changes in reaction time (RT) and accuracy 
(ACC) between center-cue conditions and no-cue conditions. The orienting 
network is studied by changes in RT and ACC between center- and spatial-cue 
conditions. Efficiency of the executive network is examined by changes in RT 
and ACC between incongruent flankers and congruent flankers 40.
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Stop Signal Task 
The stop signal task requires the subject to respond to visually presented 
go signals, and to inhibit any response when a visual stop signal is suddenly 
presented. The stop signal task is adapted 41 from an earlier version of Fillmore, 
Rush, & Hays (2002) and has been shown to be sensitive to sedative as well 
as to stimulant drugs. The go signals are the letters A, B, C and D, which are 
presented one at a time in the center of a computer screen. The subject is asked 
to respond to each letter as quickly as possible by pressing on of two response 
buttons. One button is pressed to indicate that “A” or “C” appeared, and the 
other to indicate “B” or “D”. Letters are displayed for 500 ms and the subject has 
in total 2 seconds to respond. 
 The test consists of 176 trials in which each of the 4 letters is presented 
equally often. A stop signal occurs in 48 trials during a test. The stop signal 
consists of an asterisk that appears in one of the four corners of the screen. 
Subjects are required to withhold any response when a stop-signal is presented. 
Stop signals are presented 48 times randomly at the following delays after the 
onset of a letter: 50, 150, 250 and 350 msec. Each delay of onset of a letter 
occurred 12 times. Trials always begin with a 500 msec preparation interval in 
which a fixation point appears on the center of the screen 42. Dependent variables 
are stop signal reaction time (SSRT), number of hits in Go-trials, number of 
failed inhibitions at stop trials (commission errors or misses), RT (Go-RT), and 
number of incorrect responses (omission errors or false alarms) at Go trials. 
Experimental Attention switch task (AST)
The experimental attention switch task (AST) is used to measure the subject’s 
ability to frequently switch attention between different task instructions 43. This 
task is an adjusted version of the task reported by Cepeda, Cepeda, et al. 44. 
The attention switch task consists of three separate blocks; two non-switch and 
one switch block. During the task, four stimulus types are randomly presented 
on the screen (1, 3, 111, or 333). During the first block, the subject is asked to 
respond to the question “what number?” by pressing a left button when the cue 
‘1’ or ‘111’ appears, and a right button when ‘3’ or ‘333’ appears. In the second 
block, the question “how many?” has to be answered by pressing the left button 
when the cue ‘1’ or ‘3’ appears, and the right button when the cue ‘111’ or ‘333’ 
appears. In the switch block, both afore-mentioned blocks are randomly mixed. 
 The non-switch blocks include 40 randomly presented trials each, 
consisting of 10 stimuli of each stimulus type. The switch block includes 80 
randomly presented trials, with 20 stimuli of each stimulus type. The questions 
are presented for 400 ms after which a stimulus is presented for 800 ms. After 
this, a 2000 ms response interval occurs before the next instruction appears. 
Dependent variables are mean non-switch RT and number of errors (computed 
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by averaging the non-switch blocks) and mean switch RT and number of errors 43.
Subjective measurements
The Groningen Subjective Quality of Sleep Questionnaire (GSQS) 45 was 
filled out at the beginning, and in the morning of a test session in order to 
asses the subject’s sleep quality and sleep duration of the previous night. This 
questionnaire scores sleep complaints, ranging from 0 (good sleep) to 14 (bad 
sleep). Before the laboratory tests, subjective evaluations of alertness and mood 
were assessed by using a series of 16 visual analogue scales (100 mm), which 
provide scores for ‘alertness’, ‘contentedness’, and ‘calmness’ 46. 
Statistics
As the main focus of this study was to detect the differences between morning 
dosing of hydroxyzine and evening dosing of hydroxyzine, it was of importance 
to exclude the possibility of carry-over effects from evening to morning sessions. 
Consequently, data were analyzed in two steps. First, it was determined whether 
the effects of hydroxyzine were significantly different from placebo by comparing 
performance following hydroxyzine with performance following placebo within 
evening and morning sessions separately, using paired samples t-tests. More 
precisely, HYEPM  was compared with PBOPM, and HYMAM was compared with 
PBOAM. This way, no carry-over effects that might occur in the other morning 
placebo (HYEAM) condition were measured. Secondly, to determine whether the 
effects of hydroxyzine differed between times of the day, change scores were 
calculated between hydroxyzine and placebo in the evening (HYEPM  minus 
PBOPM) and in the morning (HYMAM  minus PBOAM) using a paired samples 
t-test. 
 Performance in the switch task was analyzed using two two-way ANOVAs 
for evening and morning sessions separately, with Treatment (hydroxyzine and 
placebo) and Switch (non-switch and switch) as factors. In case of extreme 
values and non-normality, winsorization was applied 47. The Statistical Package 
for the Social Sciences (SPSS) version 15.0 was used for the achievement of all 
listings, tables and analyses.
Results
A total of 18 participants entered the study. However, only 17 participants (8 
male and 9 female) were included in the analyses, because one subject missed 
two treatment periods due to personal matters. 
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Effects of hydroxyzine compared to placebo
Critical Tracking Task 
There was no significant difference in the evening between hydroxyzine and 
placebo on the mean tracking (mm) of the critical tracking task. In the morning, 
the difference between hydroxyzine (mean ± SE: 3.33 ± 0.2) and placebo (mean 
± SE: 3.88 ± 0.2) was significant (t16=-4.61, p<0.001), indicating impairing 
effects of hydroxyzine. 
Divided Attention Task 
Mean (+SE) scores in the divided attention task of hydroxyzine and placebo in 
the morning and evening are presented in Figure 1a. The control losses in the 
divided attention task were significantly increased by hydroxyzine compared to 
placebo in both the evening (t16=3.14, p<0.01) and morning (t16=3.33, p<0.01). 
In the morning, but not in the evening, hydroxyzine significantly increased 
tracking error (t16=4.69, p<0.001) and slowed average RT (t16=4.21, p<0.01) 
compared with placebo. No differences in the number of hits were detected. 
Attention Network Test 
Analyses of accuracy scores in the attention network test showed that there was 
a significant difference between hydroxyzine and placebo in both the evening 
(t16=-2.25, p<0.05) and morning (t16=-2.70, p<0.05) in efficiency of executive 
attention (congruent – incongruent flankers), indicating that hydroxyzine 
impaired executive attention. There were no significant effects on orienting and 
alerting attention. Also, no significant effects were found on RTs. The mean 
(+SE) effects on accuracy of the alerting, orienting, and executive control 
network are shown in Figure 1b. 
Stop Signal Task 
There were no significant differences in the evening between hydroxyzine 
and placebo in the stop signal task. In the morning, hydroxyzine significantly 
reduced the number of hits in the Go-trials (t16=-2.60, p<0.05) and slowed Go-
RT (t16=2.23, p<0.05) as compared to placebo (see Figure 2). No differences 
were detected in the morning for the SSRT and the number of not inhibited 
responses on stop trials. 
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Figure 1a Mean	(+	SE)	results	of	the	Divided	Attention	Task,	divided	into	amount	of	control	losses,	
tracking	error	(mm),	and	average	reaction	time	(msec)	of	hydroxyzine	and	placebo	in	the	morning	
and	evening.	*	=	significant	differences	from	placebo	per	time	of	treatment,	indicating	performance	
impairment	in	the	hydroxyzine	condition,	p<0.01.	**	=	significant	differences	from	placebo	per	time	
of	treatment,	indicating	performance	impairment	in	the	hydroxyzine	condition,	p<0.001.	
Figure 1b	Mean	(+	SE)	amount	of	hits	of	hydroxyzine	and	placebo	in	the	morning	and	evening	for	
the	alerting,	orienting,	and	conflict	effect	of	the	Attentional	Network	Test.	*	=	significant	differences	
from	placebo	per	time	of	treatment	indicating	performance	impairment	in	the	hydroxyzine	condition,	
p<0.05.	
Figure 2	Mean	(+	SE)	results	of	the	Stop	Signal	Task	divided	into	amount	of	hits	on	Go-trials	and	
Go-reaction	time	(msec)	of	hydroxyzine	and	placebo	in	the	morning	and	evening.	*	=	significant	dif-
ferences	from	placebo	per	time	of	treatment	indicating	performance	impairment	in	the	hydroxyzine	
condition,	p<0.05.	
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Experimental Attention switch task 
A main effect of Switch on the number of errors was detected in the evening 
(F1,16 =6.48; p<0.05) as well as in the morning (F1,16 =12.44; p<0.01); the number 
of errors was significantly increased in the switch block. In addition, a main 
effect of Treatment on the number of errors was detected in the morning (F1,16 
=9.16; p<0.01); the number of errors was significantly increased after treatment 
with hydroxyzine. There was no significant interaction between Treatment and 
Switch. 
 Comparably, a main effect of Switch on the RT was detected in the evening 
(F1,16 =21.92; p<0.001) as well as in the morning (F1,16 =23.29; p<0.001); the RT 
was significantly increased in the switch block. An effect on RT was detected 
in the morning for Treatment (F1,16 =14.39; p<0.01). Additionally, a Treatment 
by Switch interaction (F1,16 =7.22; p<0.05) on RT was detected in the morning, 
showing a larger switch effect after treatment with hydroxyzine. 
Subjective measurements
There were no significant differences neither between, hydroxyzine and placebo, 
nor between the night before the test session and the morning after the test 
night on the Groningen subjective quality of sleep questionnaire (GSQS). 
In the Bond & Lader VAS (mm), there was a significant difference between 
hydroxyzine (mean ± SE: 74.28 ± 2.7) and placebo (mean ± SE: 79.12 ± 2.93) 
in the morning (t16=-2.58, p<0.05), but not in the evening, on contentedness. 
No significant differences on alertness and calmness were detected. 
Change scores in the evening versus change scores in the morning
Comparison of hydroxyzine’s effects in the evening and in the morning as 
measured by changes from placebo (HYEPM  - PBOPM versus HYMAM  - PBOAM) 
revealed significant differences in the critical tracking task, as well as for the 
divided attention task except for the amount of hits. Overall, performance 
was (more) impaired by hydroxyzine in the morning than in the evening dose 
condition. In the stop signal task the difference between evening and morning 
was significant for the hits in the Go-trials, and a significant effect could also 
be seen for contentedness in the Bond & Lader VAS. No significant differences 
between evening and morning effects were detected in the attention network 
test. A summary of the results of the afore-mentioned assessments are presented 
in Table 1. Also, no significant evening versus morning effect was detected in 
the experimental attention switch task. 
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Table 1 Summary	of	the	results	from	the	differences	between	change	scores	in	the	morning	(HYMAM		-	
PBOAM)	and	change	scores	in	the	evening	(HYEPM	-	PBOPM	).	Overall,	performance	was	(more)	impaired	
in	the	morning	than	in	the	evening	dose	condition.	Reaction	time	is	in	msec;	NS	=	not	significant;	df	
=	degrees	of	freedom.
Morning effect 
minus 
evening effect
Time of dosing effect 
Mean	±	SE t	 df	 p 
Critical Tracking Task 
Mean	 0.48	±	0.11	 	3.69	 16	 <	0.01	
Divided Attention Task 
Control	losses	 4.53	±	1.89	 	2.40	 16	 <	0.05	
Tracking	error	(mm)	 4.70	±	1.27	 	3.70	 16	 <	0.01	
Hits	 0.13	±	1.36	 	0.10	 16	 NS	
Reaction	time	 47.15	±	9.93	 	4.75	 16	 <	0.001	
Attentional Network Task
Accuracy
Alerting 1.35	±	1.04	 	1.29	 16	 NS	
Orienting 0.19	±	1.07	 	0.18	 16	 NS	
Conflict 1.12	±	1.75 	0.64	 16	 NS	
Reaction Time
Alerting		 -3.21	±	7.28 -0.44	 16	 NS	
Orienting	 3.59	±	9.43 	0.38	 16	 NS
Conflict	 -16.60	±	-1.42 -1.34	 16	 NS	
Stop Signal Task  
Hits	Go	trial	 8.19	±	3.61 2.27 16 <	0.05
Go	reaction	time 11.90	±	22.39 0.53 16 NS
Stop	Signal	Reaction	Time 3.55	±	16.57 0.21 16 NS
Failed	inhibitions	at	stop	trials 1.24	±	1.85 0.67 16 NS
Misses	 0.31	±	0.41 0.77 16 NS
Bond & Lader  VAS  
Alertness	 6.35	±	4.19 1.52 16 NS
Contentedness	 5.93	±	2.16 2.75 16 <	0.05
Calmness	 0.91	±	3.29 0.28 16 NS
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Discussion
The present study has been conducted in order to compare hydroxyzine induced 
impairment at tmax after morning dose and evening dose administration. It was 
expected that the sedative effect of hydroxyzine would be apparent in the 
evening after an evening dose condition, but would be smaller in the morning 
after a morning dose condition due to the larger release of histamine shortly after 
awakening and an increased competition between histamine and hydroxyzine in 
the CNS. Interestingly, the results of this study were exactly opposite to our 
hypothesis. In the evening, the sedative effects were only apparent in parts of the 
attention tasks (i.e. increased control losses in the divided attention task and the 
conflict effect of the attention network test), whereas in the morning hydroxyzine 
impairment was very prevalent in most of the performance outcomes. Moreover, 
performance impairments observed after a morning dose were significantly 
larger than those observed after an evening dose of hydroxyzine for several tasks 
(see table 1). As there were no differences in sleep quality between conditions 
on the night before and during treatment, it can be stated that performance was 
not affected by quality. 
 A possible explanation for the lack of reduced performance impairment 
in the morning can be that hydroxyzine was given too late in order to compete 
with the hypothesized larger histamine release. It is not known for how long this 
larger histamine release continues during onset of awakening. In the present 
study hydroxyzine was administered in the morning immediately after the 
participants were awakened. Also, because the tmax of hydroxyzine appears after 
approximately 1.5 hours, the possibility exists that before hydroxyzine had an 
effect on the participants’ performance, the histamine release was stabilized and 
could therefore not reduce the sedative side effects. 
 Alternatively, a larger impairment in the morning dose condition compared 
with the evening dose condition could also be explained by sleep inertia. Sleep 
inertia is the decreased performance and / or disorientation that can occur 
immediately after awakening 48, and is together with the amount of sleepiness 
and the time of being awake a predictor of alertness according to the three-
process model of alertness regulation 49. Research has shown that cognitive 
performance can be impaired for more than two hours after awakening 50, and 
that performance can be worse than after 26 hours of sleep deprivation 51. Sleep 
inertia may interact with the sedative effects of hydroxyzine to increase impairing 
effects on performance. 
 Also, daytime variations in pharmacokinetics may have contributed to the 
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hydroxyzine effect on performance. It has been reported that a morning dose of 
a lipophilic drug is absorbed faster in the morning compared with an evening 
dose 52. As hydroxyzine is a lipophilic antihistamine, a morning dose might be 
absorbed faster which can lead to a higher Cmax. This difference in absorption 
could, partially, explain the difference in the behavioral data. Unfortunately, as 
no plasma concentrations were analyzed for this study, it is not known whether 
there actually were differences in the pharmacokinetics of evening and morning 
dosing. 
 The unexpected results may also be related to the lack of knowledge 
concerning the actual histamine levels in the brain during evening and morning 
test sessions. It has been shown that brainstem histamine neurons fire rapidly 
during waking and much more slowly during NREM sleep. Likewise, groups 
of (sub) cortical neurons containing histamine have decreased activity during 
REM sleep, but are active during waking 24, 26, 53. However, the relationship 
between firing rate of histamine neurons and general histamine availability 
in the brain remains obscure. Our hypothesis assumed that histamine levels 
would be considerably higher right after awakening because of a high firing 
rate of histamine neurons. Alternatively, one could also argue that histamine 
levels progressively deplete during sleep because of a low firing rate of histamine 
neurons, and that histamine levels only gradually restore to normal after waking 
when histamine neurons become active again. In the latter scenario, histamine 
levels would temporarily be lower right after awakening when compared to 
‘regular’ histamine levels in the evening, even though histamine neurons are 
equally, or more active at both times. Low levels of histamine in the morning 
would imply less competition for H1-antihistamines to occupy H1Rs, leading to 
more pronounced impairments as observed in the present study. 
 Hydroxyzine effects were most prominent in psychomotor and attention 
tasks such as the critical tracking task, the divided attention task as well as the 
attention network test. The attention network test indicated that hydroxyzine 
affected the executive network of attention, but not the alerting and orienting 
network.  It has been argued by Fan et al. (2007) 40 that the executive network 
is primarily under control of the anterior cingulate cortex. Neuroimaging studies 
have shown that H1Rs are widely available at the anterior cingulate 54 and that 
hydroxyzine (30 mg) occupied about 70% of the H1Rs in the anterior cingulate 
after single dose administration 55. The pronounced effect of hydroxyzine on 
the executive network may thus be related to the strong H1R occupancy in the 
anterior cingulate.
 Hydroxyzine also affected performance in two impulsivity tasks (i.e. 
stop signal task and attention switch task). However, the impairing effects of 
hydroxyzine on stop signal task performance do not automatically indicate that 
hydroxyzine had a direct effect on impulse control. In the stop signal task, the 
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primary measure of impulsivity is the ability to inhibit a response when a stop-
signal is presented. This measure is represented by the stop reaction time 56, 
and the number of failed inhibitions (i.e. commission errors or misses) during 
stop trials. These parameters, though, were not significantly impaired after 
hydroxyzine. Hydroxyzine did increase RT to Go-trials and decreased the number 
of correct responses (hits Go trial) during Go-trials. However, these effects can 
be explained by a general decrease in attention as well. On the other hand, 
performance outcomes of the attention switch task show that hydroxyzine in 
the morning did impair overall performance on the switch task. The significant 
interaction of switch RT and treatment in the morning indicate that in the 
hydroxyzine morning condition the participants need more time to inhibit the 
previous task set. 
 Finally, it is of interest to notice that using the Bond & Lader VAS, only 
the feeling of contentedness was decreased by hydroxyzine in the morning. This 
decrease is in line with the cognitive impairments assessed in the morning.  The 
finding that alertness was not affected by hydroxyzine indicates that, although 
the performance after hydroxyzine was worse, the volunteers were unaware of 
the decrease in alertness. Similar findings have been reported before 1, 33, 57. It 
underscores the notion that users of hydroxyzine should receive explicit warnings 
about these drugs’ deleterious effects on cognitive performance regardless of 
time of dosing.
 To our knowledge, this is the first study to assess the sedative effects of 
hydroxyzine in relation to time of dosing in healthy participants. In summary, it 
can be concluded that hydroxyzine induced impairment at tmax is more prominent 
after morning doses as compared to evening doses and that the present study 
could not present direct evidence to substantiate the hypothesis that histamine 
availability inversely affects magnitude of antihistamine impairment. 
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Abstract
Research has suggested that the sedative effects caused by central 
H1 blockade may partly depend on the availability of histamine in 
the CNS, and that this histamine availability fluctuates during day 
and night. The aim therefore was to assess the role of time of dosing 
on the magnitude of sedation caused by H1-antihistamines. This 
was done by measuring the effect of hydroxyzine on electrocortical 
activity (event related potentials) after an evening dose, when 
histamine levels are relatively low, and after a morning dose, when 
histamine levels are higher. Event related potential (ERP) effects 
were compared to those of placebo using a within-subjects design 
in healthy volunteers. It was expected that the sedative effect of 
hydroxyzine would be prominent in the evening after an evening 
dose (i.e. increased peak latency and decreased peak amplitude), but 
would be smaller in the morning after a morning dose due to greater 
release of histamine shortly after awakening. Results demonstrated 
that treatment effects were more apparent in the morning after a 
morning dose, than in the evening after an evening dose for the 
divided attention task. Hydroxyzine effects on ERPs in the Attention 
Network test were in line with our hypotheses, but limited in 
number. It is concluded that, in general, the ERP data indicate that 
hydroxyzine induced impairment is more prominent after morning 
doses as compared to evening doses. Therefore, the present study 
could not completely establish direct evidence to confirm the 
hypothesis that histamine availability inversely affects magnitude of 
antihistamine impairment.
Introduction 
In the previous chapter it was hypothesized that the sedative antihistaminergic 
effects of 1st generation antihistamine hydroxyzine would be maximal in the 
evening when histamine levels are low, and less in the morning when histamine 
levels are high, as a result of increased competition between histamine and 
hydroxyzine in the CNS in the morning. However, the results of the behavioral 
data were opposite to the hypothesis. In the evening, the sedative effects were 
only apparent in parts of two attention tasks, whereas in the morning hydroxyzine 
impairment was very prevalent in most of the performance outcomes. Moreover, 
performance impairments observed after a morning dose were significantly 
larger than those observed after an evening dose of hydroxyzine for several tasks. 
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The present chapter focuses on the results from event-related potentials (ERPs) 
measured in the same study. 
 It has previously been demonstrated that event related potential (ERP) 
measures may show drug effects that go undetected in behavioral tasks 1. In a 
study assessing the stimulating effects of fexofenadine, the behavioral results 
of the divided attention task (DAT) showed no stimulating effects, whereas 
the stimulating effects did appear in the generated potentials 2. Additionally, 
it has been demonstrated that ERPs can serve as markers of specific stages 
of cognitive information processing in order to distinguish less noticeable 
effects 3, 4. Additionally, ERP measurements are useful in detecting sedation 
caused by antihistamines. For instance, research has shown that the sedative 
antihistamines chlorpheniramine impaired performance of an Odd-ball task and 
increased P300 latency 5, 6. 
 In the present chapter the effects were compared of the sedative 
antihistamine hydroxyzine on electrocortical activity (ERPs) during performance 
of the DAT and the Attention Network Test (ANT) after evening and morning 
dose administration. Effects were compared to those of placebo using a within-
subjects design in healthy volunteers. Using former studies as reference 7-9, it 
was expected that the peak latencies of the ERPs would be increased, and the 
peak amplitude would be decreased after hydroxyzine compared with placebo. 
Because in the morning hydroxyzine is less likely to bind at H1Rs due to more 
competition between hydroxyzine and histamine, a morning dose of hydroxyzine 
was expected to cause less sedation than an evening dose.  Therefore, it was 
hypothesized that in the morning, 1 hour after treatment with the sedative 
hydroxyzine, the peak latencies would be less increased and the peak amplitude 
would be less decreased compared with the ERP effects in the evening, 1 hour 
after treatment with hydroxyzine.
Methods 
Subjects
Eighteen healthy volunteers (9 male and 9 female; age range 21 to 28 years; mean 
± SD: 23.4 ± 2.0 years) were recruited through poster advertisement. Volunteers 
were selected for being neither extreme morning types nor extreme evening 
types, by using a Dutch questionnaire for the selection of morning and evening 
type individuals 10. Participants were screened using a medical questionnaire 
and a physical examination. The latter included a 12-lead electrocardiogram 
evaluation, blood chemistry and haematology, urinalysis, and drug and pregnancy 
screening. Participants had a body mass index of 19 to 30 kg/m². 
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 Exclusion criteria were a history of medical or psychiatric illness, 
hypersensitivity to H1-antihistamines, and/or seasonal allergic rhinitis or 
urticaria treated by antihistamines. Additionally, healthy volunteers with an 
alcohol consumption of more than 21 units per week; caffeine consumption of 
more than 6 cups per day; treatment by atropine or atropine like drugs; treatment 
by a drug depressant of the central nervous system, and regular use of sedatives 
were excluded from the study. Females could not participate when pregnant or 
breast feeding. Participants gave their written informed consent prior to study 
participation. 
 The study was approved by the standing medical ethics committee of 
University hospital Maastricht and Maastricht University, and was carried out 
in compliance with the code of ethics on human experimentation established 
by the Declaration of Helsinki (1964) and amended in Seoul (2008), and the 
principles of the International Conference on Harmonization guideline for Good 
Clinical Practice.
Design and treatments
The study was conducted according to a double blind, within-subjects design 
with hydroxyzine 50 mg and a placebo control. Hydroxyzine is a 1st generation 
antihistamine, with plasma peak concentrations between 1.7 and 2.5 hours after 
oral ingestion. Its half-life varies on average between 15.9 and 24.1 hours 11, 12. 
Treatment periods consisted of (i) hydroxyzine in the evening and placebo in the 
morning, (ii) placebo in the evening and hydroxyzine in the morning and (iii) 
placebo in the evening and placebo in the morning conditions. Earlier studies 
have shown that hydroxyzine causes performance impairments within 1-2 hours 
after intake 13, 14. Therefore, tests were conducted and ERP measurements were 
obtained one hour after drug intake in the evening, and one hour after drug 
intake in the morning. Treatment periods were separated by a washout period of 
at least 7 days and treatment order was randomized and counterbalanced across 
participants. All treatments were administered as identical encapsulated tablets 
to ensure blinding. The test battery included a number of performance tasks 
and 2 ERP paradigms that are described below. Performance data have been 
described elsewhere 15. The present report focuses on ERP data only.
Procedure
Before the first treatment period, participants received a training of the tests and 
a sleep habituation session. Each test session lasted from evening until morning. 
Participants were asked to have a light meal not less than 1 hour before arriving 
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on study site. Upon arrival on the study site, drug screens and pregnancy tests 
were conducted, and vital signs were measured. In the evening of the test session 
approximately one hour after medication intake, at 8:30 pm, the measurements 
were performed until 10:00 pm. Participants were instructed to go to bed at 
11:00 pm. Immediately after being woken up at 07:00 am, the medication was 
administered. One hour later the measurements were conducted for the second 
time. A detailed overview of the test sessions is presented in Figure 1.
Figure 1 Overview	of	test	sessions.
Assessments
Attention tests
The divided attention task (DAT) 16 measures the ability to divide attention 
between two tasks performed simultaneously. One task measures the subject’s 
ability to control a moving signal on a computer screen using a joystick 17. In the 
other task, the subject monitors a central display upon which single digits are 
presented for 17 milliseconds with a variable inter stimulus interval between 
1.03 and 1.23 seconds. The subject has to remove his foot from a pedal as 
rapidly as possible when the digit “2” (target) occurs in the center of the screen. 
When other digits (distracters) are presented in the center of the screen the 
subject is asked not to respond. In total, 75 targets and 375 distracters were 
presented. The task takes about 10 minutes, depending on the competence of 
the participant. ERPs were measured in relation to the secondary task, and ERP 
averages were calculated for targets and distracters 18. 
 The attention network test (ANT) combines warning cues and flanker 
displays in order to study the alerting network, the orienting network and the 
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executive control network 19, 20. The subject is asked to determine whether a 
central arrow points to the left or to the right by pressing a key. The arrow appears 
above or below a fixation point and is accompanied by four arrows that either 
point in the same direction (congruent flankers) or in the opposite direction 
(incongruent flankers). Before the display of the arrows, a cue may appear in 
the center (center cue condition), above or below a fixation cross (spatial cue 
condition), or not at all (no cue condition). Each trial begins with the presentation 
of a fixation cross and at some variable interval a cue is presented for 200 ms. 
Four hundred ms after the offset of the cue, a target display appears and remains 
visible on the screen until a response is made (pressing a key indicating the 
direction of the target arrow) 3. A shortened version of the attention network 
test was used in which 114 trials, consisting of combinations of the flankers 
and cues were randomly presented 15. Performing this version takes about 25 
minutes. Efficiency of the alerting network is examined by changes in latency 
and amplitude between center-cue and no-cue conditions. The orienting network 
is studied by changes in latency and amplitude between center- and spatial-
cue conditions. Efficiency of the executive network is examined by changes in 
latency and amplitude between incongruent flankers and congruent flankers 3.
Event Related Potentials
Recording - EEG activity was recorded from 32 electrodes according to the 
international 10-20 system 21, using Neuroscan software. All electrodes were 
filled with electrode-gel and were referenced to the left and right mastoid 
electrodes. The Fpz electrode was used as ground electrode. Eye movements 
were detected by horizontal and vertical electro-oculogram (EOG) recordings. 
All electrode impedances were kept below 5Ω. All signals were sampled at a 
500 Hz frequency and filtered online using a 250 Hz low-pass filter and a 0.05 
high-pass filter.
 Signal analysis - All sampled EEG and EOG epochs were filtered off-
line using a 30 Hz filter. EEGs were corrected for vertical and horizontal eye 
movements according the Gratton and Coles method 22. The EEG fragments 
within an epoch of 100 ms before target stimulus onset and 1000 ms after onset 
were averaged, using the pre-stimulus interval as baseline. The EEG fragments 
were averaged for each condition separately.
 ERP-components - The ERP-components of interest in the used tasks were 
P100, N100, N200 and P3b (from now on referred to as P300). Both N100 
and P100 are early sensory evoked components that are larger in response to 
attended than unattended stimuli 23-27. The occipital P100 is a positive peak 
which appears approximately between 80-130 ms after stimulus presentation 
24. In a former study conducted by Theunissen et al. (2006), P100 latency 
demonstrated significant effects for treatment by workload during the DAT, 
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testing the antihistamine fexofenadine. N100 is a negative component with latency 
around 140 and 200 ms 24 and is studied in experiments to examine selective or 
divided attention processes. Furthermore, research has demonstrated that target 
N100 significantly increases during alerting and orienting in the ANT 4. 
 The afore-mentioned higher-level components N200 and P300 were also 
measured. The N200 reflects attention switching processes 28 and is affected 
by conflict trials 29. The N200 occurs between 200 and 300 ms after stimulus-
onset. It has been demonstrated that during the ANT the N200 component can 
be seen from cue- and target-locked responses. Furthermore, there were small 
differences detected between congruent and incongruent target conditions 
in the ANT 3. The parietal P300 is a positive wave between 300 and 800 ms 
mostly demonstrated in discrimination tasks 30, and is a sensitive measure for 
sustained attention 31. However, as the P300 is detected in any task that requires 
stimulus discrimination, it is difficult to determine the functional implication 
of this component. More recently, it is hypothesized that P300 reveals neural 
inhibition of current activity in order to facilitate transmission of stimulus/task 
information, and is therefore related to processing of incoming information 32. 
Furthermore, research demonstrated that hydroxyzine increased P300 latency 
significantly compared with placebo and the non-sedative antihistamine 
cetirizine 8. Significant treatment effects of the antihistamine fexofenadine on 
P100 and P300 latency were also found during the DAT in former studies 18.
 For both tasks ERPs were analyzed at Fz, FCz, Cz, Pz, P3 and P4. The 
P100 component was established as the highest amplitude within a time 
window of 50-160 ms after stimulus onset, and N100 as the lowest amplitude 
within 80-180 ms. N200 was determined as the lowest amplitude within a time 
window of 180 – 300 ms, and the P300 component as the highest amplitude 
within 220-320 ms after stimulus onset. All the time windows were defined after 
inspection of the grand averages. Additionally, the latencies of these four peaks 
were included in the analysis. 
Statistics
The ERP data, that were normally distributed, were analyzed by means of paired 
samples t-test. The main focus of this study was to identify the differences 
between morning dosing of hydroxyzine and evening dosing of hydroxyzine. 
Therefore, it was of importance to exclude the possibility of carry-over effects 
from evening to morning sessions. For that reason, the effects of hydroxyzine 
(i.e. increased latency and decreased amplitude of ERPs) in the evening 
were compared with the effects of placebo in the evening, and the effects of 
hydroxyzine in the morning were compared with the effects of placebo in the 
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morning. This way, no carry-over effects that might occur in the other morning 
placebo condition were measured. 
 In case of extreme values and non-normality, winsorization was applied 33. 
The Statistical Package for the Social Sciences (SPSS) version 15.0 was used for 
the achievement of all listings, tables and analyses. 
Results
A total of 18 volunteers participated in the present experiment. However, 
because one subject missed two treatment periods due to personal matters, only 
17 participants (8 male and 9 female) were included in the analysis. All 17 
participants completed all three testing periods. 
Divided Attention Task (DAT)
The results of the ERPs in the DAT showed that overall, more impairing effects of 
hydroxyzine were apparent in the morning, as N100 latency was increased at Cz 
(t15=2.5, p=0.03), and P300 amplitude was decreased at Cz (t15=-2.8, p=0.015), 
Pz (t15=-2.1, p=0.05), P3 (t15=2.6, p=0.018) and P4 (t15=-2.2, p=0.042). In the 
evening, less impairing effects were apparent as P100 amplitude was significantly 
decreased after hydroxyzine at Fz (t15=2.6, p=0.013) while N200 and P300 
latency were increased at respectively Cz (t15=2.6, p=0.021) and Pz (t15=2.6, 
p=0.02). To summarize, the relationship between hydroxyzine treatment and 
P300 at Cz is plotted in Figure 2.
ANT
The results of the ERPs in the ANT showed that in the morning, a decreased 
alerting effect in N200 amplitude was apparent at Cz after hydroxyzine (t15=-
2.37, p<0.03). For the other attention networks no significant treatment 
effects were present for ERP latency or amplitude in the ANT. In the evening, 
significant differences in alerting effects (no cue minus center cue conditions) 
were present as indicated by an increase in P300 latency at P3 (t15=3.25, 
p=0.005) after hydroxyzine. Significant orienting effects (center cue minus 
spatial cue) were present in the evening as indicated by an increase in P300 
latency at Cz (t15=3.89, p=0.001), and a decrease in P300 amplitude at P3 (t15=-
2.46, p=0.027) after hydroxyzine treatment. No treatment effects were present 
for the conflict effect (incongruent minus congruent flankers). To summarize, 
the relationship between hydroxyzine treatment and amplitude and latency of 
the P3 peak is plotted in Figure 3. 
114
CNS impairing effects of hydroxyzine as a function of histamine availability
Figure 2 Grand	average	ERPs	at	Cz	of	the	DAT.	P300	latencies	are	shown	on	the	x-axis	in	millisec-
onds	and	amplitudes	are	presented	on	the	y-axis	in	microvolts.	In	the	morning,	target	amplitude	was	
significantly	decreased	after	hydroxyzine	treatment.
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Figure 3 Grand	average	ERPs	at	P3	in	the	center-cue	and	no-cue	conditions	of	the	ANT.	P3	peak	
latencies	are	shown	on	the	x-axis	in	milliseconds	and	amplitudes	are	presented	on	the	y-axis	in	mi-
crovolt.	The	shaded	bars	indicate	the	magnitude	of	the	alerting	effect	(center-cue	minus	no-cue)	on	
P3	latency.
Discussion
The aim of the present experiment was to compare hydroxyzine induced 
impairment after morning dose and evening dose administration. It was 
expected that the peak latency of the ERPs would increase and that the peak 
amplitude would decrease after hydroxyzine treatment compared with placebo, 
and that this effect would be less apparent in the morning due to the larger 
release of histamine shortly after awakening, and an increased competition 
between histamine and hydroxyzine in the CNS. The data does confirm that 
most ERP latencies increased and amplitudes decreased by hydroxyzine on 
several electrode positions. The results of the DAT did not confirm the second 
hypothesis as they did show that sedation was more apparent in the morning. 
However, in the ANT sedative effects of hydroxyzine were mostly apparent in 
the evening. 
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 ERP data of the DAT confirmed previous behavioral data 15 which 
demonstrated that hydroxyzine effects on divided attention task performance 
were worse in the morning as compared to the evening. Hydroxyzine did 
affect ERPs a-specifically, but the effects were mostly apparent at the P300 
component. Latencies increased and amplitudes decreased after hydroxyzine 
on several electrode positions, showing that sedation was more apparent in the 
morning instead of the evening for the targets. As the P300 component has been 
linked to facilitating the transmission of stimulus / task information 32, it can be 
concluded that this facilitation was inhibited after hydroxyzine treatment, with 
more effects in the morning condition.
 The ERP data of the ANT demonstrated that both the alerting and 
orienting network were significantly affected by hydroxyzine. During hydroxyzine 
treatment participants were less alert (i.e. had less benefit from a warning cue) 
both in the evening and in the morning. P300 amplitude during orienting tasks 
was mostly affected in the evening, indicating that participants had less benefit 
from a spatial cue after hydroxyzine. P300 latency at Cz was also affected by 
hydroxyzine during orienting, but here participants apparently had more benefit 
from a spatial cue in the hydroxyzine condition. As the effects were more 
prominent in the evening, the ERP data from the ANT appears to confirm our 
original hypothesis. However, the ERP data were not in line with the behavioral 
data of the ANT that we have presented before. These performance data showed 
that hydroxyzine impairment was apparent both in the evening and morning, 
and only during conflict tasks. The apparent conflicts between behavioral data 
and ERP data in the ANT tasks and between ERP latency and amplitude during 
orienting therefore indicate that the present ERP results of the ANT should be 
interpreted with caution. 
 A number of reasons may have accounted for the finding that hydroxyzine 
effects were generally worse after morning doses as compared to evening doses. 
First, the actual brain histamine levels during testing in the evening or morning 
are unknown and, as a consequence, the timing of hydroxyzine may have 
been incorrect. If hydroxyzine was given too late, excessive histamine release 
might already have stabilized or degraded, and therefore no longer be available 
to compete with histamine. Hydroxyzine may also have been given to early if 
histamine levels did not increase excessively after awakening but only gradually 
restored at re-activation of histamine neurons in morning. This would mean 
that histamine levels would temporarily be lower right after awakening when 
compared to ‘regular’ histamine levels in the evening, even though histamine 
neurons are equally, or more active at both times. This would also cause less 
competition for hydroxyzine to occupy H1Rs, which would explain more 
pronounced impairments in the morning as observed in this study. Secondly, 
a larger impairment in the morning dose condition compared with the evening 
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dose condition could also be explained by sleep inertia. As sleep inertia is the 
decreased performance immediately after awakening 34, it may interact with the 
sedative effects of hydroxyzine to increase impairing effects on performance. 
Thirdly, variations in pharmacokinetics during the day may have affected the 
pharmacodynamics of hydroxyzine 35. It is possible that hydroxyzine might be 
absorbed faster in the morning which can lead to a higher Cmax, which could, 
partially, contribute to differences in hydroxyzine effects observed in the present 
study.
 In summary, although the ANT data are in line with our hypotheses, these 
data should be interpreted with caution because the number of effects were 
limited and in contrast with hydroxyzine effects on behavioral parameters of 
the ANT.  ERP data of the DAT indicate that hydroxyzine induced impairment 
was more prominent after morning doses as compared to evening doses. 
Taken together, the present study could not provide unambiguous evidence to 
confirm the hypothesis that histamine availability inversely affects magnitude of 
antihistamine impairment.
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H1-antihistamines are agents that are widely used in the treatment of allergies, 
as well as in the treatment of disorders such as insomnia and anxiety. They can 
act both peripherally and in the CNS. The capacity of H1-antihistamines to 
cause CNS effects such as sleepiness and drowsiness is unwelcome in allergy 
treatment, but wanted in the treatment of insomnia and anxiety. CNS effects of 
antihistamines are caused by inverse agonism of the H1 receptors in the brain. 
The present dissertation focused on genetic and neuropharmacological factors 
that are believed to contribute to the magnitude of central CNS effects.
Behavioral effects of centrally acting H1-antihistamines
Actual driving performance
Driving a car is a complex, goal-directed behavior where several cognitive and 
psychomotor skills are used simultaneously 1, 2. Medications that cause sedation 
can impair driving performance and consequently can increase the risk of 
traffic accidents 1. Results on driving performance presented in chapters 2 and 
3 show the effects of a first generation and second generation antihistamine, 
and an agent with antihistaminergic properties on driving. Second generation 
antihistamines bilastine 20 and 40 mg did not increase the amount of weaving 
(i.e. SDLP) from placebo after single and repeated dosing (chapter 2). First 
generation H1-antihistamine hydroxyzine 50 mg, on the other hand, did impair 
driving performance, as the mean increase in the amount of weaving from 
placebo was significant after single dosing as well as after 1 week dosing (chapter 
2). Esmirtazapine 4.5 mg, an agent with H1-antihistaminergic properties, did 
show impaired driving performance after single-dose administration which 
resolved after 1 week of dosing (chapter 3). However, when focusing on poor 
metabolizers, driving performance after a single dose of esmirtazapine 1.5 mg 
impaired driving as well, and 4.5 mg of esmirtazapine did also still produce an 
increment in driving performance after 1 week of dosing (chapter 3).
 Bilastine is known to be an H1-antihistamine that is believed not to cross 
the BBB, because it consists of larger molecules compared with 1st generation 
antihistamines and because it is a P-gp substrate 3. The latter ensures that even 
if bilastine would be able to enter the brain, it will be pumped out of it by the 
P-gp transporter. Hydroxyzine is known to cross the BBB and to occupy up to 
70% of H1Rs in the prefrontal and cingulate cortices 4. Esmirtazapine is also 
known to penetrate the BBB and bind to H1 receptors in the brain. The driving 
studies presented in chapters 2 and 3 thus confirm that driving impairment of 
antihistamines largely depends on the ability of these drugs to cross the BBB 
and to cause CNS sedation.
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 The categorization system of the International Council on Alcohol, Drugs 
and Traffic Safety 5 is an important guideline of prescribing physicians and 
patients. The classification system ranks the propensity of individual drugs to 
cause driving impairment. Drugs are assigned to one of the following categories: 
(I) Presumed to be safe or unlikely to produce an effect; (II) Likely to produce 
minor or moderate adverse effects; (III) Likely to produce severe effects or 
presumed to be potentially dangerous. In order to illustrate the practical 
implications of these categories, the effects within the categories are compared 
with effects of different blood alcohol concentrations (BACs) 5. Driving 
impairment in categories (I), (II), and (III) is assumed to be equivalent to BACs 
< 0.5g/l, 0.5-0.8 g/l, and >0.8 g/l, respectively. 
 The lack of bilastine effects on driving performance (BAC <0.5 g/l) indicates 
that it is safe to operate a car during bilastine treatment and that bilastine should 
be categorized in category I. A single dose of hydroxyzine impaired driving 
comparable to impairment caused by a BAC of 0.8 g/l. These data imply that 
hydroxyzine should be categorized in category II. Our results show that even 
after 8 days of treatment, hydroxyzine is still close to a BAC of 0.5 g/l. These 
findings strongly suggest not to drive after a single dose of hydroxyzine as this 
can minor to moderate effects, and to consult a healthcare professional, even 
after repeated doses, in order to evaluate whether starting to drive is safe. The 
driving data of esmirtazapine after a night’s sleep demonstrated overall that a 
single dose of 4.5 mg is likely to produce minor or moderate adverse events, 
and should be classified in the second category, meaning that driving after this 
dosage should first be discussed with a health care professional. However, 
driving performance after a single dose of esmirtazapine 1.5 mg moves from 
being presumed to be safe in the overall population (category I), to being likely 
to produce even possible severe effects in poor metabolizers (category III). Also, 
when focusing on poor metabolizers, 4.5 mg of esmirtazapine still produced an 
increment in driving performance after 1 week of dosing. Taken together, the 
driving data presented in this dissertation underline the importance of advising 
users of antihistamines about potential hazardous effects.
 A substantial difference between the studies described in chapter 2 and 
chapter 3 is that different statistical analyses were used. In chapter 2 the effects 
of bilastine on driving performance were tested and analyzed using repeated 
measures ANOVA in a between-group design. This analysis is useful to 
determine if group outcomes are different from each other, and tells us whether 
the difference between two groups is zero or not 6, 7. The study described in 
chapter 3, on the other hand, used a non-inferiority design in order to determine 
whether the effect of esmirtazapine on driving was similar to driving with a BAC 
of less than 0.5 g/l. Non-inferiority was concluded when the upper limit of a 
two-sided 95% confidence interval of the mean difference in weaving between 
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esmirtazapine and placebo was below 2.5 cm. Even though the first method 
of repeated measures ANOVA is widely used, it might be advantageous to use 
the more strict and informative method of analysis such as the non-inferiority 
design when investigating driving safety, because this method gives, by being 
more conservative, more information about possible clinically relevant effects.
Attention
Attention is a broad term and can refer to many phenomena and processes 8, 
9, and can be thought of as the allocation of processing resources in order to 
select relevant stimuli. Attention is related to arousal, which is a global state 
of the brain ranging from deep sleep to maximum wakefulness 10. Attention 
and arousal are heterogeneous processes believed to be related in an inverted 
U-shaped function 8, 10. Low levels of arousal are associated with inattentiveness, 
mid-arousal with effective attention, and high arousal with ineffective attention. 
Present dissertation investigated the sedative actions of H1-antihistamines (i.e. 
low levels of arousal) and measured these by focusing on 4 aspects of attention, 
i.e.: divided attention (measured with the divided attention task), alerting 
attention, orienting attention, and executive control (all three measured with 
the attention network test).
 Divided attention is defined as dividing attention between two or more 
stimuli 8 and was impaired after esmirtazapine administration (chapter 3) and 
after hydroxyzine administration (chapter 5). Hydroxyzine also affected P300 
during divided attention task performance (chapter 6). P300 is associated 
with facilitating transmissions of stimulus information 11 and is known to be 
modulated by attention 8. Therefore, the ERP results support the conclusion 
that central antihistaminergic effects impair divided attention.
 The attention network test (ANT) measures alerting, orienting, and 
executive control. Alerting is defined as response readiness to a warning cue 
(phasic alertness) as well as cognitive control of wakefulness and arousal (tonic 
alertness) 12. Centrally acting cetirizine (caused by blocking the P-gp efflux 
transporter) did affect alerting. Cetirizine impaired the response to no-cue 
conditions as evidenced by prolonged reaction times and a decrement in brain 
activation in the right superior temporal gyrus (chapter 4). Both findings confirm 
that centrally acting cetirizine impairs wakefulness. Orienting is the allocation 
of attentional focus to a potentially relevant area. Hydroxyzine affected ERP 
measures of orienting (chapter 6) but did not impair behavioral measures (chapter 
5). Executive control is the more complex operation of resolving conflict amongst 
responses. Hydroxyzine impaired behavioral measures of executive attention 
(chapter 5), but not ERP measures (chapter 6). The discrepancy between 
behavioral and ERP measures might be caused by using a shorter version of the 
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ANT, thereby lessening the valid use of the test. It is suggested to repeat these 
studies using the complete attention network test. 
The difference in behavior when comparing ANT results between centrally acting 
cetirizine and hydroxyzine might be caused by chemical and pharmacological 
differences between both H1-antihistamines. Cetirizine is the major metabolite 
of hydroxyzine and is more selective for H1 receptors. Hydroxyzine also affects 
other receptors that might be involved in sedation such as dopamine D2 receptors 
13. Indeed, it is believed that executive attention is modulated by dopamine 12, 
14, 15. Further research into the effects of hydroxyzine on the complete attention 
network test could confirm this assumption. 
Impulsivity and attention
Impulsivity is a construct in personality theories associated with acting unplanned 
without considering the consequences 16. Behaviors reflecting impulsivity are, 
amongst other, (lack of) response inhibition and attention switching 16, 17, and 
these can be affected by pharmacological factors 18. In the present dissertation, 
response inhibition was measured by means of a Stop Signal Task, and attention 
switching by means of an Attention Switch Task. 
 Esmirtazapine did not affect response inhibition (chapter 3), which could 
mean that impulsivity is not affected by central H1-antihistamine. Hydroxyzine, 
on the other hand, did affect the Stop Signal Task outcomes (chapter 4). However, 
hydroxyzine did not affect the parameter representing response inhibition, but 
increased reaction times and decreased the number of correct responses. These 
effects can be explained by a general decrease in attention, indicating again 
that impulsivity was not affected. That this general decrease in attention was 
only present after hydroxyzine treatment and not present after treatment with 
esmirtazapine, can be explained by the fact that hydroxyzine also affects other 
receptors that might be involved in sedation such as dopamine D2 receptors 13. 
Attention switching was impaired by central antihistamine effects caused by 
hydroxyzine (chapter 4). Switching between two tasks reflects the degree of 
readiness to perform a task, as well as the ability to inhibit earlier information. 
It is therefore believed that attention switching poses high demands on 
impulsivity, but also on attention 16, 19. It could be argued that the impairment 
in attention switching after hydroxyzine may therefore indicate that lower levels 
of arousal increased the time needed to inhibit a previous task set (i.e. impaired 
impulsivity), but also that attention may have been impaired. 
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Subjective measurements
Subjective feelings of sedation were measured using visual analogue scales. 
Results show that participants did not acknowledge sedative central antihistamine 
effects (chapter 2, 4, 5) even though sedation was demonstrated objectively. 
Participants did not expect that hydroxyzine would affect their driving ability, 
but acknowledged that their driving had been impaired after completion of the 
driving test (chapter 2). The lack of subjective awareness of impairments caused 
by antihistamines has also been found in previous research 20, 21, and further 
underscores the notion that users of sedative antihistamines should receive 
explicit warnings about possible deleterious effects.
Mechanisms of central H1-antihistamine action
Human variability in CYP2D6 metabolism
It was hypothesized that the variability in CYP2D6 metabolism also produces 
variation in central antihistamine actions (chapter 3). As mentioned before, 
data indeed showed that poor metabolizers of CYP2D6 experienced greater 
driving impairments as compared with extensive metabolizers after treatment 
with the CYP2D6 substrate esmirtazapine. These findings confirm the role 
of CYP2D6 metabolism in central H1-antihistamine effects, as in poor 
metabolizers the exposure to esmirtazapine is higher, resulting in higher central 
antihistamine action and consequently more sedation. Moreover, these findings 
stress the importance of taking individual genetic variances into account when 
administering H1-antihistamines. The results suggest that it is of importance 
to consider the distinction between poor and extensive metabolizers in future 
studies related to drugs and traffic safety which may lead to an extended ICADTS 
classification system that includes those genetic differences. Also, assessing 
CYP2D6 phenotypes before starting treatment can be beneficial and is thought 
to be an important step in moving towards tailor-made treatments.
 Besides for antihistamines, CYP2D6 is the major route of metabolism for 
20-25% of clinically used drugs such as antidepressants, antipsychotics, and 
opioids 22, Our results indicate that poor metabolizers may be in general at risk 
of being exposed to higher levels of CYP2D6 substrates which have the potential 
to impair car driving as well as other performances, emphasizing all the more the 
importance of taking inter-individual variability into account in drug treatments.
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P-glycoprotein at the blood-brain barrier
P-glycoprotein is a mechanism at the blood-brain barrier that is believed to 
play a role in central actions of antihistamines. Even though a substrate for 
P-glycoprotein can enter the brain through diffusion, the penetration of brain 
tissue can be decreased by this efflux transport. Cetirizine is a mildly-sedative 
H1-antihistamine causing slight sedation at low doses 4, meaning it can (partially) 
enter the brain through diffusion. Cetirizine is also known to be a P-glycoprotein 
substrate 23, which is thought to be a reason for the lack of highly sedative effects. 
Chapter 4 confirms that P-glycoprotein plays a role in central effects of cetirizine, 
as the combination of blocking the transporter and administering cetirizine 
increased sedative effects on alerting. Besides in the blood-brain barrier, 
P-glycoprotein is expressed in the small intestine, liver and kidney 24, resulting 
in reduced absorption and enhanced elimination of substrates. Therefore, 
P-glycoprotein inhibition was expected to increase plasma concentrations of 
cetirizine. Besides behavioral effects, an increase of cetirizine after blocking 
P-glycoprotein was indeed present in plasma concentrations, confirming data 
from animal models 25-27. Both the behavioral and pharmacokinetic data confirm 
that P-glycoprotein is a mechanism playing a substantial role in the presence 
and/or absence of central antihistamine effects. 
 Similar to CYP2D6, there are genetic differences in P-glycoprotein 
activity. P-glycoprotein is encoded by the ABCB1 gene and individuals with a 
TT genotype show lower activity of the transporter 28. The frequency in the 
healthy population of low P-gp activity is between 17 en 30% 29. This genetic 
variation may play a role in response differences such as seen in polymorphisms 
of CYP2D6 (chapter 3). In individuals with lower P-gp activity substrates will 
be pumped out of the brain less, and will therefore show increased action in 
the brain. For instance, even though 2nd generation antihistamines are known to 
impair driving performance to a lesser degree than 1st generation antihistamines, 
the amount of impairment caused by 2nd generation antihistamines can still 
differ greatly among individuals 30. This variation could be linked to a difference 
in P-gp activity. More knowledge about genetic variations is therefore important 
in order to fully understand variations in treatment response.
 P-glycoprotein also plays a role in the distribution of many drugs besides 
antihistamines, such as antipsychotics, antidepressants and anti-cancer 
treatments. Concerning those treatments, P-glycoprotein may play a role in 
treatment resistance. Research has shown that, for instance, antipsychotics 
appear to be P-gp substrates, which makes them less effective in the treatment 
of schizophrenia as P-gp reduces their distribution in the CNS and consequently 
their effectiveness 31, 32. Additionally, research suggests that individual differences 
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in P-gp activity caused by genetic variation may play a role in this difference 
in response. In patients with lower P-gp activity, antipsychotics appear more 
effective, because in those patients the ability to pump an antipsychotic out of 
the brain is less 28. More knowledge about these individual genetic variations is 
imperative in order to fully understand the variation in antipsychotic response. 
These results emphasize again the importance of taking inter-individual variances 
into account in drug treatments. Investigating the variation in P-gp expression 
is of additional interest because research has shown that, for instance, during 
a longer, more chronic course of schizophrenia P-gp activity increases 33. The 
magnitude of the consequences of increased P-gp function for treatment is 
not well known, but it shows that p-glycoprotein is an important mechanism in 
central treatment effects, and is becoming a more and more significant research 
area concerning pharmacological treatments.  
 P-gp inhibitors are also apparent in certain foods. For instance, flavanoids 
(plant pigments that are anti-oxidants) are relatively specific inhibitors of 
P-glycoprotein that are found in, amongst others, apples, onioins, red fruits 
and chocolate 34. These types of food could therefore interact with substrates 
such as cetirizine. These possible interactions can change the amount of the 
substrate in the CNS, and can consequently change the effectiveness or toxicity 
of treatments. Therefore, possible interactions should be further investigated, to 
ensure that patients do not unknowingly (and perhaps unwantedly) increase the 
amount of certain medication in the CNS.
Circadian fluctuations in brain histamine levels
It was expected that circadian variation in histamine firing rate might be another 
mechanism playing a role in central antihistamine actions. It was expected 
that the sedative effects of first generation antihistamine hydroxyzine would be 
maximal in the evening when histamine levels were assumed to be low, and 
less in the morning when histamine levels were assumed to be high, as a result 
of increased competition between histamine and hydroxyzine in the CNS in 
the morning. Results indicated however that hydroxyzine induced impairment 
is more prominent after morning doses as compared to evening doses (chapter 5 
and 6). A recent post-mortem study confirms that histamine release in the active 
period is higher as compared to the sleep period. However, it was also found 
that maximal expression of histamine was apparent in the early evening, and 
minimal expression shortly after midnight 35. These results may account for the 
opposite findings from our hypotheses in chapter 5 and 6. Taken these findings 
and our findings together, circadian histamine fluctuations may account for 
differences in central antihistamine effects, and it is suggested to use sedating 
H1-antihistamines in the evening and not in the morning, in order to minimize 
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CNS impairment during the day. But nonetheless, it is strongly encouraged to 
further investigate the precise action of histamine release in healthy volunteers 
in order to verify our findings.
Concluding remarks and future directions
Since the identification of histamine in 1907 and the discovery of the first 
antihistamines in the 1930s, the knowledge and subsequent improvement of 
antihistamines has increased drastically. However, further improvements are 
still paramount in the treatment of human diseases with antihistamines. 
 Our results underline the presence of sedative central effects of H1-
antihistamines, because centrally acting antihistamines can significantly impair 
driving performance and attention. These behavioral central effects were 
confirmed by ERP and fMRI measures of brain responses to antihistamine 
treatment. Furthermore, our results suggest and confirm the role of a number of 
neuropharmacological mechanisms that contribute to the magnitude of central 
actions of H1-antihistamines in humans. The role of P-glycoprotein in central 
histamine effects has shown to be an important quality for minimizing central 
effects of antihistamines. Additionally, the role of genetic variation in CYP2D6 
metabolism emphasizes the importance of taking individual variances in 
treatments into account, as genetic inter-individual variation affects treatment 
response. This genetic variation is also suggested to be present in P-glycoprotein 
activity. Furthermore, both mechanisms play a role in a broad range of treatments 
such as depression, schizophrenia and cancer. It is therefore recommended to 
further investigate the (possible) consequences of individual variations, not only 
in regards to antihistamines, but also regarding other treatments concerning 
both CYP2D6 and P-glycoprotein.  
 Overall, findings in present thesis (i) underline the importance of 
moving towards tailor-made H1-antihistamines treatments, and (ii) help the 
understanding of mechanisms causing sedation by antihistamines, which may in 
the future result in the improvement of treatments with antihistamines, whether 
the central antihistamine actions are wanted or unwanted.
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Summary
H1-antihistamines acting in the central nervous system can cause sedation 
by inhibiting the wake-promoting effects of histamine in the brain. In case 
of allergy treatment this sedation is considered an unwanted non-therapeutic 
effect. However, the same sedative action is widely used and wanted in the 
treatment of insomnia and anxiety. Recent research indicates that several 
mechanisms contribute to (possible) sedative effects of antihistamines i.e.: (i) 
the metabolism of H1-antihistamines; (ii) the ability of antihistamines to bind 
at the P-glycoprotein transporter; and (iii) the time of administration relative to 
circadian fluctuation in brain histamine levels. Gaining further knowledge about 
these mechanisms and their effects in humans may lead to an optimization of 
antihistaminergic treatments.
 The aim of this dissertation is to (i) reestablish the pharmacodynamics 
of centrally acting antihistamines, and to (ii) investigate three possible 
pharmacokinetic mechanisms of central action.
Chapter 1 gives a general introduction on the function of histamine and 
antihistamines, as well as on the three possible mechanisms that might play a 
role in central effects of antihistamines. Finally, the aim and the outline of the 
dissertation are described.
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Chapter 2 describes a study investigating the role of H1-antihistamines on actual 
driving performance in order to establish the difference between centrally and 
not centrally acting antihistamines. The effects of two doses of bilastine (20 
and 40 mg) on actual driving after single and repeated dosing were assessed. 
Hydroxyzine 50 mg, a highly sedative antihistamine, was included as a control 
treatment to demonstrate the sensitivity of the performance measures. Twenty-
two healthy volunteers (11 female and 11 males) were included and the study 
was conducted according to a randomized, double-blind, 4-way cross-over 
design. Participants were treated with once daily doses for 8 consecutive days. 
On day 1 and 8 of each treatment period participants conducted the actual 
highway driving test. In this standardized driving test participants operate a 
specially instrumented automobile over a 100 km (62 mile) primary highway 
circuit. The participants task was to maintain a constant speed of 95 km/hour 
(59 miles/hour), and a steady lateral position between the delineated boundaries 
of the right (slower) traffic lane. A licensed driving instructor accompanied the 
participants.
 Contrasting each drug with the placebo showed that weaving, the primary 
measure of the highway driving test, was significantly increased after treatment 
with hydroxyzine on both day 1 and day 8, but not after treatment with either 
bilastine 20 mg or 40 mg. It was concluded that bilastine 20 mg and 40 mg had 
no significant impairing effects on driving performance. However, hydroxyzine 
50 mg produced impairing effects on driving performance, with no development 
of full tolerance after one week of treatment.
Chapter 3 presents the results of a study on the effects of antihistamine action 
on driving and the additional role of CYP2D6 phenotype on those effects. Thirty-
two healthy subjects (16 females and 16 males) participated in a randomized, 
double-blind, placebo-controlled study in order to assess effects of single and 
repeated doses of esmirtazapine 1.5 mg and 4.5 mg on driving performance. 
Zopiclone 7.5 mg was included as an active control. All subjects were subjected 
to P450 2D6 (CYP2D6) phenotyping in order to distinguish poor metabolizers 
from extensive metabolizers of esmirtazapine. Performance was assessed 
using the afore-mentioned standardized on-the-road driving test. Treatment 
conditions were defined as follows: (i) 1.5 mg esmirtazapine on Day 1-7; (ii) 
4.5 mg esmirtazapine on Day 1-7; (iii) placebo on Day 1-7; and (iv) placebo on 
Day 1-6 and zopiclone 7.5 mg on Day 7. All treatments were administered as 
nocturnal doses.
 Overall, low doses of esmirtazapine (1.5 mg) did not produce any clinically 
relevant change in weaving after single and repeated dosing compared to 
placebo. Driving impairment, i.e. a significant rise in the amount of weaving, 
did occur after a single-dose administration of the higher esmirtazapine dose 
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(4.5 mg), but was resolved after repeated doses. A single dose zopiclone 7.5 mg 
also increased weaving (i.e. impaired driving) as expected. It was concluded 
that single and repeated evening administration of esmirtazapine 1.5 mg are 
generally not associated with impaired driving the next morning. A single-dose of 
esmirtazapine 4.5 mg significantly impaired driving, but generally resolved after 
repeated administration. Exploratory analysis in a small group of poor CYP2D6 
metabolizers (N=7) suggested that these subjects are more sensitive to the 
impairing effects of esmirtazapine on car driving. Acute driving impairment was 
more pronounced after both doses of esmirtazapine in that select group of poor 
metabolizers. These results emphasize the need to take factors into account 
which cause inter-individual variability in either treatment response or drug 
metabolism when investigating the drug effects on driving performance.
Chapter 4 focuses on a study investigating the role of P-glycoprotein (P-gp) in 
central antihistamine effects. An fMRI study was conducted according to a 
double-blind, randomized, placebo-controlled, cross-over design in 13 healthy 
volunteers. Participants received cetirizine 15 mg (an antihistamine); verapamil 
120 mg (a P-gp blocker); a combination of cetirizine + verapamil; and a placebo 
on different days. Brain activity was assessed while conducting an attention 
network task (ANT) in a 3-T magnetic resonance scanner. The ANT measures 3 
independent attention domains: i.e. alerting, orienting and executive attention. 
It was expected that the combined treatment of cetirizine with verapamil would 
prevent efflux of cetirizine from the CNS and would therefore increase attentional 
impairment, as compared to cetirizine when administered alone. The reason for 
this expected impairment increase is that when a non-sedative antihistamine 
is not pumped out of the brain by the Pgp transporter, the antihistamine is 
able to bind at the histamine 1 receptors and will cause cognitive side effects 
comparable with sedative antihistamines. 
 The study provided evidence that the P-gp transporter is involved in central 
antihistamine effects in humans. Subjects were less alert during the combination 
of cetirizine and verapamil as indicated by longer reaction times and decreased 
BOLD response in the right superior temporal gyrus. It is concluded that the 
P-gp affinity of antihistamines plays a major role in the absence or occurrence of 
CNS sedation.
Chapter 5 comprises a study exploring the effects of evening and morning doses 
on cognition. It was expected that the sedative effect of hydroxyzine would 
be apparent in the evening after an evening dose, but would be smaller in the 
morning after a morning dose due to the greater release of histamine shortly 
after awakening. Eighteen participants (9 females and 9 males) participated 
in a placebo-controlled, randomized, double-blind, 3-way cross-over design. 
138
Summary
Cognitive performance was assessed using attention and impulsivity tests. 
Treatment periods consisted of (i) hydroxyzine in the evening and placebo in 
the morning, (ii) placebo in the evening and hydroxyzine in the morning, and 
(iii) placebo in the evening and in the morning. Tests were performed one hour 
following drug or placebo intake in the evening, and one hour following drug or 
placebo intake in the morning.
 In the evening, the sedative effects were only apparent in some variables 
of the tasks, whereas in the morning hydroxyzine impairment was prevalent 
in most of the performance outcomes. Moreover, performance impairments 
observed after a morning dose were significantly larger than those observed 
after an evening dose of hydroxyzine for several tasks. It was concluded that 
hydroxyzine-induced impairment is more prominent after morning doses as 
compared to evening doses, and that the present study could not find direct 
evidence to substantiate the hypothesis that histamine availability inversely 
affects the magnitude of antihistamine impairment.
In chapter 6 it is evaluated to what extend event-related potentials (ERPs) are 
affected by time of administration of a 1st generation H1-antihistamine such as 
described in the former chapter. Hydroxyzine effects on ERPs in the attention 
network test were limited in number, but in line with our hypotheses. However, 
these results contrast with hydroxyzine effects on behavioral parameters of 
the attention network test. ERP data of a divided attention test indicate that 
hydroxyzine induced impairment was more prominent after morning doses as 
compared to evening doses and supports previous behavioral data. Therefore, 
no unambiguous evidence could be provided to confirm the hypothesis that 
histamine availability inversely affects magnitude of antihistamine impairment.
Chapter 7 summarizes and discusses the results from the studies described 
in the previous chapters, and puts these results in a broader perspective. The 
effects of central actions of H1-antihistamines are discussed, focusing on driving 
performance, attention, impulsivity and subjective measurements. Additionally, 
the three mechanisms of central action (i.e. (i) human variability in CYP2D6 
metabolism; (ii) P-glycoprotein at the blood-brain barrier; and (iii) circadian 
fluctuations in brain histamine levels) are discussed. From this chapter, it 
becomes clear that variations in CYP2D6 phenotype and P-glycoprotein may 
play an essential role in central histamine effects, additionally emphasizing the 
role of inter-individual differences in antihistaminergic treatments.
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Antihistamines met effecten in het centrale zenuwstelsel kunnen sedatie 
veroorzaken, omdat zij de waakbevorderende effecten van histamine in de 
hersenen afremmen. Bij de behandeling van allergieën wordt deze sedatie 
als een bijwerking beschouwd en wordt getracht deze te voorkomen. Echter, 
hetzelfde sederende effect is gewild in de behandeling van insomnie en angsten. 
Recent onderzoek heeft aangetoond dat verscheidene mechanismen bijdragen 
tot (mogelijke) sederende effecten van antihistaminica zoals: (i) het metabolisme 
van H1-antihistaminica, (ii) het vermogen van antihistaminica om te binden aan 
de P-glycoproteïne transporter, en (iii) de tijd van administratie ten opzichte 
van de circadiaanse fluctuatie van histamine niveaus in het brein. Meer kennis 
opdoen over deze mechanismen en hun effecten op mensen kan leiden tot een 
optimalisatie van behandelingen met antihistaminica. 
 Het doel van dit proefschrift is om (i) farmacodynamiek van centraal werkende 
antihistaminica te herbepalen, en om (ii) drie mogelijke farmacokinetische 
mechanismen van de centrale werking van antihistaminica te onderzoeken. 
In hoofdstuk 1 wordt een algemene introductie gegeven over de functie van 
histamine en antihistamines, en wordt ingegaan op 3 mechanismen die 
betrokken kunnen zijn bij de centrale effecten van antihistaminica. Ten laatste 
wordt het doel van het proefschrift besproken en opgesomd wat er per hoofdstuk 
Samenvatting
140
beschreven staat.
In hoofdstuk 2 wordt een studie naar de effecten van H1-antihistamines op 
rijgedrag besproken, om de verschillen tussen centraal werkende en niet centraal 
werkende antihistaminica te bepalen. De effecten van twee doseringen van 
bilastine (20 en 40 mg) op rijgedrag werden onderzocht na eenmalige en herhaalde 
doseringen. Hydroxyzine (50 mg) is een zeer sederend antihistaminicum, en was 
daarom geïncludeerd als controle behandeling om de gevoeligheid van de rijtest 
aan te tonen. 
 Tweeëntwintig gezonde vrijwilligers (11 vrouwen en 11 mannen) werden 
getest, en de studie werd uitgevoerd volgens een gerandomiseerd, dubbel-
blind, 4-wegs gekruist design. Deelnemers werden behandeld met eenmalige 
doseringen tijdens 8 opeenvolgende dagen. Op dag 1 en 8 van elke periode 
voerden de deelnemers de snelwegrit uit. Tijdens deze gestandariseerde rijtest 
besturen de deelnemers een geinstrumenteerde auto voor 100 km op de snelweg. 
De taak van de deelnemers was om een constante snelheid van 95 km/uur aan 
te houden, en om een zo constant mogelijke laterale positie te houden op de 
rechter rijbaan tussen de aangegeven lijnen. Een hiervoor opgeleide rijinstructeur 
begeleidde de deelnemers. 
 Door elke conditie te vergelijken met de placebo conditie, werd duidelijk 
dat het slingeren van de auto, de primaire maat van de snelwegrit, significant 
gestegen was na de behandeling met hydroxyzine, op zowel dag 1 als dag 8, 
maar niet na behandeling met bilastine 20 of 40 mg. De conclusie was dat 
bilastine in een dosering van 20 en 40 mg geen schadelijke effecten heeft op 
rijgedrag. Hydroxyzine, aan de andere kant, zorgde voor verslechterd rijgedrag, 
en na toediening gedurende een week was nog steeds geen volledige tolerantie 
aanwezig. 
Hoofdstuk 3 laat de resultaten zien van een studie naar de effecten van 
antihistamines op rijgedrag, en de functie die het CYP2D6 fenotype heeft op 
deze effecten. Tweeendertig gezonde vrijwilligers (16 vrouwen en 16 mannen) 
namen deel in deze dubbel-blinde, placebo-gecontroleerde studie om de 
effecten van eenmalige en herhaalde doseringen van esmirtazapine 1.5 mg en 
4.5 mg op rijgedrag de dag na inname te meten. Zopiclone 7.5 mg werd als active 
controle gebruikt. Het P450 2D6 (CYP2D6) fenotype van de deelnemers werd 
geanalyseerd om een onderscheidt te kunnen maken tussen deelnemers met 
een snel of vertraagd metabolisme van esmirtazapine. Prestatievermogen werd 
gemeten met de al eerder genoemde snelwegrit. Er waren de volgende condities: 
(i) esmirtazapine 1.5 mg op dag 1-7; (ii) esmirtazapine 4.5 mg op dag 1-7; (iii) 
placebo op dag 1-7; en (iv) placebo op dag 1-6 en zopiclone 7.5 mg op dag 7. Alle 
middelen werden als avonddosering toegediend.
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 Over het algemeen zorgde de lage dosering van esmirtazapine (1.5 mg), 
zowel na dag 1 als na dag 7, niet voor klinisch relevante veranderingen in de 
mate van slingering vergeleken met placebo. Na eenmalige toediening van de 
hogere dosering van esmirtazapine (4.5 mg) werd wel een significante stijging 
in slingering gevonden. Deze verslechtering in rijgedrag was na herhaalde 
dosering verdwenen. Een eenmalige toediening van zopiclone 7.5 mg zorgde, 
zoals verwacht, voor een stijging in slingering. De uiteindelijke conclusie 
was dat eenmalige en herhaalde toediening van 1.5 mg esmirtazapine over 
het algemeen niet word geassocieerd met verslechterd rijgedrag de volgende 
ochtend. Eenmalige toediening van esmirtazapine 4.5 mg zorgde voor een 
significante verslechtering van rijgedrag, maar deze verslechtering verdween naar 
herhaalde toedieningen. Verdere analyse in een kleine groep van deelnemers 
met een vertraagd CYP2D6 metabolisme (N=7) geeft aan dat deze deelnemers 
gevoeliger zijn voor de verslechterende effecten die esmirtazapine kan hebben 
op rijgedrag. Acute verslechtering in rijgedrag was sterker aanwezig na beide 
esmirtazapine doseringen in deze selecte groep deelnemers met een vertraagd 
metabolisme. Deze resultaten benadrukken het belang om in studies die de 
effecten van medicatie op rijgedrag meten, rekening te houden met factoren die 
kunnen zorgen voor inter-individuele variabliteit met betrekking tot de reactie 
op medicatie, zoals het metabolisme.
Hoofdstuk 4 richt zich op een studie naar de rol van P-glycoporteïne (P-gp) bij 
centrale effecten van antihistamines. Een fMRI studie werd uitgevoerd met 
een dubbel-blind, gerandomizeerd, placebo-gecontroleerd gekruist design in 13 
gezonde vrijwilligers. Deelnemers kregen cetirizine 15 mg (een anthistaminicum); 
verapamil 120 mg (een P-gp blokker); een combinatie van cetirizine + verapamil; 
en een placebo toegediend op verschillende dagen. Hersenactiviteit werd in een 
3-T scanner gemeten terwijl de deelnemers de aandacht netwerk test (ANT) 
uitvoerden. De ANT meet 3 onafhankelijke aandachtsgebieden, zijnde alertheid, 
aandacht richten naar een bepaalde lokatie (oriëntatie), en executieve aandacht. 
Het werd verwacht dat de combinatie van cetirizine en verapamil de efflux van 
cetirizine uit het brein zou voorkomen. Dit zou zorgen voor een verslechtering 
in aandacht in vergelijking tot de toediening van alleen maar cetirizine. De 
reden hiervoor zou zijn dat door de P-gp transporter te blokkeren een normaal 
niet sederend antihistaminicum niet meer uit het brein vervoerd wordt en 
hierdoor aan histamine 1 receptoren in het brein kan binden, en zodoende 
cognitieve bijwerkingen kan veroorzaken die vergelijkbaar zijn met sederende 
antihistamines. 
 De studie leverde bewijs dat de P-gp transporter betrokken is bij centrale 
effecten van antihistaminica in mensen. Deelnemers waren minder alert na 
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toediening van de combinatie van cetirizine en verapamil, als werd aangegeven 
door langere reactie tijden en een daling in herenactiviteit in de rechter superieure 
temporale gyrus. Er werd geconcludeerd dat affiniteit van antihistamines voor 
de P-gp transporter een belangrijke rol speelt in de aan- en afwezigheid van 
sederende effecten. 
Hoofdstuk 5 beschrijft een studie die de effecten van ochtend en avond 
doseringen van antihistamines op cognitie onderzocht. Er werd verwacht dat 
de sederende effecten van hydroxyzine aanwezig zouden zijn in de avond na een 
avonddosering, en minder zouden zijn in de ochtend na een ochtenddosering, 
vanwege de sterkere vrijlating van histamine kort na het ontwaken. Achttien 
vrijwilligers (9 vrouwen en 9 mannen) namen deel aan een placebo gecontroleerd, 
gerandomiseerd, dubbel-blind 3-wegs gekruist design. Cognitieve prestaties 
werden gemeten door aandachtstaken en impulsiviteitstaken te gebruiken. 
Er waren de volgende condities: (i) hydroxyzine in de avond en placebo in de 
ochtend; (ii) placebo in de avond en hydroxyzine in de ochtend; (iii) placebo in 
de avond en in de ochtend. De taken werden een uur na medicatie inname in de 
avond, en een uur na medicatie inname in de ochtend uitgevoerd. 
 In de avondconditie waren de sederende effecten alleen aanwezig in 
sommige onderdelen van de taken, in de ochtend waren de verslechterende 
effecten van hydroxyzine sterker aanwezig. Verder waren de sederende 
effecten van hydroxyzine significant sterker na de ochtenddosering dan na een 
avonddosering in de meeste taken. Er werd geconcludeerd dat de sederende 
effecten van hydroxyzine sterker aanwezig waren in de ochtend vergeleken met 
de avond, en dat geen direct bewijs gevonden kon worden voor de hypothese 
dat de hoeveelheid histamine een omkerend effect heeft op de mate van sedatie 
veroorzaakt door antihistamines.
In hoofdstuk 6 word besproken in welke mate zogenaamde event-related 
potentials (ERPs) beïnvloedt worden door de toediening van een 1e generatie 
H1-antihistamine zoals in het vorige hoofdstuk besproken. Er waren slechts een 
aantal hydroxyzine effecten op ERPs in de aandacht netwerk test, maar deze 
effecten kwamen overeen met onze hypothese. Deze resultaten kwamen echter 
niet overeen met de gedragsdata van dezelfde taak. ERP data van een verdeelde 
aandachtstaak lieten zien dat verslechtering door hydroxyzine sterker aanwezig 
was na ochtend doseringen dan na avond doseringen, en staan wel in lijn met 
de gedragsdata. Hierdoor kon geen eenduidig bewijs geleverd worden voor de 
hypothese dat de aanwezigheid van histamine de mate van door antihistamine 
veroorzaakte verslechtering kan verminderen. 
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In hoofdstuk 7 worden de resultaten van de studies die in de vorige hoofdstukken 
beschreven zijn samengevat en besproken, en in een breder perspectief gezet. 
De effecten van centraal werkende H1-antihistamines worden besproken met 
betrekking tot rijgedrag, aandacht, impulsiviteit en subjectieve maten. Verder 
worden de drie al eerder genoemde mechanismen besproken die een rol kunnen 
spelen in de centrale effecten van anthistamines (zijnde (i) variabiliteit in 
CYP2D6 metabolisme; (ii) P-glycoproteïne aan de bloed-hersen barriere; en (iii) 
circardiaanse fluctuaties in histamine niveaus in het brein). Hierdoor wordt in 
dit hoofdstuk duidelijk dat variaties in CYP2D6 fenotype en in P-glycoproteïne 
activiteit een essentiële rol kunnen spelen in de mate van centrale antihistamine 
effecten, waardoor de rol van inter-individuele verschillen in behandelingen met 
antihistaminica benadrukt wordt. 
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Irma Brauers, bedankt voor alle logistieke werkzaamheden tijdens de studies 
en het begeleiden van de proefpersonen tijdens hun deelname. Cees van 
Leeuwen wil ik graag bedanken voor de medische supervisie. Anita, bedankt 
voor je onmisbare hulp bij alle studies! Verder wil ik graag de student-assistenten 
en stagiaires, Natalie Valle Guzman, Lieke Heil, Eva Drexler, Emma Kremer, 
Melinda Ravlic en Ilja Croymans, bedanken voor hun inzet en tijd. De mannen 
van de instrumentatie wil ik bedanken voor hun hulp en geduld bij het aanpassen 
van de taken. Michiel en Charlie wil ik hierbij ook bedanken voor hun inzet 
bij het Groot Nationaal Onderzoek. De mannen van de ICT wil ik ook voor 
hun geduld bedanken en voor alle hulp bij hard-en software problemen. Extra 
dank aan Maurice: ik denk dat ik nog nooit zo hard gelachen heb over mail met 
betrekking tot ICT en oma’s met rollators. Ook wil ik alle proefpersonen danken 
voor hun deelname. 
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 Marcel Schrijnemaekers, dank je dat je altijd enthousiast gereageerd hebt 
op onze plannen en ons altijd gesteund hebt om deze te realiseren. Zonder jouw 
hulp waren veel activiteiten niet mogelijk geweest. 
 The last four years wouldn’t have been such a great experience without 
the talks and laughs with all the colleagues in the Neuropsychology and 
Psychopharmacology department: Rob, Wim, Zoe, Esther, Aimee, Rosa, Alex, 
Luciana, Ellen, Anique, Christine, Janelle, Anne, Katja, Inge, Anke L., Eliza, 
Wendy, Petra, Erik, Kim, Joep, Eef, Anke S., Maria, Lisbeth, Jeroen, Elian, 
Anita, Sven, Arjan, Jan, Caroline, Annemiek & Pascal, thank you! En lieve Ellen, 
je wordt gemist. Also thanks to the best Maastricht-roomies: Tim, Peter and 
Stefan (ofwel Timmie, Pjotr en Nefats), thanks for the great advice and the good 
times! 
 Aimee en Anke S., ik ben blij dat we samenwerken aan het Groot Nationaal 
Onderzoek, en Tim en Anke S., hetzelfde geldt voor ons studentenjournal. Jullie 
enthousiasme in wat jullie doen en hoe jullie projecten aanpakken heeft altijd 
inspirerend gewerkt. Also a special thanks to Luciana for organizing crazy parties 
and girl nights. Kim, Inge, Anke L. en Aimee bedankt voor de te gekke congressen, 
het lijkt me leuk om nog eens samen naar een te gaan. Ik heb altijd enorm met 
jullie kunnen lachen en goed met jullie kunnen praten, dank jullie wel! Wendy, 
wie had gedacht dat nachten achter elkaar proefpersonen wakker houden zo 
vermakelijk zou zijn. Maar ook daarna was het altijd super samenwerken en 
gezellig om samen uit eten te gaan en natuurlijk ook bedankt voor alle fijne 
gesprekken. Katja, ik ben blij dat ik je op het werk heb leren kennen en dat we 
nog steeds vrienden zijn, zonder jou waren de vier jaar beslist minder makkelijk 
geweest. 
 I would also like to thank Prof. Bill Deakin for giving me the opportunity 
to work at his department in Manchester, and all the new colleagues (especially 
my new roomies Richard, Emma and Holly) at the Neuroscience and Psychiatry 
Unit for making me feel at home. 
 Lieve paranimfen Janneke (pnimf) en Tim (ptimf), ik vind het een eer dat 
jullie mij bijstaan tijdens mijn promotie. Ik had mij geen betere paranimfen 
kunnen wensen, dank jullie wel, jullie zijn te gek! 
 Ik heb het geluk dat ik geweldige vrienden heb die mij steunen door dik en 
dun: dank jullie allemaal voor te gekke gesprekken, fijne avonden en gestoorde 
feesten! Jullie zijn met teveel om iedereen op te noemen. Een aantal wil ik 
toch bij naam noemen, omdat zij het meeste mijn promotie-perikelen moesten 
verdragen, dit dapper hebben gedaan en ook nog kans zagen om mij als nodig 
op te vrolijken: Janneke, Linda, Marijn, Keetje, Erik, Toon, Kimberly, Maries, 
Wouter, Jaro, Jeroen, Krullen-Wouter, Evelien, Liv, Marcel, Ruudje, Jacob en 
Floris...dank jullie wel! Jaro ook bedankt voor het te gekke ontwerp van de 
omslag van dit proefschrift. 
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 Gerdine, Harald, Bram, Simon, Nina, Astrid, Stef en Boris wil ik bij deze 
bedanken voor de altijd gezellige en fijne avonden in Brabant. 
 To the best sisters in the world: Nicole, Jeannie und Sonja, vielen Dank 
für alles: dass Ihr immer Tag und Nacht für mich da seit, mich immer tröstet 
wenn nötig, guten feedback gibt, und auch noch extrem witzig in all dem seit! 
Natürlich auch viel Dank an Mehmet, Fabienne, Kaya und Tarik, die auch 
immer bereit sind, sich allen Quatsch an zu hören. 
 Liebe Mama und lieber Jürgen, ihr seit immer für mich da und habt mich 
immer in allem was ich machen wollte unterstützt. Ihr seit beide eine riesige 
Inspiration für mich: Danke für alles.
 Lieve lieve Joris, ik zou niet weten wat ik zonder jou zou moeten doen, maar 
ik weet wel dat zonder jou alles minder mooi zou zijn. You’re my boilin’ pot! 
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